Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 88
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

From Wet-Lab to Variations: Concordance and Speed of Bioinformatics Pipelines for Whole Genome and Whole Exome Sequencing

  • Laurie, Steven, 1973-
  • Fernández Callejo, Marcos
  • Marco Sola, Santiago
  • Trotta, Jean-Remi
  • Camps-Puchadas, Jordi
  • Chacón, Alejandro
  • Espinosa, Antonio
  • Gut, Marta
  • Gut, Ivo Glynne
  • Heath, Simon
  • Beltran, Sergi
As whole genome sequencing becomes cheaper and faster, it will progressively substitute targeted next-generation sequencing as standard practice in research and diagnostics. However, computing cost–performance ratio is not advancing at an equivalent rate. Therefore, it is essential to evaluate the robustness of the variant detection process taking into account the computing resources required. We have benchmarked six combinations of state-of-the-art read aligners (BWA-MEM and GEM3) and variant callers (FreeBayes, GATK HaplotypeCaller, SAMtools) on whole genome and whole exome sequencing data from the NA12878 human sample. Results have been compared between them and against the NIST Genome in a Bottle (GIAB) variants reference dataset. We report differences in speed of up to 20 times in some steps of the process and have observed that SNV, and to a lesser extent InDel, detection is highly consistent in 70% of the genome. SNV, and especially InDel, detection is less reliable in 20% of the genome, and almost unfeasible in the remaining 10%. These findings will aid in choosing the appropriate tools bearing in mind objectives, workload, and computing infrastructure available., Contract Grant Sponsors: Spanish Ministry of Economy and Competitiveness; Generalitat de Catalunya; European Regional Development Fund (ERDF); RD-Connect Project (EC FP7/2007-2013 #305444); ELIXIR-EXCELERATE (EC H2020 #676559); MICINN (TIN2014-53234- C2-1-R).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Linked Registries: Connecting Rare Diseases Patient Registries through a Semantic Web Layer

  • Sernadela, Pedro
  • Queralt Rosinach, Núria
  • Oliveira, José Luis
Patient registries are an essential tool to increase current knowledge regarding rare diseases. Understanding these data is a vital step to improve patient treatments and to create the most adequate tools for personalized medicine. However, the growing number of disease-specific patient registries brings also new technical challenges. Usually, these systems are developed as closed data silos, with independent formats and models, lacking comprehensive mechanisms to enable data sharing. To tackle these challenges, we developed a Semantic Web based solution that allows connecting distributed and heterogeneous registries, enabling the federation of knowledge between multiple independent environments. This semantic layer creates a holistic view over a set of anonymised registries, supporting semantic data representation, integrated access, and querying. The implemented system gave us the opportunity to answer challenging questions across disperse rare disease patient registries. The interconnection between those registries using Semantic Web technologies benefits our final solution in a way that we can query single or multiple instances according to our needs. The outcome is a unique semantic layer, connecting miscellaneous registries and delivering a lightweight holistic perspective over the wealth of knowledge stemming from linked rare disease patient registries., The research leading to these results has received funding from the European Community’s Seventh Framework Programme (FP7/2007–2013) under Grant Agreement no.305444—the RD-Connect project. Pedro Sernadela is funded by Fundac¸ao para a Ci ˜ encia e Tecnologia (FCT) under the ˆGrant Agreement SFRH/BD/52484/2014. Lorena Gonzalez- ´Castro is funded by the Xunta de Galicia, including funding from the operative program FSE Galicia 2007–2013, under the Grant Agreement IN809A 19/2015.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Comparison of algorithms for the detection of cancer drivers at subgene resolution

  • Porta-Pardo, Eduard
  • Kamburov, Atanas
  • Tamborero Noguera, David
  • Pons, Tirso
  • Grases, Daniela
  • Valencia, Alfonso
  • López Bigas, Núria
  • Getz, Gad
  • Godzik, Adam
Understanding genetic events that lead to cancer initiation and progression remains one of the biggest challenges in cancer biology. Traditionally, most algorithms for cancer-driver identification look for genes that have more mutations than expected from the average background mutation rate. However, there is now a wide variety of methods that look for nonrandom distribution of mutations within proteins as a signal for the driving role of mutations in cancer. Here we classify and review such subgene-resolution algorithms, compare their findings on four distinct cancer data sets from The Cancer Genome Atlas and discuss how predictions from these algorithms can be interpreted in the emerging paradigms that challenge the simple dichotomy between driver and passenger genes., E.P.-P. and A.G. acknowledge the support from the Cancer Center grants P30 CA030199 (to our institute) and R35 GM118187 (A.G.). A.K. was supported by startup funds of G.G. and by a collaboration with Bayer AG. D.T. is supported by project SAF2015-74072-JIN, which is funded by the Agencia Estatal de Investigacion (AEI) and Fondo Europeo de Desarrollo Regional (FEDER). N.L.-B. acknowledges funding from the European Research Council (consolidator grant 682398). A.V. and T.P. acknowledge funding by the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 305444 (RD-Connect)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Remote visualization of large-scale genomic alignments for collaborative clinical research and diagnosis of rare diseases

  • Corvò, Alberto
  • Matalonga, Leslie
  • Laurie, Steven, 1973-
  • Picó-Amador, Daniel
  • Fernández Callejo, Marcos
  • Paramonov, Ida
  • Gut, Ivo Glynne
  • Piscia, Davide
  • Beltran, Sergi
The Solve-RD project objectives include solving undiagnosed rare diseases (RD) through collaborative research on shared genome-phenome datasets. The RD-Connect Genome-Phenome Analysis Platform (GPAP), for data collation and analysis, and the European Genome-Phenome Archive (EGA), for file storage, are two key components of the Solve-RD infrastructure. Clinical researchers can identify candidate genetic variants within the RD-Connect GPAP and, thanks to the developments presented here as part of joint ELIXIR activities, are able to remotely visualize the corresponding alignments stored at the EGA. The Global Alliance for Genomics and Health (GA4GH) htsget streaming application programming interface (API) is used to retrieve alignment slices, which are rendered by an integrated genome viewer (IGV) instance embedded in the GPAP. As a result, it is no longer necessary for over 11,000 datasets to download large alignment files to visualize them locally. This work highlights the advantages, from both the user and infrastructure perspectives, of implementing interoperability standards for establishing federated genomics data networks., This study was partially funded by ELIXIR Implementation Studies “Remote real-time visualization of human RDs genomics data (RD-Connect) stored at the EGA ELIXIR” (2017–2018), “Integration of ELIXIR-IIB in ELIXIR Rare Disease activities (2017–2018),” and “Rare Disease Infrastructure ELIXIR (2019–2020)” and the Solve-RD project, which received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 779257. Data were analyzed using the RD-Connect Genome-Phenome Analysis Platform, which has received funding from EU projects RD-Connect, Solve-RD, and EJP-RD (grant nos. FP7 305444, H2020 779257, and H2020 825575), Instituto de Salud Carlos III (grant nos. PT13/0001/0044 and PT17/0009/0019; Instituto Nacional de Bioinformática, INB), and ELIXIR Implementation Studies. We acknowledge the support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

RD-Connect, NeurOmics and EURenOmics: collaborative European initiative for rare diseases

  • Lochmüller, Hanns
  • Badowska, Dorota M.
  • Thompson, Rachel
  • Knoers, Nine V.
  • Aartsma-Rus, Annemieke
  • Gut, Ivo Glynne
  • Wood, Libby
  • Harmuth, Tina
  • Durudas, Andre
  • Graessner, Holm
  • Schaefer, Franz
  • Riess, Olaf
  • RD-Connect consortium
  • NeurOmics consortium
  • EURenOmics consortium
Although individually uncommon, rare diseases (RDs) collectively affect 6-8% of the population. The unmet need of the rare disease community was recognized by the European Commission which in 2012 funded three flagship projects, RD-Connect, NeurOmics, and EURenOmics, to help move the field forward with the ambition of advancing -omics research and data sharing at their core in line with the goals of IRDiRC (International Rare Disease Research Consortium). NeurOmics and EURenOmics generate -omics data and improve diagnosis and therapy in rare renal and neurological diseases, with RD-Connect developing an infrastructure to facilitate the sharing, systematic integration and analysis of these data. Here, we summarize the achievements of these three projects, their impact on the RD community and their vision for the future. We also report from the Joint Outreach Day organized by the three projects on the 3rd of May 2017 in Berlin. The workshop stimulated an open, multi-stakeholder discussion on the challenges of the rare diseases, and highlighted the cross-project cooperation and the common goal: the use of innovative genomic technologies in rare disease research., This work has received funding from the European Community’s Seventh Framework Program (FP7/2007–2013) under grant agreement n° 305444 “RD-CONNECT: An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research”, grant agreement n° 2012-305121 “Integrated European –omics research project for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases (NEUROMICS)” and n° 305608 “EURenOmics”. Hanns Lochmüller has received funding from the Medical Research Council UK (grant reference G1002274, grant ID 98482). We would like to thank Victoria Hedley for her support in dissemination of the RD-Connect project and Ana Töpf for her feedback, which helped to develop the Genome-Phenome Analysis Platform.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease

  • Wood, Libby
  • Lochmüller, Hanns
Background: Myotonic Dystrophy is the most common form of muscular dystrophy in adults, affecting an estimated 10 per 100,000 people. It is a multisystemic disorder affecting multiple generations with increasing severity. There are currently no licenced therapies to reverse, slow down or cure its symptoms. In 2009 TREAT-NMD (a global alliance with the mission of improving trial readiness for neuromuscular diseases) and the Marigold Foundation held a workshop of key opinion leaders to agree a minimal dataset for patient registries in myotonic dystrophy. Eight years after this workshop, we surveyed 22 registries collecting information on myotonic dystrophy patients to assess the proliferation and utility the dataset agreed in 2009. These registries represent over 10,000 myotonic dystrophy patients worldwide (Europe, North America, Asia and Oceania). Results: The registries use a variety of data collection methods (e.g. online patient surveys or clinician led) and have a variety of budgets (from being run by volunteers to annual budgets over €200,000). All registries collect at least some of the originally agreed data items, and a number of additional items have been suggested in particular items on cognitive impact. Conclusions: The community should consider how to maximise this collective resource in future therapeutic programmes., This work has received funding from the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 305444 “RD-CONNECT: An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research”, Hanns Lochmüller has received funding from the Medical Research Council UK (grant reference G1002274, grant ID 98482).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Solving patients with rare diseases through programmatic reanalysis of genome-phenome data

  • Matalonga, Leslie
  • Hernández Ferrer, Carles
  • Piscia, Davide
  • Tonda, Raúl
  • Laurie, Steven, 1973-
  • Fernández Callejo, Marcos
  • Picó, Daniel
  • Garcia-Linares, Carles
  • Papakonstantinou, Anastasios
  • Corvò, Alberto
  • Joshi, Ricky S.
  • Diez, Hector
  • Gut, Ivo Glynne
  • Beltran, Sergi
  • Solve-RD Consortium
Reanalysis of inconclusive exome/genome sequencing data increases the diagnosis yield of patients with rare diseases. However, the cost and efforts required for reanalysis prevent its routine implementation in research and clinical environments. The Solve-RD project aims to reveal the molecular causes underlying undiagnosed rare diseases. One of the goals is to implement innovative approaches to reanalyse the exomes and genomes from thousands of well-studied undiagnosed cases. The raw genomic data is submitted to Solve-RD through the RD-Connect Genome-Phenome Analysis Platform (GPAP) together with standardised phenotypic and pedigree data. We have developed a programmatic workflow to reanalyse genome-phenome data. It uses the RD-Connect GPAP's Application Programming Interface (API) and relies on the big-data technologies upon which the system is built. We have applied the workflow to prioritise rare known pathogenic variants from 4411 undiagnosed cases. The queries returned an average of 1.45 variants per case, which first were evaluated in bulk by a panel of disease experts and afterwards specifically by the submitter of each case. A total of 120 index cases (21.2% of prioritised cases, 2.7% of all exome/genome-negative samples) have already been solved, with others being under investigation. The implementation of solutions as the one described here provide the technical framework to enable periodic case-level data re-evaluation in clinical settings, as recommended by the American College of Medical Genetics., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257. Data were analysed using the RD‐Connect Genome‐Phenome Analysis Platform, which received funding from EU projects RD‐Connect, Solve-RD and EJP-RD (grant numbers FP7 305444, H2020 779257, H2020 825575), Instituto de Salud Carlos III (grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB) and ELIXIR Implementation Studies.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Solving unsolved rare neurological diseases-a Solve-RD viewpoint

  • Matalonga, Leslie
  • Timmann, Dagmar
  • Erasmus, Corrie E.
  • Reichbauer, Jennifer
  • Wayand, Melanie
  • Solve-RD-DITF-RND
  • van de Warrenburg, Bart
  • Schöls, Ludger
  • Wilke, Carlo
  • Bevot, Andrea
  • Zuchner, Stephan
  • Beltran, Sergi
  • Laurie, Steven, 1973-
  • Matalonga, Leslie
  • Graessner, Holm
  • Synofzik, Matthis
  • Solve-RD Consortium
Rare genetic neurological disorders (RND; ORPHA:71859) are a heterogeneous group of disorders comprising >1700 distinct genetic disease entities. However, genetic discoveries have not yet translated into dramatic increases of diagnostic yield and indeed rates of molecular genetic diagnoses have been stuck at about 30–50% across NGS modalities and RND phenotypes [1, 2]. Existence of yet unknown disease genes as well as shortcomings of commonly employed NGS technologies and analysis pipelines in detecting certain variant types are typically cited to explain the low diagnosis rates. To increase the diagnostic yield in RNDs - one of the four focus disease groups in Solve-RD - we follow two major approaches, that we will here present and exemplify: (i) systematic state-of the art re-analysis of large cohorts of unsolved whole-exome/genome sequencing (WES/WGS) RND datasets; and (ii) novel-omics approaches. Based on the way Solve-RD systematically organizes researchers’ expertise to channel this approach [3], the European Reference Network for Rare Neurological Diseases (ERN-RND) has established its own Data Interpretation Task Force (DITF) within SOLVE-RD, which is currently composed of clinical and genetic experts from 29 sites in 15 European countries., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No. 779257. Data were analysed using the RD‐Connect Genome‐Phenome Analysis Platform, which received funding from EU projects RD‐Connect, Solve-RD and EJP-RD (Grant Numbers FP7 305444, H2020 779257, H2020 825575), Instituto de Salud Carlos III (Grant Numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB) and ELIXIR Implementation Studies. The study was further funded by the Federal Ministry of Education and Research, Germany, through the TreatHSP network (01GM1905 to RS and LS), the National Institute of Neurological Diseases and Stroke (R01NS072248 to SZ and RS), the European Joint Program on Rare Diseases-EJP-RD COFUND-EJP N° 825575 through funding for the PROSPAX consortium (441409627 to MS, RS and BvW). CW was supported by the PATE program of the Medical Faculty, University of Tübingen. CEE received support from the Dutch Princess Beatrix Muscle Fund and the Dutch Spieren voor Spieren Muscle fund. Authors on this paper are members of the European Reference Network for Rare Neurological Diseases (ERN-RND, Project ID 739510)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

GA4GH: International policies and standards for data sharing across genomic research and healthcare

  • Rehm, Heidi L.
  • Beltran, Sergi
  • Guigó Serra, Roderic
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Palumbo, Emilio
  • Rambla de Argila, Jordi
  • Birney, Ewan
The Global Alliance for Genomics and Health (GA4GH) aims to accelerate biomedical advances by enabling the responsible sharing of clinical and genomic data through both harmonized data aggregation and federated approaches. The decreasing cost of genomic sequencing (along with other genome-wide molecular assays) and increasing evidence of its clinical utility will soon drive the generation of sequence data from tens of millions of humans, with increasing levels of diversity. In this perspective, we present the GA4GH strategies for addressing the major challenges of this data revolution. We describe the GA4GH organization, which is fueled by the development efforts of eight Work Streams and informed by the needs of 24 Driver Projects and other key stakeholders. We present the GA4GH suite of secure, interoperable technical standards and policy frameworks and review the current status of standards, their relevance to key domains of research and clinical care, and future plans of GA4GH. Broad international participation in building, adopting, and deploying GA4GH standards and frameworks will catalyze an unprecedented effort in data sharing that will be critical to advancing genomic medicine and ensuring that all populations can access its benefits., B.P.C. acknowledges funding from Abigail Wexner Research Institute at Nationwide Children’s Hospital; T.H. Nyrönen acknowledges funding from Academy of Finland grant #31996; A.M.-J., K.N., T.F.B., O.M.H., and Z.S. acknowledge funding from Australian Medical Research Future Fund; M.S. acknowledges funding from Biobank Japan; D. Bujold and S.J.M.J. acknowledge funding from Canada Foundation for Innovation; L.J.D. acknowledges funding from Canada Foundation for Innovation Cyber Infrastructure grant #34860; D. Bujold and G.B. acknowledge funding from CANARIE; L.J.D. acknowledges funding from CANARIE Research Data Management contract #RDM-090 (CHORD) and #RDM2-053 (ClinDIG); K.K.-L. acknowledges funding from CanSHARE; T.L.T. acknowledges funding from Chan Zuckerberg Initiative; T. Burdett acknowledges funding from Chan Zuckerberg Initiative grant #2017-171671; D. Bujold, G.B., and L.D.S. acknowledge funding from CIHR; L.J.D. acknowledges funding from CIHR grant #404896; M.J.S.B. acknowledges funding from CIHR grant #SBD-163124; M. Courtot and M. Linden acknowledge funding from CINECA project EU Horizon 2020 grant #825775; D. Bujold and G.B. acknowledge funding from Compute Canada; F.M.-G. acknowledges funding from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – NFDI 1/1 “GHGA – German Human Genome-Phenome Archive; R.M.H.-S. acknowledges funding from Duke-Margolis Center for Health Policy; S.B. and A.J.B. acknowledge funding from EJP-RD EU Horizon 2020 grant #825575; A. Niewielska, A.K., D.S., G.I.S., J.A.T., J.R., M.A.K., M. Baudis, M. Linden, S.B., S.S., T.H. Nyrönen, and T.M.K. acknowledge funding from ELIXIR; A. Niewielska acknowledges funding from EOSC-Life EU Horizon 2020 grant #824087; J.-P.H. acknowledges funding from ETH Domain Strategic Focal Area “Personalized Health and Related Technologies (PHRT)” grant #2017-201; F.M.-G. acknowledges funding from EUCANCan EU Horizon 2020 grant #825835; B.M.K., D. Bujold, G.B., L.D.S., M.J.S.B., N.S., S.E.W., and Y.J. acknowledge funding from Genome Canada; B.M.K., M.J.S.B., S.E.W., and Y.J. acknowledge funding from Genome Quebec; F.M.-G. acknowledges funding from German Human Genome-Phenome Archive; C. Voisin acknowledges funding from Google; A.J.B. acknowledges funding from Health Data Research UK Substantive Site Award; D.H. acknowledges funding from Howard Hughes Medical Institute; S.B. acknowledges funding from Instituto de Salud Carlos III; S.-S.K. and K.T. acknowledge funding from Japan Agency for Medical Research and Development (AMED); S. Ogishima acknowledges funding from Japan Agency for Medical Research and Development (AMED) grant #20kk0205014h0005; C.Y. and K. Kosaki acknowledge funding from Japan Agency for Medical Research and Development (AMED) grant #JP18kk0205012; GEM Japan acknowledges funding from Japan Agency for Medical Research and Development (AMED) grants #19kk0205014h0004, #20kk0205014h0005, #20kk0205013h0005, #20kk0205012h0005, #20km0405401h0003, and #19km0405001h0104; J.R. acknowledges funding from La Caixa Foundation under project #LCF/PR/GN13/50260009; R.R.F. acknowledges funding from Mayo Clinic Center for Individualized Medicine; Y.J. and S.E.W. acknowledge funding from Ministère de l’Économie et de l’Innovation du Québec for the Can-SHARE Connect Project; S.E.W. and S.O.M.D. acknowledge funding from Ministère de l’Économie et de l’Innovation du Québec for the Can-SHARE grant #141210; M.A.H., M.C.M.-T., J.O.J., H.E.P., and P.N.R. acknowledge funding from Monarch Initiative grant #R24OD011883 and Phenomics First NHGRI grant #1RM1HG010860; A.L.M. and E.B. acknowledge funding from MRC grant #MC_PC_19024; P.T. acknowledges funding from National University of Singapore and Agency for Science, Technology and Research; J.M.C. acknowledges funding from NHGRI; A.H.W. acknowledges funding from NHGRI awards K99HG010157, R00HG010157, and R35HG011949; A.M.-J., K.N., D.P.H., O.M.H., T.F.B., and Z.S. acknowledge funding from NHMRC grants #GNT1113531 and #GNT2000001; D.L.C. acknowledges funding from NHMRC Ideas grant #1188098; A.B.S. acknowledges funding from NHMRC Investigator Fellowship grant #APP177524; J.M.C. and L.D.S. acknowledge funding from NIH; A.A.P. acknowledges funding from NIH Anvil; A.V.S. acknowledges funding from NIH contract #HHSN268201800002I (TOPMed Informatics Research Center); S.U. acknowledges funding from NIH ENCODE grant #UM1HG009443; M.C.M.-T. and M.A.H. acknowledge funding from NIH grant #1U13CA221044; R.J.C. acknowledges funding from NIH grants #1U24HG010262 and #1U2COD023196; M.G. acknowledges funding from NIH grant #R00HG007940; J.B.A., S.L., P.G., E.B., H.L.R., and L.S. acknowledge funding from NIH grant #U24HG011025; K.P.E. acknowledges funding from NIH grant #U2C-RM-160010; J.A.E. acknowledges funding from NIH NCATS grant #U24TR002306; M.M. acknowledges funding from NIH NCI contract #HHSN261201400008c and ID/IQ Agreement #17X146 under contract #HHSN2612015000031 and #75N91019D00024; R.M.C.-D. acknowledges funding from NIH NCI grant #R01CA237118; M. Cline acknowledges funding from NIH NCI grant #U01CA242954; K.P.E. acknowledges funding from NIH NCI ITCR grant #1U24CA231877-01; O.L.G. acknowledges funding from NIH NCI ITCR grant #U24CA237719; R.L.G. acknowledges funding from NIH NCI task order #17X147F10 under contract #HHSN261200800001E; A.F.R. acknowledges funding from NIH NHGRI grant #RM1HG010461; N.M. and L.J.Z. acknowledge funding from NIH NHGRI grant #U24HG006941; R.R.F., T.H. Nelson, L.J.B., and H.L.R. acknowledge funding from NIH NHGRI grant #U41HG006834; B.J.W. acknowledges funding from NIH NHGRI grant #UM1HG009443A; M. Cline acknowledges funding from NIH NHLBI BioData Catalyst Fellowship grant #5118777; M.M. acknowledges funding from NIH NHLBI BioData Catalyst Program grant #1OT3HL142478-01; N.C.S. acknowledges funding from NIH NIGMS grant #R35-GM128636; M.C.M.-T., M.A.H., P.N.R., and R.R.F. acknowledge funding from NIH NLM contract #75N97019P00280; E.B. and A.L.M. acknowledge funding from NIHR; R.G. acknowledges funding from Project Ris3CAT VEIS; S.B. acknowledges funding from RD-Connect, Seventh Framework Program grant #305444; J.K. acknowledges funding from Robertson Foundation; S.B. and A.J.B. acknowledge funding from Solve-RD, EU Horizon 2020 grant #779257; T.S. and S. Oesterle acknowledge funding from Swiss Institute of Bioinformatics (SIB) and Swiss Personalized Health Network (SPHN), supported by the Swiss State Secretariat for Education, Research and Innovation SERI; S.J.M.J. acknowledges funding from Terry Fox Research Institute; A.E.H., M.P.B., M. Cupak, M.F., and J.F. acknowledge funding from the Digital Technology Supercluster; D.F.V. acknowledges funding from the Australian Medical Research Future Fund, as part of the Genomics Health Futures Mission grant #76749; M. Baudis acknowledges funding from the BioMedIT Network project of Swiss Institute of Bioinformatics (SIB) and Swiss Personalized Health Network (SPHN); B.M.K. acknowledges funding from the Canada Research Chair in Law and Medicine and CIHR grant #SBD-163124; D.S., G.I.S., M.A.K., S.B., S.S., and T.H. Nyrönen acknowledge funding from the EU Horizon 2020 Beyond 1 Million Genomes (B1MG) Project grant #951724; P.F., A.D.Y., F.C., H.S., I.U.L., D. Gupta, M. Courtot, S.E.H., T. Burdett, T.M.K., and S.F. acknowledge funding from the European Molecular Biology Laboratory; Y.J. and S.E.W. acknowledge funding from the Government of Canada; P.G. acknowledges funding from the Government of Canada through Genome Canada and the Ontario Genomics Institute (OGI-206); J.Z. acknowledges funding from the Government of Ontario; C.K.Y. acknowledges funding from the Government of Ontario, Canada Foundation for Innovation; C. Viner and M.M.H. acknowledge funding from the Natural Sciences and Engineering Research Council of Canada (grant #RGPIN-2015-03948 to M.M.H. and Alexander Graham Bell Canada Graduate Scholarship to C.V.); K.K.-L. acknowledges funding from the Program for Integrated Database of Clinical and Genomic Information; J.K. acknowledges funding from the Robertson Foundation; D.F.V. acknowledges funding from the Victorian State Government through the Operational Infrastructure Support (OIS) Program; A.M.L., R.N., and H.V.F. acknowledge funding from Wellcome (collaborative award); F.C., H.S., P.F., and S.E.H. acknowledge funding from Wellcome Trust grant #108749/Z/15/Z; A.D.Y., H.S., I.U.L., M. Courtot, H.E.P., P.F., and T.M.K. acknowledge funding from Wellcome Trust grant #201535/Z/16/Z; A.M., J.K.B., R.J.M., R.M.D., and T.M.K. acknowledge funding from Wellcome Trust grant #206194; E.B., P.F., P.G., and S.F. acknowledge funding from Wellcome Trust grant #220544/Z/20/Z; A. Hamosh acknowledges funding from NIH NHGRI grant U41HG006627 and U54HG006542; J.S.H. acknowledges funding from National Taiwan University #91F701-45C and #109T098-02; the work of K.W.R. was supported by the Intramural Research Program of the National Library of Medicine, NIH. For the purpose of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. H.V.F. acknowledges funding from Wellcome Grant 200990/A/16/Z ‘Designing, developing and delivering integrated foundations for genomic medicine'.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

CARGO: effective format-free compressed storage of genomic information

  • Roguski, Łukasz
  • Ribeca, Paolo
Includes supplementary materials for the online appendix., The recent super-exponential growth in the amount of sequencing data generated worldwide has put techniques for compressed storage into the focus. Most available solutions, however, are strictly tied to specific bioinformatics formats, sometimes inheriting from them suboptimal design choices; this hinders flexible and effective data sharing. Here, we present CARGO (Compressed ARchiving for GenOmics), a high-level framework to automatically generate software systems optimized for the compressed storage of arbitrary types of large genomic data collections. Straightforward applications of our approach to FASTQ and SAM archives require a few lines of code, produce solutions that match and sometimes outperform specialized format-tailored compressors and scale well to multi-TB datasets. All CARGO software components can be freely downloaded for academic and non-commercial use from http://bio-cargo.sourceforge.net., Biotechnology and Biological Sciences Research Council (BBSRC) [grant BBS/E/I/00001942 to P.R.]; European Union's Seventh Framework Programme (FP7/2007-2013) [grant agreement No. 305444 (RD-Connect) to Ł.R.]; European Union's European Social Fund [INTERKADRA project UDAPOKL-04.01.01-00-014/10-00 to Ł.R.]. Funding for open access charge: CNAG (own funds) and BBSRC (grant for article processing charges to The Pirbright Institute).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Increasing phenotypic annotation improves the diagnostic rate of exome sequencing in a rare neuromuscular disorder

  • Thompson, Rachel
  • Papakonstantinou, Anastasios
  • Beltran, Sergi
  • Topf, Ana
  • de Paula Estephan, Eduardo
  • Poloavarapu, Kiran
  • Hoen, Peter A. C.
  • Missier, Paolo
  • Lochmüller, Hanns
Phenotype-based filtering and prioritization contribute to the interpretation of genetic variants detected in exome sequencing. However, it is currently unclear how extensive this phenotypic annotation should be. In this study, we compare methods for incorporating phenotype into the interpretation process and assess the extent to which phenotypic annotation aids prioritization of the correct variant. Using a cohort of 29 patients with congenital myasthenic syndromes with causative variants in known or newly discovered disease genes, exome data and the Human Phenotype Ontology (HPO)-coded phenotypic profiles, we show that gene-list filters created from phenotypic annotations perform similarly to curated disease-gene virtual panels. We use Exomiser, a prioritization tool incorporating phenotypic comparisons, to rank candidate variants while varying phenotypic annotation. Analyzing 3,712 combinations, we show that increasing phenotypic annotation improved prioritization of the causative variant, from 62% ranked first on variant alone to 90% with seven HPO annotations. We conclude that any HPO-based phenotypic annotation aids variant discovery and that annotation with over five terms is recommended in our context. Although focused on a constrained cohort, this provides real-world validation of the utility of phenotypic annotation for variant prioritization. Further research is needed to extend this concept to other diseases and more diverse cohorts., Data was analyzed using the RD‐Connect Genome‐Phenome Analysis Platform developed under the 2012‐2018 FP7‐funded project RD‐ Connect (Grant Agreement No.: 305444). R. T., S. B., A. P. N., P. tH., and H. L. received support from the EU FP7 projects 305444 (RD‐ Connect) and 305121 (NeurOmics). S. B. received support from the EU FP7 project 313010 (BBMRI‐LPC). S. B. and P. tH. received support from the EU Horizon 2020 project 779257 (Solve‐RD). S. B., P. tH., and H. L. received support from the EU Horizon 2020 project 825575 (EJP‐RD). H. L. is supported by a project grant of the Canadian Institutes of Health Research (CIHR PJT 162265)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Multifocal demyelinating motor neuropathy and hamartoma syndrome associated with a de novo PTEN mutation

  • Bansagi, Boglarka
  • Phan, Vietxuan
  • Baker, Mark R.
  • O'Sullivan, Julia
  • Jennings, Matthew J.
  • Whittaker, Roger G.
  • Müller, Juliane
  • Duff, Jennifer
  • Griffin, Helen
  • Miller, James A.L.
  • Gorman, Grainne S.
  • Lochmüller, Hanns
  • Chinnery, Patrick F.
  • Roos, Andreas
  • Swan, Laura E.
  • Horvath, Rita
Objective: To describe a patient with a multifocal demyelinating motor neuropathy with onset in childhood and a mutation in phosphatase and tensin homolog (PTEN), a tumor suppressor gene associated with inherited tumor susceptibility conditions, macrocephaly, autism, ataxia, tremor, and epilepsy. Functional implications of this protein have been investigated in Parkinson and Alzheimer diseases. Methods: We performed whole-exome sequencing in the patient's genomic DNA validated by Sanger sequencing. Immunoblotting, in vitro enzymatic assay, and label-free shotgun proteomic profiling were performed in the patient's fibroblasts. Results: The predominant clinical presentation of the patient was a childhood onset, asymmetric progressive multifocal motor neuropathy. In addition, he presented with macrocephaly, autism spectrum disorder, and skin hamartomas, considered as clinical criteria for PTEN-related hamartoma tumor syndrome. Extensive tumor screening did not detect any malignancies. We detected a novel de novo heterozygous c.269T>C, p.(Phe90Ser) PTEN variant, which was absent in both parents. The pathogenicity of the variant is supported by altered expression of several PTEN-associated proteins involved in tumorigenesis. Moreover, fibroblasts showed a defect in catalytic activity of PTEN against the secondary substrate, phosphatidylinositol 3,4-trisphosphate. In support of our findings, focal hypermyelination leading to peripheral neuropathy has been reported in PTEN-deficient mice. Conclusion: We describe a novel phenotype, PTEN-associated multifocal demyelinating motor neuropathy with a skin hamartoma syndrome. A similar mechanism may potentially underlie other forms of Charcot-Marie-Tooth disease with involvement of the phosphatidylinositol pathway., R.H. is a Wellcome Trust Investigator (109915/Z/15/Z) who receives support from the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), Medical Research Council (UK) (MR/N025431/1), and the European Research Council (309548). H.L. receives funding from the European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement no. 305444 (RD-Connect) and 305121 (Neuromics), from the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z), and from the Newton Fund (UK/Turkey, MR/N027302/1). P.F.C. is a Wellcome Trust Senior Fellow in Clinical Science (101876/Z/13/Z) and a UK NIHR Senior Investigator, who receives support from the Medical Research Council Mitochondrial Biology Unit (MC_UP_1501/2), the Medical Research Council (UK) Centre for Translational Muscle Disease (G0601943), EU FP7 TIRCON, and the National Institute for Health Research (NIHR) Biomedical Research Centre based at Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. A.R. received financial support from the Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen, the Senatsverwaltung für Wirtschaft, Technologie und Forschung des Landes Berlin and the Bundesministerium für Bildung und Forschung. L.E.S. was supported by Wellcome Trust (105616/Z/14/Z) and the Medical Research Council (MRC/N010035/1).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy

  • Signorelli, Mirko
  • Ayoglu, Burcu
  • Johansson, Camilla
  • Lochmüller, Hanns
  • Straub, Volker
  • Muntoni, Francesco
  • Niks, Erik
  • Tsonaka, Roula
  • Persson, Anja
  • Aartsma-Rus, Annemieke
  • Nilsson, Peter
  • Al-Khalili Szigyarto, Cristina
  • Spitali, Pietro
BACKGROUND: Duchenne muscular dystrophy (DMD) is a fatal disease for which no cure is available. Clinical trials have shown to be largely underpowered due to inter-individual variability and noisy outcome measures. The availability of biomarkers able to anticipate clinical benefit is highly needed to improve clinical trial design and facilitate drug development. METHODS: In this study, we aimed to appraise the value of protein biomarkers to predict prognosis and monitor disease progression or treatment outcome in patients affected by DMD. We collected clinical data and 303 blood samples from 157 DMD patients in three clinical centres; 78 patients contributed multiple blood samples over time, with a median follow-up time of 2 years. We employed linear mixed models to identify biomarkers that are associated with disease progression, wheelchair dependency, and treatment with corticosteroids and performed survival analysis to find biomarkers whose levels are associated with time to loss of ambulation. RESULTS: Our analysis led to the identification of 21 proteins whose levels significantly decrease with age and nine proteins whose levels significantly increase. Seven of these proteins are also differentially expressed in non-ambulant patients, and three proteins are differentially expressed in patients treated with glucocorticosteroids. Treatment with corticosteroids was found to partly counteract the effect of disease progression on two biomarkers, namely, malate dehydrogenase 2 (MDH2, P = 0.0003) and ankyrin repeat domain 2 (P = 0.0005); however, patients treated with corticosteroids experienced a further reduction on collagen 1 serum levels (P = 0.0003), especially following administration of deflazacort. A time to event analysis allowed to further support the use of MDH2 as a prognostic biomarker as it was associated with an increased risk of wheelchair dependence (P = 0.0003). The obtained data support the prospective evaluation of the identified biomarkers in natural history and clinical trials as exploratory biomarkers. CONCLUSIONS: We identified a number of serum biomarkers associated with disease progression, loss of ambulation, and treatment with corticosteroids. The identified biomarkers are promising candidate prognostic and surrogate biomarkers, which may support drug developers if confirmed in prospective studies. The serum levels of MDH2 are of particular interest, as they correlate with disease stage and response to treatment with corticosteroids, and are also associated with the risk of wheelchair dependency and pulmonary function., We acknowledge the Association Française Contre les Myopathies (grant no. 17724) and the Stichting Duchenne Parent Project for funding this work. We thank all members of the Affinity Proteomics group at SciLifeLab for technical assistance, as well as Prof. Mathias Uhlén and the entire staff of the Human Protein Atlas for their efforts. H.L. received funding by the Medical Research Council (MRC) Centre for Neuromuscular Diseases UK (reference G1002274 and grant ID 98482) and by the European Commission through the projects Neuromics (no. 305121) and RD‐Connect (no. 305444). The authors thank the MRC Centre for Neuromuscular Diseases for its support through the Neuromuscular Disease BioBank and the Muscular Dystrophy UK for its support to the Neuromuscular Centre at UCL. F.M. is supported by the NIHR Great Ormond Street Hospital Biomedical Research Centre; the views expressed in this paper are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. The authors of this manuscript certify that they comply with the ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A Solve-RD ClinVar-based reanalysis of 1522 index cases from ERN-ITHACA reveals common pitfalls and misinterpretations in exome sequencing

  • Denommé-Pichon, Anne-Sophie
  • Matalonga, Leslie
  • Faivre, Laurence
Purpose: Within the Solve-RD project (https://solve-rd.eu/), the European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies aimed to investigate whether a reanalysis of exomes from unsolved cases based on ClinVar annotations could establish additional diagnoses. We present the results of the "ClinVar low-hanging fruit" reanalysis, reasons for the failure of previous analyses, and lessons learned. Methods: Data from the first 3576 exomes (1522 probands and 2054 relatives) collected from European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies was reanalyzed by the Solve-RD consortium by evaluating for the presence of single-nucleotide variant, and small insertions and deletions already reported as (likely) pathogenic in ClinVar. Variants were filtered according to frequency, genotype, and mode of inheritance and reinterpreted. Results: We identified causal variants in 59 cases (3.9%), 50 of them also raised by other approaches and 9 leading to new diagnoses, highlighting interpretation challenges: variants in genes not known to be involved in human disease at the time of the first analysis, misleading genotypes, or variants undetected by local pipelines (variants in off-target regions, low quality filters, low allelic balance, or high frequency). Conclusion: The "ClinVar low-hanging fruit" analysis represents an effective, fast, and easy approach to recover causal variants from exome sequencing data, herewith contributing to the reduction of the diagnostic deadlock., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement number 779257. Data were analyzed using the RD-Connect Genome-Phenome Analysis Platform, which received funding from the EU projects RD-Connect, Solve-RD, and European Joint Programme on Rare Diseases (grant numbers FP7 305444, H2020 779257, H2020 825575), Instituto de Salud Carlos III (grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática), and ELIXIR Implementation Studies. The collaborations in this study were facilitated by the European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies, one of the 24 European Reference Networks approved by the European Reference Network Board of Member States, cofunded by the European Commission. This project was supported by the Czech Ministry of Health (number 00064203) and by the Czech Ministry of Education, Youth and Sports (number - LM2018132) to M.M.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

High diagnostic rate of trio exome sequencing in consanguineous families with neurogenetic diseases

  • Kurul, Semra Hiz
  • Matalonga, Leslie
  • Paramonov, Ida
  • Laurie, Steven, 1973-
  • Beltran, Sergi
  • Lochmüller, Hanns
  • Horvath, Rita
Consanguineous marriages have a prevalence rate of 24% in Turkey. These carry an increased risk of autosomal recessive genetic conditions, leading to severe disability or premature death, with a significant health and economic burden. A definitive molecular diagnosis could not be achieved in these children previously, as infrastructures and access to sophisticated diagnostic options were limited. We studied the cause of neurogenetic disease in 246 children from 190 consanguineous families, recruited in three Turkish hospitals between 2016 and 2020. All patients underwent deep phenotyping and trio whole exome sequencing, and data were integrated in advanced international bioinformatics platforms. We detected causative variants in 119 known disease genes in 72% of families. Due to overlapping phenotypes 52% of the confirmed genetic diagnoses would have been missed on targeted diagnostic gene panels. Likely pathogenic variants in 27 novel genes in 14% of the families increased the diagnostic yield to 86%. Eighty-two% of causative variants (141/172) were homozygous, 11 of which were detected in genes previously only associated with autosomal dominant inheritance. Eight families carried two pathogenic variants in different disease genes. De novo (9.3%), X-linked recessive (5.2%) and compound heterozygous (3.5%) variants were less frequent compared to non-consanguineous populations. This cohort provided a unique opportunity to better understand the genetic characteristics of neurogenetic diseases in a consanguineous population. Contrary to what may be expected, causative variants were often not on the longest run of homozygosity and the diagnostic yield was lower in families with the highest degree of consanguinity, due to the high number of homozygous variants in these patients. Pathway analysis highlighted that protein synthesis/degradation defects and metabolic diseases are the most common pathways underlying paediatric neurogenetic disease. In our cohort 164 families (86%) received a diagnosis, enabling prevention of transmission and targeted treatments in 24 patients (10%). We generated an important body of genomic data with lasting impacts on the health and wellbeing of consanguineous families, and economic benefit for the healthcare system in Turkey and elsewhere. We demonstrate that an untargeted next generation sequencing approach is far superior to a more targeted gene panel approach, and can be performed without specialised bioinformatics knowledge by clinicians using established pipelines in populations with high rates of consanguinity., The project is supported by TUBITAK (The Scientific and Technological Research Council of Turkey) Project No. 216S771. YO is supported by the Turkish Academy of Sciences’ Young Investigator award, TÜBA-GEBİP (2017). PFC is a Wellcome Trust Principal Research Fellow (212219/Z/18/Z), and a UK NIHR Senior Investigator, who receives support from the Medical Research Council Mitochondrial Biology Unit (MC_UU_00015/9), the Leverhulme Trust (RPG-2018-408), an MRC research grant (MR/S035699/1), an Alzheimer's Society Project Grant (AS-PG-18b-022). This research was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). RH was supported by the European Research Council [309548], the Wellcome Investigator Award [109915/Z/15/Z]. the Medical Research Council (UK) [MR/N025431/1]; the Wellcome Trust Pathfinder Scheme [201064/Z/16/Z], the Newton Fund [UK/Turkey, MR/N027302/1], the Lily Foundation and the Evelyn Trust. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). Sequencing and analysis were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant UM1 HG008900 and in part by National Human Genome Research Institute grant R01 HG009141. Data was analysed using the RD-Connect Genome-Phenome Analysis platform developed under FP7/2007-2013 funded project (grant agreement nº 305444) and funding from EJP-RD and INB/ELIXIR-ES. The study was further supported by the Horizon 2020 research and innovation program via grant 779257 “Solve-RD” (RH, SB, AT and HL). RH, PFC and YO were supported by an MRC strategic award to establish an International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD) MR/S005021/1
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Recommendations for improving the quality of rare disease registries

  • Kodra, Yllka
  • Lochmüller, Hanns
  • Taruscio, Domenica
Rare diseases (RD) patient registries are powerful instruments that help develop clinical research, facilitate the planning of appropriate clinical trials, improve patient care, and support healthcare management. They constitute a key information system that supports the activities of European Reference Networks (ERNs) on rare diseases. A rapid proliferation of RD registries has occurred during the last years and there is a need to develop guidance for the minimum requirements, recommendations and standards necessary to maintain a high-quality registry. In response to these heterogeneities, in the framework of RD-Connect, a European platform connecting databases, registries, biobanks and clinical bioinformatics for rare disease research, we report on a list of recommendations, developed by a group of experts, including members of patient organizations, to be used as a framework for improving the quality of RD registries. This list includes aspects of governance, Findable, Accessible, Interoperable and Reusable (FAIR) data and information, infrastructure, documentation, training, and quality audit. The list is intended to be used by established as well as new RD registries. Further work includes the development of a toolkit to enable continuous assessment and improvement of their organizational and data quality., Supported by the RD-CONNECT: an integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research, which received funding from the European Union within the framework of FP7 Collaborative projectHEALTH.2012.2.1.1-1-C [Grant agreement number: 305444]. Supported partly also by EuRRECa: European Registries for Rare Endocrine Conditions, which received funding from the European Union within the framework of CHAFEA Health Programme (2014–2020) [Grant agreement number: 777215] and the COST Action CA16210 “Maximising Impact of research in NeuroDevelopmental Disorders”.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Autosomal recessive variants in TUBGCP2 alter the γ-tubulin ring complex leading to neurodevelopmental disease

  • Gungor, Serdal
  • Aranguren-Ibáñez, Álvaro
  • Laurie, Steven, 1973-
  • Beltran, Sergi
  • Vernos, Isabelle, 1959-
  • Horvath, Rita
Microtubules help building the cytoskeleton of neurons and other cells. Several components of the gamma-tubulin (γ-tubulin) complex have been previously reported in human neurodevelopmental diseases. We describe two siblings from a consanguineous Turkish family with dysmorphic features, developmental delay, brain malformation, and epilepsy carrying a homozygous mutation (p.Glu311Lys) in TUBGCP2 encoding the γ-tubulin complex 2 (GCP2) protein. This variant is predicted to disrupt the electrostatic interaction of GCP2 with GCP3. In primary fibroblasts carrying the variant, we observed a faint delocalization of γ-tubulin during the cell cycle but normal GCP2 protein levels. Through mass spectrometry, we observed dysregulation of multiple proteins involved in the assembly and organization of the cytoskeleton and the extracellular matrix, controlling cellular adhesion and of proteins crucial for neuronal homeostasis including axon guidance. In summary, our functional and proteomic studies link TUBGCP2 and the γ-tubulin complex to the development of the central nervous system in humans., This study was supported by the Turkish Scientific and Research Council (TÜBITAK) research grant 216S771. Y.O. is supported by Turkish Academy of Sciences Young Investigator Programme (TUBA-GEBIP). R.H. is a Wellcome Trust Investigator (109915/Z/15/Z), who receives support from the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), Medical Research Council (UK) (MR/N025431/1), the European Research Council (309548), the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z), the Newton Fund (UK/Turkey, MR/N027302/1), Evelyn Trust, Lily Foundation, and MRC strategic award to establish an International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD, MR/S005021/1). A.R. received financial support by the French Muscular Dystrophy Association (AFM-Téléthon; grant 21466). Sequence analysis was provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics and was funded by the National Human Genome Research Institute (UM1 HG008900 and R01 HG009141) with supplemental funding provided by the National Heart, Lung, and Blood Institute under the Trans-Omics for Precision Medicine (TOPMed) program and the National Eye Institute. I.V. and Á.A.I. were supported by the CRG internal funds, grant 2017 SGR 478 from AGAUR and grant PGC2018-096976-B-I00 from the Spanish ministry of science, innovation and universities. H.L. receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). Data were analyzed using the RD-Connect Genome-Phenome Analysis Platform developed under FP7/2007-2013 funded project (grant agreement nº 305444) and funding from European Joint Programme in Rare Disease (EJP-RD) and INB/ELIXIR-ES
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Solving the genetic aetiology of hereditary gastrointestinal tumour syndromes- a collaborative multicentre endeavour within the project Solve-RD

  • Sommer, Anna K.
  • Te Paske, Iris B.A.W.
  • Garcia-Pelaez, José
  • Laner, Andreas
  • Holinski-Feder, Elke
  • Steinke-Lange, Verena
  • Peters, Sophia
  • Valle, Laura
  • Spier, Isabel
  • Huntsman, David
  • Solve-RD-GENTURIS group
  • Oliveira, Carla
  • de Voer, Richarda M.
  • Hoogerbrugge, Nicoline
  • Aretz, Stefan
Background: Patients and families with suspected, but genetically unexplained (unsolved) genetic tumour risk syndromes lack appropriate treatment and prevention, leading to preventable morbidity and mortality. To tackle this problem, patients from the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS) are analysed in the European Commission's research project "Solving the unsolved rare diseases" (Solve-RD). The aim is to uncover known and novel cancer predisposing genes by reanalysing available whole-exome sequencing (WES) data of large cohorts in a combined manner, and applying a multidimensional omics approach. Approach: Around 500 genetically unsolved cases with suspected hereditary gastrointestinal tumour syndromes (polyposis, early-onset/familial colorectal cancer and gastric cancer) from multiple European centres are aimed to be included. Currently, clinical and germline WES data from 294 cases have been analysed. In addition, an extensive molecular profiling of gastrointestinal tumours from these patients is planned and deep learning techniques will be applied. The ambitious, multidisciplinary project is accompanied by a number of methodical, technical, and logistic challenges, which require the development and implementation of new analysis tools, the standardisation of bioinformatics pipelines, and strategies to exchange data and knowledge. Results: and Outlook. The first re-analysis of 229 known and proposed cancer predisposition genes allowed solving 2-3% of previously unsolved GENTURIS cases. The integration of expert knowledge and new technologies will help to identify the genetic basis of additional unsolved cases within the ongoing project. The ERN GENTURIS approach might serve as a model for other genomic initiatives., This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 779257 (Solve-RD). This study makes use of data shared/provided through RD-Connect, which received funding from the European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement No. 305444.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Phenotypic similarity-based approach for variant prioritization for unsolved rare disease: a preliminary methodological report

  • Lagorce, David
  • Lebreton, Emeline
  • Matalonga, Leslie
  • Hongnat, Oscar
  • Chahdil, Maroua
  • Piscia, Davide
  • Paramonov, Ida
  • Ellwanger, Kornelia
  • Köhler, Sebastian
  • Robinson, Peter N.
  • Graessner, Holm
  • Beltran, Sergi
  • Lucano, Caterina
  • Hanauer, Marc
  • Rath, Ana
Data de publicació electrònica: 06-11-2023, Rare diseases (RD) have a prevalence of not more than 1/2000 persons in the European population, and are characterised by the difficulty experienced in obtaining a correct and timely diagnosis. According to Orphanet, 72.5% of RD have a genetic origin although 35% of them do not yet have an identified causative gene. A significant proportion of patients suspected to have a genetic RD receive an inconclusive exome/genome sequencing. Working towards the International Rare Diseases Research Consortium (IRDiRC)'s goal for 2027 to ensure that all people living with a RD receive a diagnosis within one year of coming to medical attention, the Solve-RD project aims to identify the molecular causes underlying undiagnosed RD. As part of this strategy, we developed a phenotypic similarity-based variant prioritization methodology comparing submitted cases with other submitted cases and with known RD in Orphanet. Three complementary approaches based on phenotypic similarity calculations using the Human Phenotype Ontology (HPO), the Orphanet Rare Diseases Ontology (ORDO) and the HPO-ORDO Ontological Module (HOOM) were developed; genomic data reanalysis was performed by the RD-Connect Genome-Phenome Analysis Platform (GPAP). The methodology was tested in 4 exemplary cases discussed with experts from European Reference Networks. Variants of interest (pathogenic or likely pathogenic) were detected in 8.8% of the 725 cases clustered by similarity calculations. Diagnostic hypotheses were validated in 42.1% of them and needed further exploration in another 10.9%. Based on the promising results, we are devising an automated standardized phenotypic-based re-analysis pipeline to be applied to the entire unsolved cases cohort., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257. This study makes use of data shared/provided through RD-Connect, which received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement No. 305444.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

GNE genotype explains 20% of phenotypic variability in GNE myopathy

  • Pogoryelova, Oksana
  • Wilson, Ian J.
  • Mansbach, Hank
  • Argov, Zohar
  • Nishino, Ichizo
  • Lochmüller, Hanns
Objective: To test the hypothesis that common GNE mutations influence disease severity; using statistical analysis of patient cohorts from different countries. Methods: Systematic literature review identified 11 articles reporting 759 patients. GNE registry data were used as a second data set. The relative contributions of the GNE mutations, homozygosity, and country to the age at onset were explored using linear modeling, and relative importance measures were calculated. The rate of ambulation loss for GNE mutations, homozygosity, country, and age at onset was analyzed using Cox proportional hazards models. Results: A spectrum of symptoms and large variability of age at onset and nonambulatory status was observed within families and cohorts. We estimated that 20% of variability is explained by GNE mutations. Individuals harboring p.Asp207Val have an expected age at onset 8.0 (s.e1.0) years later than those without and probability of continued ambulation at age 40 of 0.98 (95% confidence interval [CI] 0.96–1). In contrast, p.Leu539Ser results in onset on average 7.2 (s.e.2.7) years earlier than those without this mutation, and p.Val603Leu has a probability of continued ambulance of 0.61 (95% CI 0.50–0.74) at age 40, but has a nonsignificant effect on age at onset. Conclusions: GNE myopathy severity significantly varies in all cohorts, with 20% of variability explained by the GNE mutation. Atypical symptoms and clinical presentation suggest that physical and instrumental examination should include additional clinical tests. Proven and measurable effect of GNE mutations on the disease severity should be factored in patient management and clinical research study for a better data interpretation., This work was supported by European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement No. 305444 (RD-Connect) and Medical Research Council UK (reference G1002274, grant ID 98482).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Severe neurodevelopmental disease caused by a homozygous TLK2 variant

  • Topf, Ana
  • Oktay, Yavuz
  • Balaraju, Sunitha
  • Yilmaz, Elmasnur
  • Sonmezler, Ece
  • Yis, Uluc
  • Laurie, Steven, 1973-
  • Thompson, Rachel
  • Roos, Andreas
  • MacArthur, Daniel G.
  • Yaramis, Ahmet
  • Güngör, Serdal
  • Lochmüller, Hanns
  • Hiz, Semra
  • Horvath, Rita
A distinct neurodevelopmental phenotype characterised mainly by mild motor and language delay and facial dysmorphism, caused by heterozygous de novo or dominant variants in the TLK2 gene has recently been described. All cases reported carried either truncating variants located throughout the gene, or missense changes principally located at the C-terminal end of the protein mostly resulting in haploinsufficiency of TLK2. Through whole exome sequencing, we identified a homozygous missense variant in TLK2 in a patient showing more severe symptoms than those previously described, including cerebellar vermis hypoplasia and West syndrome. Both parents are heterozygous for the variant and clinically unaffected highlighting that recessive variants in TLK2 can also be disease causing and may act through a different pathomechanism., The project is supported by TUBITAK (The Scientific and Technological Research Council of Turkey) Project No. 216S771. RH is a Wellcome Trust Investigator (109915/Z/15/Z), who receives support from the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), Medical Research Council (UK) (MR/N025431/1), the European Research Council (309548), the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z) and the Newton Fund (UK/Turkey, MR/N027302/1). The Broad Centre for Mendelian Genomics (UM1 HG008900) is funded by the National Human Genome Research Institute with supplemental funding provided by the National Heart, Lung, and Blood Institute under the Trans-Omics for Precision Medicine (TOPMed) programme and the National Eye Institute. Data were analysed using the RD-Connect Genome-Phenome Analysis platform developed under FP7/2007-2013 funded project (grant agreement no. 305444)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Mutations in glycyl-tRNA synthetase impair mitochondrial metabolism in neurons

  • Boczonadi, Veronika
  • Meyer, Kathrin
  • Gonczarowska-Jorge, Humberto
  • Griffin, Helen
  • Roos, Andreas
  • Bartsakoulia, Marina
  • Bansagi, Boglarka
  • Ricci, Giulia
  • Palinkas, Fanni
  • Zahedi, René P.
  • Bruni, Francesco
  • Kaspar, Brian
  • Lochmüller, Hanns
  • Boycott, Kym M.
  • Müller, Juliane
  • Horvath, Rita
The nuclear-encoded glycyl-tRNA synthetase gene (GARS) is essential for protein translation in both cytoplasm and mitochondria. In contrast, different genes encode the mitochondrial and cytosolic forms of most other tRNA synthetases. Dominant GARS mutations were described in inherited neuropathies, while recessive mutations cause severe childhood-onset disorders affecting skeletal muscle and heart. The downstream events explaining tissue-specific phenotype-genotype relations remained unclear. We investigated the mitochondrial function of GARS in human cell lines and in the GarsC210R mouse model. Human-induced neuronal progenitor cells (iNPCs) carrying dominant and recessive GARS mutations showed alterations of mitochondrial proteins, which were more prominent in iNPCs with dominant, neuropathy-causing mutations. Although comparative proteomic analysis of iNPCs showed significant changes in mitochondrial respiratory chain complex subunits, assembly genes, Krebs cycle enzymes and transport proteins in both recessive and dominant mutations, proteins involved in fatty acid oxidation were only altered by recessive mutations causing mitochondrial cardiomyopathy. In contrast, significant alterations of the vesicle-associated membrane protein-associated protein B (VAPB) and its downstream pathways such as mitochondrial calcium uptake and autophagy were detected in dominant GARS mutations. The role of VAPB has been supported by similar results in the GarsC210R mice. Our data suggest that altered mitochondria-associated endoplasmic reticulum (ER) membranes (MAM) may be important disease mechanisms leading to neuropathy in this condition., R.H. is a Wellcome Investigator (109915/Z/15/Z) supported by the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), who receives support from the Medical Research Council (UK) (MR/N025431/1), the European Research Council (309548) and the Mitochondrial European Educational Training (MEET), ITN MARIE CURIE PEOPLE, (317433). H.L. receives funding from the European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement No. 305444 (RD-Connect), 305121 (Neuromics), the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z) and the Newton Fund (UK/Turkey, MR/N027302/1). H.J.G., A.R. and R.P.Z. acknowledge the financial support by the Ministeriumfür Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen, the SenatsverwaltungfürWirtschaft, Technologie und Forschung des Landes Berlin, and the BundesministeriumfürBildung und Forschung. H.G.J. further thanks the CAPES Foundation for financial support.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A mosaic PIK3CA variant in a young adult with diffuse gastric cancer: case report

  • Te Paske, Iris B.A.W.
  • Garcia-Pelaez, José
  • Sommer, Anna K.
  • Matalonga, Leslie
  • Starzynska, Teresa
  • Jakubowska, Anna
  • Solve-RD-GENTURIS group
  • van der Post, Rachel S.
  • Lubinski, Jan
  • Oliveira, Carla
  • Hoogerbrugge, Nicoline
  • de Voer, Richarda M.
Hereditary diffuse gastric cancer (HDGC) is associated with germline deleterious variants in CDH1 and CTNNA1. The majority of HDGC-suspected patients are still genetically unresolved, raising the need for identification of novel HDGC predisposing genes. Under the collaborative environment of the SOLVE-RD consortium, re-analysis of whole-exome sequencing data from unresolved gastric cancer cases (n = 83) identified a mosaic missense variant in PIK3CA in a 25-year-old female with diffuse gastric cancer (DGC) without familial history for cancer. The variant, c.3140A>G p.(His1047Arg), a known cancer-related somatic hotspot, was present at a low variant allele frequency (18%) in leukocyte-derived DNA. Somatic variants in PIK3CA are usually associated with overgrowth, a phenotype that was not observed in this patient. This report highlights mosaicism as a potential, and understudied, mechanism in the etiology of DGC., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257. The research work at i3S/Ipatimup is supported by the European Regional Development Fund (ERDF) through COMPETE 2020 - Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020, and by Portuguese funds through FCT/ Ministério da Ciência, Tecnologia e Inovação in the framework of the project “Institute for Research and Innovation in Health Sciences” (POCI-01-0145-FEDER-007274) and Project Ref. POCI-01-0145-FEDER-030164. Data was reanalysed using the RD‐Connect Genome‐Phenome Analysis Platform, which received funding from EU projects RD‐Connect, Solve-RD and EJP-RD (grant numbers FP7 305444, H2020 779257, H2020 825575), Instituto de Salud Carlos III (grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB) and ELIXIR Implementation Studies.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion

  • McMacken, Grace M.
  • Lochmüller, Hanns
  • Bansagi, Boglarka
  • Pyle, Angela
  • Lochmüller, Angela
  • Chinnery, Patrick F.
  • Laurie, Steven, 1973-
  • Beltran, Sergi
  • Matalonga, Leslie
  • Horvath, Rita
Background: Behr syndrome is a clinically distinct, but genetically heterogeneous disorder characterized by optic atrophy, progressive spastic paraparesis, and motor neuropathy often associated with ataxia. The molecular diagnosis is based on gene panel testing or whole-exome/genome sequencing. Methods: Here, we report the clinical presentation of two siblings with a novel genetic form of Behr syndrome. We performed whole-exome sequencing in the two patients and their mother. Results: Both patients had a childhood-onset, slowly progressive disease resembling Behr syndrome, starting with visual impairment, followed by progressive spasticity, weakness, and atrophy of the lower legs and ataxia. They also developed scoliosis, leading to respiratory problems. In their late 30's, both siblings developed a hypertrophic cardiomyopathy and died of sudden cardiac death at age 43 and 40, respectively. Whole-exome sequencing identified the novel homozygous c.627_629del; p.(Gly210del) deletion in UCHL1. Conclusions: The presentation of our patients raises the possibility that hypertrophic cardiomyopathy may be an additional feature of the clinical syndrome associated with UCHL1 mutations, and highlights the importance of cardiac follow-up and treatment in neurodegenerative disease associated with UCHL1 mutations., The study was supported by the Newton Fund UK/Turkey (MR/N027302/1 to HL and RH), the Medical Research Council (UK) (MR/N025431/1 to RH), the Wellcome Investigator fund (109915/Z/15/Z to RH), the Lily Foundation UK (to RH), the European Research Council (309548 to RH), and the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z to HL and RH). HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). The study was further supported by the Horizon 2020 research and innovation program via grant 779257 “Solve-RD”. Data were analyzed using the RD-Connect Genome-Phenome Analysis platform developed under FP7/2007-2013 funded project (grant agreement no. 305444).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Improved diagnosis of rare disease patients through systematic detection of runs of homozygosity

  • Matalonga, Leslie
  • Laurie, Steven, 1973-
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Mereu, Elisabetta
  • Bullich, Gemma
  • Thompson, Rachel
  • Horvath, Rita
  • Pérez Jurado, Luis Alberto
  • Riess, Olaf
  • Gut, Ivo Glynne
  • van Ommen, Gert-Jan
  • Lochmüller, Hanns
  • Beltran, Sergi
  • RD–Connect Genome-Phenome Analysis Platform and URD-Cat Data Contributors
Autozygosity is associated with an increased risk of genetic rare disease, thus being a relevant factor for clinical genetic studies. More than 2400 exome sequencing data sets were analyzed and screened for autozygosity on the basis of detection of >1 Mbp runs of homozygosity (ROHs). A model was built to predict if an individual is likely to be a consanguineous offspring (accuracy, 98%), and probability of consanguinity ranges were established according to the total ROH size. Application of the model resulted in the reclassification of the consanguinity status of 12% of the patients. The analysis of a subset of 79 consanguineous cases with the Rare Disease (RD)-Connect Genome-Phenome Analysis Platform, combining variant filtering and homozygosity mapping, enabled a 50% reduction in the number of candidate variants and the identification of homozygous pathogenic variants in 41 patients, with an overall diagnostic yield of 52%. The newly defined consanguinity ranges provide, for the first time, specific ROH thresholds to estimate inbreeding within a pedigree on disparate exome sequencing data, enabling confirmation or (re)classification of consanguineous status, hence increasing the efficiency of molecular diagnosis and reporting on secondary consanguinity findings, as recommended by American College of Medical Genetics and Genomics guidelines., Supported by European Union projects RD-Connect, Solve-RD, and European Joint Programme of Rare Diseases (EJP-RD) grants FP7 305444, H2020 779257, and H2020 825575; Instituto de Salud Carlos III grants PT13/0001/0044 and PT17/0009/0019; Instituto Nacional de Bioinformática; ELIXIR Implementation Studies; European Union projects BBMRI-LPC EU FP7 313010, NeurOmics EU FP7 305121, and Undiagnosed Rare Disease Program of Catalonia (Departament de Salut, Generalitat de CatalunyaSLT002/16/00174); Canadian Institutes of Health Research Foundation grant FDN-167281 (H.L.); the European Research Council309548 (R.H.); the Wellcome Investigator Award 109915/Z/15/Z (R.H.); the Medical Research Council (United Kingdom) MR/N025431/1 (R.H.); the Wellcome Trust Pathfinder Scheme 201064/Z/16/Z (R.H. and H.L.); the Newton Fund (United Kingdom/Turkey) MR/N027302/1 (R.H. and H.L.); the Spanish Ministry of Economy, Industry and Competitiveness to the European Molecular Biology Laboratory (EMBL) partnership; the Centro de Excelencia Severo Ochoa; the Centres de Recerca de Catalunya (CERCA) Program/Generalitat de Catalunya; the Generalitat de Catalunya through the Department of Health and Department of Business and Knowledge; the Spanish Ministry of Economy, Industry and Competitiveness with funds from the European Regional Development Fund corresponding to the 2014 to 2020 Smart Growth Operating Program.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The European Genome-phenome Archive of human data consented for biomedical research

  • Lappalainen, Ilkka
  • Carreño Torres, Angel
  • Rambla de Argila, Jordi
  • Martinez Llobet, Oscar
  • Sitges Puy, Marc
  • Alberich, Mario
  • Torre, Sabela de la
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Flicek, Paul
The European Genome-phenome Archive (EGA) is a permanent archive that promotes the distribution and sharing of genetic and phenotypic data consented for specific approved uses but not fully open, public distribution. The EGA follows strict protocols for information management, data storage, security and dissemination. Authorized access to the data is managed in partnership with the data-providing organizations. The EGA includes major reference data collections for human genetics research., The EGA has received support from the European Molecular Biology Laboratory, the European Union ELIXIR Technical Feasibility Study, the Wellcome Trust (grant WT 085475/C/08/Z), the UK Medical Research Council (grant G0800681), the Spanish Instituto de Salud Carlos III Instituto Nacional de Bioinformática (grant PT13/0001/0026), the Spanish Ministerio de Economía y Competitividad (MINECO) and Centro de Excelencia Severo Ochoa (grant SEV-2012-0208), the Fundació La Caixa and the Barcelona Supercomputing Centre. The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013 under grant agreements 211601–ELIXIR, 200754–GEN2PHEN, 262055–ESGI, 242006–BASIS, 261376–IHMS and 305444–RD-CONNECT).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Targeted therapies for congenital myasthenic syndromes: systematic review and steps towards a treatabolome

  • Thompson, Rachel
  • Bonne, Gisèle
  • Missier, Paolo
  • Lochmüller, Hanns
Despite recent scientific advances, most rare genetic diseases - including most neuro-muscular diseases - do not currently have curative gene-based therapies available. However, in some cases, such as vitamin, cofactor or enzyme deficiencies, channelopathies and disorders of the neuromuscular junction, a confirmed genetic diagnosis provides guidance on treatment, with drugs available that may significantly alter the disease course, improve functional ability and extend life expectancy. Nevertheless, many treatable patients remain undiagnosed or do not receive treatment even after genetic diagnosis. The growth of computer-aided genetic analysis systems that enable clinicians to diagnose their undiagnosed patients has not yet been matched by genetics-based decision-support systems for treatment guidance. Generating a 'treatabolome' of treatable variants and the evidence for the treatment has the potential to increase treatment rates for treatable conditions. Here, we use the congenital myasthenic syndromes (CMS), a group of clinically and genetically heterogeneous but frequently treatable neuromuscular conditions, to illustrate the steps in the creation of a treatabolome for rare inherited diseases. We perform a systematic review of the evidence for pharmacological treatment of each CMS type, gathering evidence from 207 studies of over 1000 patients and stratifying by genetic defect, as treatment varies depending on the underlying cause. We assess the strength and quality of the evidence and create a dataset that provides the foundation for a computer-aided system to enable clinicians to gain easier access to information about treatable variants and the evidence they need to consider., H.L. and R.T. received support from the EU under RD-Connect [FP7 Grant Agreement No. 305444] and the U.K. Medical Research Council [G1002274/98482]. G.B. receives support under the Solve-RD project, which has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 779257 [H2020 Grant Agreement No. 779257].
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A novel, pathogenic dinucleotide deletion in the mitochondrial MT-TY gene causing myasthenia-like features

  • Lim, Albert Z.
  • McMacken, Grace M.
  • Rastelli, Francesca
  • Oláhová, Monika
  • Baty, Karen
  • Hopton, Sila
  • Falkous, Gavin
  • Töpf, Ana
  • Lochmüller, Hanns
  • Marini-Bettolo, Chiara
  • McFarland, Robert
  • Taylor, Robert W.
Mitochondrial DNA (mtDNA)-related diseases often pose a diagnostic challenge and require rigorous clinical and laboratory investigation. Pathogenic variants in the mitochondrial tRNA gene MT-TY, which encodes the tRNATyr, are a rare cause of mitochondrial disease. Here we describe a novel m.5860delTA anticodon variant in the MT-TY gene in a patient who initially presented with features akin to a childhood onset myasthenic syndrome. Using histochemical, immunohistochemical and protein studies we demonstrate that this mutation leads to severe biochemical defects of mitochondrial translation, which is reflected in the early onset and progressive phenotype. This case highlights the clinical overlap between mtDNA-related diseases and other neuromuscular disorders, and demonstrates the potential pitfalls in analysis of next generation sequencing results, given whole exome sequencing of a blood DNA sample failed to make a genetics diagnosis. Muscle biopsy remains an important requirement in the diagnosis of mitochondrial disease and in establishing the pathogenicity of novel mtDNA variants., AL, RM and RWT are supported by the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z); RM and RWT also receive support from the Medical Research Council (MRC) International Centre for Genomic Medicine in Neuromuscular Disease, the Mitochondrial Disease Patient Cohort (UK) (G0800674), Newcastle University Centre for Ageing and Vitality (supported by the Biotechnology and Biological Sciences Research Council and Medical Research Council L016354), UK NIHR Biomedical Research Centre for Ageing and Age-related disease award to the Newcastle upon Tyne Hospitals NHS Foundation Trust, the Lily Foundation and the UK NHS Specialist Commissioners which funds the “Rare Mitochondrial Disorders of Adults and Children” Diagnostic Service in Newcastle upon Tyne (http://www.newcastle-mitochondria.com/). GM is supported by the Association of British Neurologists Clinical Research Training Fellowship. Biobanking and Biomedical Resources Research Infrastructure ‐ large prospective cohorts (BBMRI‐LPC) 2016 access call for Whole Exome Sequencing (FP7/2007‐2013), Grant Number: 313010. Data were analyzed using the RD‐Connect Genome‐Phenome Analysis platform developed under FP7/2007‐2013 funded project, Grant Number: 305444.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The RD-Connect Genome-Phenome Analysis Platform: Accelerating diagnosis, research, and gene discovery for rare diseases

  • Laurie, Steven, 1973-
  • Piscia, Davide
  • Matalonga, Leslie
  • Corvò, Alberto
  • Fernández Callejo, Marcos
  • Garcia-Linares, Carles
  • Hernandez-Ferrer, Carles, 1987-
  • Luengo, Cristina
  • Martínez, Inés
  • Papakonstantinou, Anastasios
  • Picó-Amador, Daniel
  • Protasio, Joan
  • Tonda, Raúl
  • Bayés, Mònica
  • Bullich, Gemma
  • Camps-Puchadas, Jordi
  • Paramonov, Ida
  • Trotta, Jean-Remi
  • Pérez Jurado, Luis Alberto
  • Rambla de Argila, Jordi
  • Gut, Ivo Glynne
  • Lochmüller, Hanns
  • Beltran, Sergi
Rare disease patients are more likely to receive a rapid molecular diagnosis nowadays thanks to the wide adoption of next-generation sequencing. However, many cases remain undiagnosed even after exome or genome analysis, because the methods used missed the molecular cause in a known gene, or a novel causative gene could not be identified and/or confirmed. To address these challenges, the RD-Connect Genome-Phenome Analysis Platform (GPAP) facilitates the collation, discovery, sharing, and analysis of standardized genome-phenome data within a collaborative environment. Authorized clinicians and researchers submit pseudonymised phenotypic profiles encoded using the Human Phenotype Ontology, and raw genomic data which is processed through a standardized pipeline. After an optional embargo period, the data are shared with other platform users, with the objective that similar cases in the system and queries from peers may help diagnose the case. Additionally, the platform enables bidirectional discovery of similar cases in other databases from the Matchmaker Exchange network. To facilitate genome-phenome analysis and interpretation by clinical researchers, the RD-Connect GPAP provides a powerful user-friendly interface and leverages tens of information sources. As a result, the resource has already helped diagnose hundreds of rare disease patients and discover new disease causing genes., We acknowledge the support of the developers of PhenoTips, which was used in the past by RD-Connect and NeurOmics as the primary tool to collate phenotypic data. We would also like to thank the leaders and members of the Instituto Nacional de Bioinformática (INB) and ELIXIR for their support and collaboration throughout the years. RD-Connect (RD-Connect, an integrated platform connecting registries, biobanks, and clinical bioinformatics) received funding from the Seventh Framework (FP7) Programme of the European Union under grant agreement No 305444. Data were analyzed using the RD-Connect GPAP, which received funding from EU projects Solve-RD, EJP-RD (grant numbers H2020 779257, H2020 825575), Instituto de Salud Carlos III (Grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB), ELIXIR-EXCELERATE (Grant number EU H2020 #676559) and ELIXIR Implementation Studies (Remote real-time visualization of human rare disease genomics data (RD-Connect) stored at the EGA ELIXIR. 2017-2018; ELIXIR IT-2017-INTEGRATION, Rare Disease Infrastructure ELIXIR, 2019-2020 and the Beacon ELIXIR, 2019-2021). The RD-Connect GPAP has leveraged developments funded through project VEIS (001-P-001647 co-financed by the European Regional Development Fund of the European Union in the framework of the Operational Program FEDER of Catalonia 2014-2020 with the support of the Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement de la Generalitat de Catalunya) and URD-Cat (PERIS SLT002/16/00174, Departament de Salut, Generalitat de Catalunya). The research leading to these results has received funding from Consequitur (Newton Fund UK/Turkey, MR/N027302/1), BBMRI-LPC (EU FP7 #313010), NeurOmics (EU FP7 #305121), the Economic Development Department of the Navarra Government (Grant number 001114112017), the European Reference Network for Rare Neurological Diseases (Project ID number 739510) and NIH, National Institute of Child Health and Human Development (1R01HD103805-01). We acknowledge the support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program/Generalitat de Catalunya. We also acknowledge the support of the Generalitat de Catalunya through Departament de Salut and Departament d'Empresa i Coneixement and Co-financing by the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) with funds from the European Regional Development Fund (ERDF) corresponding to the 2014-2020 Smart Growth Operating Program. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Systematic collaborative reanalysis of genomic data improves diagnostic yield in neurologic rare diseases

  • Bullich, Gemma
  • Matalonga, Leslie
  • Pujadas, Montserrat
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Tonda, Raúl
  • González, Juan Ramón
  • Laurie, Steven, 1973-
  • Luengo, Cristina
  • Ovelleiro, David
  • Parra Farré, Genís
  • Pérez Jurado, Luis Alberto
  • Beltran, Sergi
  • Undiagnosed Rare Disease Program of Catalonia (URD-Cat) Consortium
Many patients experiencing a rare disease remain undiagnosed even after genomic testing. Reanalysis of existing genomic data has shown to increase diagnostic yield, although there are few systematic and comprehensive reanalysis efforts that enable collaborative interpretation and future reinterpretation. The Undiagnosed Rare Disease Program of Catalonia project collated previously inconclusive good quality genomic data (panels, exomes, and genomes) and standardized phenotypic profiles from 323 families (543 individuals) with a neurologic rare disease. The data were reanalyzed systematically to identify relatedness, runs of homozygosity, consanguinity, single-nucleotide variants, insertions and deletions, and copy number variants. Data were shared and collaboratively interpreted within the consortium through a customized Genome-Phenome Analysis Platform, which also enables future data reinterpretation. Reanalysis of existing genomic data provided a diagnosis for 20.7% of the patients, including 1.8% diagnosed after the generation of additional genomic data to identify a second pathogenic heterozygous variant. Diagnostic rate was significantly higher for family-based exome/genome reanalysis compared with singleton panels. Most new diagnoses were attributable to recent gene-disease associations (50.8%), additional or improved bioinformatic analysis (19.7%), and standardized phenotyping data integrated within the Undiagnosed Rare Disease Program of Catalonia Genome-Phenome Analysis Platform functionalities (18%)., Supported by Generalitat de Catalunya through Departament de Salut (SLT002/16/00174 to URD-Cat consortium) and Departament d’Empresa i Coneixement and the CERCA Program; FP7 and H2020 EU projects RD-Connect, Solve-RD, and EJP-RD grants FP7 305444, H2020 779257, and H2020 825575 for CNAG-CRG; Spanish Ministry of Science and Innovation to the EMBL partnership and through the Instituto de Salud Carlos III grants PT13/0001/0044 and PT17/0009/0019 for CNAG-CRG and grants PI16/01048, PI19/01310, PI18/00451, PI18/00498, and PI21/00935 for IDIBAPS (Instituto Nacional de Bioinformática); ELIXIR Implementation Studies (CNAG-CRG); Centro de Investigaciones Biomédicas en Red de Enfermedades Raras; Centro de Excelencia Severo Ochoa grant SEV-2016-0571 (CNAG-CRG) and grant CEX 2018-000806-S (ISGLOBAL); and cofinancing with funds from the European Regional Development Fund by the Spanish Ministry of Science and Innovation corresponding to the Programa Operativo FEDER Plurirregional de España (POPE) 2014 to 2020 and by the Secretaria d’Universitats i Recerca, Departament d’Empresa i Coneixement of the Generalitat de Catalunya corresponding to the Programa Operatiu FEDER de Catalunya 2014 to 2020.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

GNE myopathy: from clinics and genetics to pathology and research strategies

  • Pogoryelova, Oksana
  • González Coraspe, José Andrés
  • Nikolenko, Nikoletta
  • Lochmüller, Hanns
  • Roos, Andreas
GNE myopathy is an ultra-rare autosomal recessive disease, which starts as a distal muscle weakness and ultimately leads to a wheelchair bound state. Molecular research and animal modelling significantly moved forward understanding of GNE myopathy mechanisms and suggested therapeutic interventions to alleviate the symptoms. Multiple therapeutic attempts are being made to supplement sialic acid depleted in GNE myopathy muscle cells. Translational research field provided valuable knowledge through natural history studies, patient registries and clinical trial, which significantly contributed to bringing forward an era of GNE myopathy treatment. In this review, we are summarising current GNE myopathy, scientific trends and open questions, which would be of significant interest for a wide neuromuscular diseases community., We gratefully acknowledge the financial support from the Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen. Work by the authors has been supported by the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement No. 305444 (RD-Connect) and 305121 (NeurOmics). This work was further supported by a grant from the DGM (Deutsche Gesellschaft für Muskelkranke).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

GFPT1 deficiency in muscle leads to myasthenia and myopathy in mice

  • Issop, Yasmin
  • Hathazi, Denisa
  • Khan, Muzamil Majid
  • Rudolf, Rüdiger
  • Weis, Joachim
  • Spendiff, Sally
  • Slater, Clarke R.
  • Roos, Andreas
  • Lochmüller, Hanns
Glutamine-fructose-6-phosphate transaminase 1 (GFPT1) is the rate-limiting enzyme in the hexosamine biosynthetic pathway which yields precursors required for protein and lipid glycosylation. Mutations in GFPT1 and other genes downstream of this pathway cause congenital myasthenic syndrome (CMS) characterized by fatigable muscle weakness owing to impaired neurotransmission. The precise pathomechanisms at the neuromuscular junction (NMJ) owing to a deficiency in GFPT1 is yet to be discovered. One of the challenges we face is the viability of Gfpt1-/- knockout mice. In this study, we use Cre/LoxP technology to generate a muscle-specific GFPT1 knockout mouse model, Gfpt1tm1d/tm1d, characteristic of the human CMS phenotype. Our data suggest a critical role for muscle derived GFPT1 in the development of the NMJ, neurotransmission, skeletal muscle integrity and highlight that a deficiency in skeletal muscle alone is sufficient to cause morphological postsynaptic NMJ changes that are accompanied by presynaptic alterations despite the conservation of neuronal GFPT1 expression. In addition to the conventional morphological NMJ changes and fatigable muscle weakness, Gfpt1tm1d/tm1d mice display a progressive myopathic phenotype with the presence of tubular aggregates in muscle, characteristic of the GFPT1-CMS phenotype. We further identify an upregulation of skeletal muscle proteins glypican-1, farnesyltransferase/geranylgeranyltransferase type-1 subunit α and muscle-specific kinase, which are known to be involved in the differentiation and maintenance of the NMJ. The Gfpt1tm1d/tm1d model allows for further investigation of pathophysiological consequences on genes and pathways downstream of GFPT1 likely to involve misglycosylation or hypoglycosylation of NMJs and muscle targets., This work was supported by a studentship of The Barbour Foundation and the Medical Research Council (UK) to Y.I.; the Medical Research Council as part of the MRC Centre for Neuromuscular Diseases (reference G1002274, grant ID 98482), a Wellcome Trust Pathfinder Award (201064/Z/16/Z) to H.L.; the European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement No. 305444 (RD-Connect) and 305121 (NeurOmics) to H.L.; an award from the French Muscular Dystrophy Association (AFM-Téléthon) No. 20870 to H.L.; the German Research Fund (RU923/8-2) to R.R., and by the Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen, the Senatsverwaltung für Wirtschaft, Technologie und Forschung des Landes Berlin, and the Bundesministerium für Bildung und Forschung. Funding to pay the Open Access publication charges for this article was provided by The Medical Research Council (MRC).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Clinical manifestations in a girl with NAA10-related syndrome and genotype-phenotype correlation in females

  • Maini, Ilenia
  • Caraffi, Stefano G.
  • Peluso, Francesca
  • Valeri, Lara
  • Nicoli, Davide
  • Laurie, Steven, 1973-
  • Baldo, Chiara
  • Zuffardi, Orsetta
  • Garavelli, Livia
Since 2011, eight males with an X-linked recessive disorder (Ogden syndrome, MIM #300855) associated with the same missense variant p.(Ser37Pro) in the NAA10 gene have been described. After the advent of whole exome sequencing, many NAA10 variants have been reported as causative of syndromic or non-syndromic intellectual disability in both males and females. The NAA10 gene lies in the Xq28 region and encodes the catalytic subunit of the major N-terminal acetyltransferase complex NatA, which acetylates almost half the human proteome. Here, we present a young female carrying a de novo NAA10 [NM_003491:c.247C > T, p.(Arg83Cys)] variant. The 18-year-old girl has severely delayed motor and language development, autistic traits, postnatal growth failure, facial dysmorphisms, interventricular septal defect, neuroimaging anomalies and epilepsy. Our attempt is to expand and compare genotype-phenotype correlation in females with NAA10-related syndrome. A detailed clinical description could have relevant consequences for the clinical management of known and newly identified individuals., This work has received funding from the European Community’s Seventh Framework Program (FP7/2007–2013) under grant agreement n 305444 “RD-CONNECT: An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research”.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Novel insights into PORCN mutations, associated phenotypes and pathophysiological aspects

  • Arlt, Annabelle
  • Kohlschmidt, Nicolai
  • Hentschel, Andreas
  • Bartels, Enrika
  • Groß, Claudia
  • Töpf, Ana
  • Edem, Pinar
  • Szabo, Nora
  • Sickmann, Albert
  • Meyer, Nancy
  • Schara-Schmidt, Ulrike
  • Lau, Jarred
  • Lochmüller, Hanns
  • Horvath, Rita
  • Oktay, Yavuz
  • Roos, Andreas
  • Hiz, Semra
Background: Goltz syndrome (GS) is a X-linked disorder defined by defects of mesodermal- and ectodermal-derived structures and caused by PORCN mutations. Features include striated skin-pigmentation, ocular and skeletal malformations and supernumerary or hypoplastic nipples. Generally, GS is associated with in utero lethality in males and most of the reported male patients show mosaicism (only three non-mosaic surviving males have been described so far). Also, precise descriptions of neurological deficits in GS are rare and less severe phenotypes might not only be caused by mosaicism but also by less pathogenic mutations suggesting the need of a molecular genetics and functional work-up of these rare variants. Results: We report two cases: one girl suffering from typical skin and skeletal abnormalities, developmental delay, microcephaly, thin corpus callosum, periventricular gliosis and drug-resistant epilepsy caused by a PORCN nonsense-mutation (c.283C > T, p.Arg95Ter). Presence of these combined neurological features indicates that CNS-vulnerability might be a guiding symptom in the diagnosis of GS patients. The other patient is a boy with a supernumerary nipple and skeletal anomalies but also, developmental delay, microcephaly, cerebral atrophy with delayed myelination and drug-resistant epilepsy as predominant features. Skin abnormalities were not observed. Genotyping revealed a novel PORCN missense-mutation (c.847G > C, p.Asp283His) absent in the Genome Aggregation Database (gnomAD) but also identified in his asymptomatic mother. Given that non-random X-chromosome inactivation was excluded in the mother, fibroblasts of the index had been analyzed for PORCN protein-abundance and -distribution, vulnerability against additional ER-stress burden as well as for protein secretion revealing changes. Conclusions: Our combined findings may suggest incomplete penetrance for the p.Asp283His variant and provide novel insights into the molecular etiology of GS by adding impaired ER-function and altered protein secretion to the list of pathophysiological processes resulting in the clinical manifestation of GS., Open Access funding enabled and organized by Projekt DEAL. We gratefully acknowledge the financial support by the Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen and the Bundesministerium für Bildung und Forschung. This work was also supported by a Grant of the French Muscular Dystrophy Association (AFM-Téléthon) (#21466) to AR. Parts of this study were financed in the framework of the NME-GPS project by the European Regional Development Fund (ERDF). The project is supported by TUBITAK (The Scientific and Technological Research Council of Turkey) Project No. 216S771. RH was supported by the European Research Council [309548], the Wellcome Investigator Award [109915/Z/15/Z]. The Medical Research Council (UK) [MR/N025431/1]; the Wellcome Trust Pathfinder Scheme [201064/Z/16/Z], the Newton Fund [UK/Turkey, MR/N027302/1], the Lily Foundation and the Evelyn Trust. Sequencing and analysis of patient 2 were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute Grant UM1 HG008900 and in part by National Human Genome Research Institute Grant R01 HG009141. Sequencing of patient 1 was carried out through the Biobanking and Biomedical Resources Research Infrastructure ‐ large prospective cohorts (BBMRI‐LPC) 2016 access call for Whole Exome Sequencing (FP7/2007‐2013), Grant Number: 313010. Data was analyzed using the RD‐Connect Genome‐Phenome Analysis platform developed under FP7/2007‐2013 funded project, Grant Number: 305444. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). The study was further supported by the Horizon 2020 research and innovation program via Grant 779257 “Solve-RD” (RH and HL). USS, RH and HL are members of the European Reference Network for Rare Neuromuscular Diseases (EURO-NMD). YO is supported by the Turkish Academy of Sciences’ Young Investigator Award (TÜBA-GEBIP).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Consent codes: upholding standard data use conditions

  • Dyke, Stephanie O. M.
  • Philippakis, Anthony A.
  • Rambla de Argila, Jordi
  • Paltoo, Dina N.
  • Luetkemeier, Erin S.
  • Knoppers, Bartha M.
  • Brookes, Anthony J.
  • Spalding, J. Dylan
  • Thompson, Mark
  • Roos, Marco
  • Boycott, Kym M.
  • Brudno, Michael
  • Hurles, Matthew
  • Rehm, Heidi L.
  • Matern, Andreas
  • Fiume, Marc
  • Sherry, Stephen T.
A systematic way of recording data use conditions that are based on consent permissions as found in the datasets of the main public genome archives (NCBI dbGaP and EMBL-EBI/CRG EGA)., SOMD is supported by the Canadian Institutes of Health Research (grants EP1-120608; EP2-120609), the Canada Research Chair in Law and Medicine, and the Public Population Project in Genomics and Society (P3G). DNP and ESL are supported, in part, by the Intramural Research Program of the NIH, Office of the Director, Office of Science Policy. BMK is supported by the Canada Research Chairs Program. MT and MR are sponsored by ODEX4all (NWO 650.002.002) and funding from the European Commission (FP-7 project RD-Connect, grant agreement No. 305444)
Repisalud
Publicación Artículo científico (JournalArticle)

Improved Diagnosis of Rare Disease Patients through Systematic Detection of Runs of Homozygosity

  • Matalonga, Leslie
  • Laurie, Steven
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Mereu, Elisabetta
  • Bullich, Gemma
  • Thompson, Rachel
  • Horvath, Rita
  • Pérez-Jurado, Luis Alberto
  • Riess, Olaf
  • Gut, Ivo
  • van Ommen, Gert-Jan
  • Lochmüller, Hanns
  • Beltran, Sergi
  • RD–Connect Genome-Phenome Analysis Platform
  • URD-Cat Data Contributors
  • Posada De la Paz, Manuel
Autozygosity is associated with an increased risk of genetic rare disease, thus being a relevant factor for clinical genetic studies. More than 2400 exome sequencing data sets were analyzed and screened for autozygosity on the basis of detection of >1 Mbp runs of homozygosity (ROHs). A model was built to predict if an individual is likely to be a consanguineous offspring (accuracy, 98%), and probability of consanguinity ranges were established according to the total ROH size. Application of the model resulted in the reclassification of the consanguinity status of 12% of the patients. The analysis of a subset of 79 consanguineous cases with the Rare Disease (RD)-Connect Genome-Phenome Analysis Platform, combining variant filtering and homozygosity mapping, enabled a 50% reduction in the number of candidate variants and the identification of homozygous pathogenic variants in 41 patients, with an overall diagnostic yield of 52%. The newly defined consanguinity ranges provide, for the first time, specific ROH thresholds to estimate inbreeding within a pedigree on disparate exome sequencing data, enabling confirmation or (re)classification of consanguineous status, hence increasing the efficiency of molecular diagnosis and reporting on secondary consanguinity findings, as recommended by American College of Medical Genetics and Genomics guidelines.
Repisalud
Publicación Artículo científico (JournalArticle)

Clinical Outcomes in Duchenne Muscular Dystrophy: A Study of 5345 Patients from the TREAT-NMD DMD Global Database

  • Koeks, Zaïda
  • Bladen, Catherine L
  • Salgado, David
  • van Zwet, Erik
  • Pogoryelova, Oksana
  • McMacken, Grace
  • Monges, Soledad
  • Foncuberta, Maria E
  • Kekou, Kyriaki
  • Kosma, Konstantina
  • Dawkins, Hugh
  • Lamont, Leanne
  • Bellgard, Matthew I
  • Roy, Anna J
  • Chamova, Teodora
  • Guergueltcheva, Velina
  • Chan, Sophelia
  • Korngut, Lawrence
  • Campbell, Craig
  • Dai, Yi
  • Wang, Jen
  • Barišić, Nina
  • Brabec, Petr
  • Lähdetie, Jaana
  • Walter, Maggie C
  • Schreiber-Katz, Olivia
  • Karcagi, Veronika
  • Garami, Marta
  • Herczegfalvi, Agnes
  • Viswanathan, Venkatarman
  • Bayat, Farhad
  • Buccella, Filippo
  • Ferlini, Alessandra
  • Kimura, En
  • van den Bergen, Janneke C
  • Rodrigues, Miriam
  • Roxburgh, Richard
  • Lusakowska, Anna
  • Kostera-Pruszczyk, Anna
  • Santos, Rosário
  • Neagu, Elena
  • Artemieva, Svetlana
  • Rasic, Vedrana Milic
  • Vojinovic, Dina
  • Posada De la Paz, Manuel
  • Bloetzer, Clemens
  • Klein, Andrea
  • Díaz-Manera, Jordi
  • Gallardo, Eduard
  • Karaduman, A Ayşe
  • Oznur, Tunca
  • Topaloğlu, Haluk
  • El Sherif, Rasha
  • Stringer, Angela
  • Shatillo, Andriy V
  • Martin, Ann S
  • Peay, Holly L
  • Kirschner, Jan
  • Flanigan, Kevin M
  • Straub, Volker
  • Bushby, Kate
  • Béroud, Christophe
  • Verschuuren, Jan J
  • Lochmüller, Hanns
Background: Recent short-term clinical trials in patients with Duchenne Muscular Dystrophy (DMD) have indicated greater disease variability in terms of progression than expected. In addition, as average life-expectancy increases, reliable data is required on clinical progression in the older DMD population. Objective: To determine the effects of corticosteroids on major clinical outcomes of DMD in a large multinational cohort of genetically confirmed DMD patients. Methods: In this cross-sectional study we analysed clinical data from 5345 genetically confirmed DMD patients from 31 countries held within the TREAT-NMD global DMD database. For analysis patients were categorised by corticosteroid background and further stratified by age. Results: Loss of ambulation in non-steroid treated patients was 10 years and in corticosteroid treated patients 13 years old (p = 0.0001). Corticosteroid treated patients were less likely to need scoliosis surgery (p < 0.001) or ventilatory support (p < 0.001) and there was a mild cardioprotective effect of corticosteroids in the patient population aged 20 years and older (p = 0.0035). Patients with a single deletion of exon 45 showed an increased survival in contrast to other single exon deletions. Conclusions: This study provides data on clinical outcomes of DMD across many healthcare settings and including a sizeable cohort of older patients. Our data confirm the benefits of corticosteroid treatment on ambulation, need for scoliosis surgery, ventilation and, to a lesser extent, cardiomyopathy. This study underlines the importance of data collection via patient registries and the critical role of multi-centre collaboration in the rare disease field.
Repisalud
Publicación Artículo científico (JournalArticle)

The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations

  • Bladen, Catherine L
  • Salgado, David
  • Monges, Soledad
  • Foncuberta, Maria E
  • Kekou, Kyriaki
  • Kosma, Konstantina
  • Dawkins, Hugh
  • Lamont, Leanne
  • Roy, Anna J
  • Chamova, Teodora
  • Guergueltcheva, Velina
  • Chan, Sophelia
  • Korngut, Lawrence
  • Campbell, Craig
  • Dai, Yi
  • Wang, Jen
  • Barišić, Nina
  • Brabec, Petr
  • Lähdetie, Jaana
  • Walter, Maggie C
  • Schreiber-Katz, Olivia
  • Karcagi, Veronika
  • Garami, Marta
  • Viswanathan, Venkatarman
  • Bayat, Farhad
  • Buccella, Filippo
  • Kimura, En
  • Koeks, Zaïda
  • van den Bergen, Janneke C
  • Rodrigues, Miriam
  • Roxburgh, Richard
  • Lusakowska, Anna
  • Kostera-Pruszczyk, Anna
  • Zimowski, Janusz
  • Santos, Rosário
  • Neagu, Elena
  • Artemieva, Svetlana
  • Rasic, Vedrana Milic
  • Vojinovic, Dina
  • Posada De la Paz, Manuel
  • Bloetzer, Clemens
  • Jeannet, Pierre-Yves
  • Joncourt, Franziska
  • Díaz-Manera, Jordi
  • Gallardo, Eduard
  • Karaduman, A Ayşe
  • Topaloğlu, Haluk
  • El Sherif, Rasha
  • Stringer, Angela
  • Shatillo, Andriy V
  • Martin, Ann S
  • Peay, Holly L
  • Bellgard, Matthew I
  • Kirschner, Jan
  • Flanigan, Kevin M
  • Straub, Volker
  • Bushby, Kate
  • Verschuuren, Jan
  • Aartsma-Rus, Annemieke
  • Béroud, Christophe
  • Lochmüller, Hanns
Analyzing the type and frequency of patient-specific mutations that give rise to Duchenne muscular dystrophy (DMD) is an invaluable tool for diagnostics, basic scientific research, trial planning, and improved clinical care. Locus-specific databases allow for the collection, organization, storage, and analysis of genetic variants of disease. Here, we describe the development and analysis of the TREAT-NMD DMD Global database (http://umd.be/TREAT_DMD/). We analyzed genetic data for 7,149 DMD mutations held within the database. A total of 5,682 large mutations were observed (80% of total mutations), of which 4,894 (86%) were deletions (1 exon or larger) and 784 (14%) were duplications (1 exon or larger). There were 1,445 small mutations (smaller than 1 exon, 20% of all mutations), of which 358 (25%) were small deletions and 132 (9%) small insertions and 199 (14%) affected the splice sites. Point mutations totalled 756 (52% of small mutations) with 726 (50%) nonsense mutations and 30 (2%) missense mutations. Finally, 22 (0.3%) mid-intronic mutations were observed. In addition, mutations were identified within the database that would potentially benefit from novel genetic therapies for DMD including stop codon read-through therapies (10% of total mutations) and exon skipping therapy (80% of deletions and 55% of total mutations).
Repisalud
Publicación Artículo científico (JournalArticle)

The RD-Connect Genome-Phenome Analysis Platform: Accelerating diagnosis, research, and gene discovery for rare diseases

  • Laurie, Steven
  • Piscia, Davide
  • Matalonga, Leslie
  • Corvó, Alberto
  • Fernández-Callejo, Marcos
  • Garcia-Linares, Carles
  • Hernández-Ferrer, Carles
  • Luengo, Cristina
  • Martínez, Inés
  • Papakonstantinou, Anastasios
  • Picó-Amador, Daniel
  • Protasio, Joan
  • Thompson, Rachel
  • Tonda, Raul
  • Bayés, Mònica
  • Bullich, Gemma
  • Camps-Puchadas, Jordi
  • Paramonov, Ida
  • Trotta, Jean-Rémi
  • Alonso, Angel
  • Attimonelli, Marcella
  • Béroud, Christophe
  • Bros-Facer, Virginie
  • Buske, Orion J
  • Cañada-Pallarés, Andrés
  • Fernández, José M
  • Hansson, Mats G
  • Horvath, Rita
  • Jacobsen, Julius O B
  • Kaliyaperumal, Rajaram
  • Lair-Préterre, Séverine
  • Licata, Luana
  • Lopes, Pedro
  • Lopez-Martin, Estrella
  • Mascalzoni, Deborah
  • Monaco, Lucia
  • Pérez-Jurado, Luis Alberto
  • Posada De la Paz, Manuel
  • Rambla, Jordi
  • Rath, Ana
  • Riess, Olaf
  • Robinson, Peter N
  • Salgado, David
  • Smedley, Damian
  • Spalding, Dylan
  • 't Hoen, Peter A C
  • Töpf, Ana
  • Zaharieva, Irina
  • Graessner, Holm
  • Gut, Ivo G
  • Lochmüller, Hanns
  • Beltran, Sergi
Rare disease patients are more likely to receive a rapid molecular diagnosis nowadays thanks to the wide adoption of next-generation sequencing. However, many cases remain undiagnosed even after exome or genome analysis, because the methods used missed the molecular cause in a known gene, or a novel causative gene could not be identified and/or confirmed. To address these challenges, the RD-Connect Genome-Phenome Analysis Platform (GPAP) facilitates the collation, discovery, sharing, and analysis of standardized genome-phenome data within a collaborative environment. Authorized clinicians and researchers submit pseudonymised phenotypic profiles encoded using the Human Phenotype Ontology, and raw genomic data which is processed through a standardized pipeline. After an optional embargo period, the data are shared with other platform users, with the objective that similar cases in the system and queries from peers may help diagnose the case. Additionally, the platform enables bidirectional discovery of similar cases in other databases from the Matchmaker Exchange network. To facilitate genome-phenome analysis and interpretation by clinical researchers, the RD-Connect GPAP provides a powerful user-friendly interface and leverages tens of information sources. As a result, the resource has already helped diagnose hundreds of rare disease patients and discover new disease causing genes.
Repisalud
Publicación Artículo científico (JournalArticle)

Solving patients with rare diseases through programmatic reanalysis of genome-phenome data

  • Matalonga, Leslie
  • Hernández-Ferrer, Carles
  • Piscia, Davide
  • Schüle, Rebecca
  • Synofzik, Matthis
  • Töpf, Ana
  • Vissers, Lisenka E L M
  • de Voer, Richarda
  • Tonda, Raul
  • Laurie, Steven
  • Fernández-Callejo, Marcos
  • Picó, Daniel
  • Garcia-Linares, Carles
  • Papakonstantinou, Anastasios
  • Corvó, Alberto
  • Joshi, Ricky
  • Diez, Hector
  • Gut, Ivo
  • Hoischen, Alexander
  • Graessner, Holm
  • Beltran, Sergi
  • Solve-RD Consortia
  • Cuesta de la Plaza, Isabel
  • Lopez-Martin, Estrella
  • Posada De la Paz, Manuel
  • Bermejo-Sanchez, Eva
  • Martinez-Delgado, Beatriz
  • Alonso, Javier
Reanalysis of inconclusive exome/genome sequencing data increases the diagnosis yield of patients with rare diseases. However, the cost and efforts required for reanalysis prevent its routine implementation in research and clinical environments. The Solve-RD project aims to reveal the molecular causes underlying undiagnosed rare diseases. One of the goals is to implement innovative approaches to reanalyse the exomes and genomes from thousands of well-studied undiagnosed cases. The raw genomic data is submitted to Solve-RD through the RD-Connect Genome-Phenome Analysis Platform (GPAP) together with standardised phenotypic and pedigree data. We have developed a programmatic workflow to reanalyse genome-phenome data. It uses the RD-Connect GPAP's Application Programming Interface (API) and relies on the big-data technologies upon which the system is built. We have applied the workflow to prioritise rare known pathogenic variants from 4411 undiagnosed cases. The queries returned an average of 1.45 variants per case, which first were evaluated in bulk by a panel of disease experts and afterwards specifically by the submitter of each case. A total of 120 index cases (21.2% of prioritised cases, 2.7% of all exome/genome-negative samples) have already been solved, with others being under investigation. The implementation of solutions as the one described here provide the technical framework to enable periodic case-level data re-evaluation in clinical settings, as recommended by the American College of Medical Genetics.
Repisalud
Publicación Artículo científico (JournalArticle)

Improving the informed consent process in international collaborative rare disease research: effective consent for effective research

  • Gainotti, Sabina
  • Turner, Cathy
  • Woods, Simon
  • Kole, Anna
  • McCormack, Pauline
  • Lochmüller, Hanns
  • Riess, Olaf
  • Straub, Volker
  • Posada De la Paz, Manuel
  • Taruscio, Domenica
  • Mascalzoni, Deborah
The increased international sharing of data in research consortia and the introduction of new technologies for sequencing challenge the informed consent (IC) process, adding complexities that require coordination between research centres worldwide. Rare disease consortia present special challenges since available data and samples may be very limited. Thus, it is especially relevant to ensure the best use of available resources but at the same time protect patients' right to integrity. To achieve this aim, there is an ethical duty to plan in advance the best possible consent procedure in order to address possible ethical and legal hurdles that could hamper research in the future. Therefore, it is especially important to identify key core elements (CEs) to be addressed in the IC documents for international collaborative research in two different situations: (1) new research collections (biobanks and registries) for which information documents can be created according to current guidelines and (2) established collections obtained without IC or with a previous consent that does not cover all CEs. We propose here a strategy to deal with consent in these situations. The principles have been applied and are in current practice within the RD-Connect consortia - a global research infrastructure funded by the European Commission Seventh Framework program but forward looking in terms of issues addressed. However, the principles established, the lessons learned and the implications for future research are of direct relevance to all internationally collaborative rare-disease projects.
Repisalud
Publicación Artículo científico (JournalArticle)

A Solve-RD ClinVar-based reanalysis of 1522 index cases from ERN-ITHACA reveals common pitfalls and misinterpretations in exome sequencing

  • Denommé-Pichon, Anne-Sophie
  • Matalonga, Leslie
  • de Boer, Elke
  • Jackson, Adam
  • Benetti, Elisa
  • Banka, Siddharth
  • Bruel, Ange-Line
  • Ciolfi, Andrea
  • Clayton-Smith, Jill
  • Dallapiccola, Bruno
  • Duffourd, Yannis
  • Ellwanger, Kornelia
  • Fallerini, Chiara
  • Gilissen, Christian
  • Graessner, Holm
  • Haack, Tobias B
  • Havlovicova, Marketa
  • Hoischen, Alexander
  • Jean-Marçais, Nolwenn
  • Kleefstra, Tjitske
  • Lopez-Martin, Estrella
  • Macek, Milan
  • Mencarelli, Maria Antonietta
  • Moutton, Sébastien
  • Pfundt, Rolph
  • Pizzi, Simone
  • Posada De la Paz, Manuel
  • Radio, Francesca Clementina
  • Renieri, Alessandra
  • Rooryck, Caroline
  • Ryba, Lukas
  • Safraou, Hana
  • Schwarz, Martin
  • Tartaglia, Marco
  • Thauvin-Robinet, Christel
  • Thevenon, Julien
  • Tran Mau-Them, Frederic
  • Trimouille, Aurélien
  • Votypka, Pavel
  • de Vries, Bert B A
  • Willemsen, Marjolein H
  • Zurek, Birte
  • Verloes, Alain
  • Philippe, Christophe
  • Vitobello, Antonio
  • Vissers, Lisenka E L M
  • Faivre, Laurence
Purpose: Within the Solve-RD project (https://solve-rd.eu/), the European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies aimed to investigate whether a reanalysis of exomes from unsolved cases based on ClinVar annotations could establish additional diagnoses. We present the results of the "ClinVar low-hanging fruit" reanalysis, reasons for the failure of previous analyses, and lessons learned. Methods: Data from the first 3576 exomes (1522 probands and 2054 relatives) collected from European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies was reanalyzed by the Solve-RD consortium by evaluating for the presence of single-nucleotide variant, and small insertions and deletions already reported as (likely) pathogenic in ClinVar. Variants were filtered according to frequency, genotype, and mode of inheritance and reinterpreted. Results: We identified causal variants in 59 cases (3.9%), 50 of them also raised by other approaches and 9 leading to new diagnoses, highlighting interpretation challenges: variants in genes not known to be involved in human disease at the time of the first analysis, misleading genotypes, or variants undetected by local pipelines (variants in off-target regions, low quality filters, low allelic balance, or high frequency). Conclusion: The "ClinVar low-hanging fruit" analysis represents an effective, fast, and easy approach to recover causal variants from exome sequencing data, herewith contributing to the reduction of the diagnostic deadlock.
Repisalud
Publicación Artículo científico (JournalArticle)

The risk of re-identification versus the need to identify individuals in rare disease research

  • Hansson, Mats G
  • Lochmüller, Hanns
  • Riess, Olaf
  • Schaefer, Franz
  • Orth, Michael
  • Rubinstein, Yaffa
  • Molster, Caron
  • Dawkins, Hugh
  • Taruscio, Domenica
  • Posada De la Paz, Manuel
  • Woods, Simon
There is a growing concern in the ethics literature and among policy makers that de-identification or coding of personal data and biospecimens is not sufficient for protecting research subjects from privacy invasions and possible breaches of confidentiality due to the possibility of unauthorized re-identification. At the same time, there is a need in medical science to be able to identify individual patients. In particular for rare disease research there is a special and well-documented need for research collaboration so that data and biosamples from multiple independent studies can be shared across borders. In this article, we identify the needs and arguments related to de-identification and re-identification of patients and research subjects and suggest how the different needs may be balanced within a framework of using unique encrypted identifiers.
Repisalud
Publicación Artículo científico (JournalArticle)

The EuroBioBank Network: 10 years of hands-on experience of collaborative, transnational biobanking for rare diseases

  • Mora, Marina
  • Angelini, Corrado
  • Bignami, Fabrizia
  • Bodin, Anne-Mary
  • Crimi, Marco
  • Di Donato, Jeanne-Hélène
  • Felice, Alex
  • Jaeger, Cécile
  • Karcagi, Veronika
  • LeCam, Yann
  • Lynn, Stephen
  • Meznaric, Marija
  • Moggio, Maurizio
  • Monaco, Lucia
  • Politano, Luisa
  • Posada De la Paz, Manuel
  • Saker, Safaa
  • Schneiderat, Peter
  • Ensini, Monica
  • Garavaglia, Barbara
  • Gurwitz, David
  • Johnson, Diana
  • Muntoni, Francesco
  • Puymirat, Jack
  • Reza, Mojgan
  • Voit, Thomas
  • Baldo, Chiara
  • Bricarelli, Franca Dagna
  • Goldwurm, Stefano
  • Merla, Giuseppe
  • Pegoraro, Elena
  • Renieri, Alessandra
  • Zatloukal, Kurt
  • Filocamo, Mirella
  • Lochmüller, Hanns
The EuroBioBank (EBB) network (www.eurobiobank.org) is the first operating network of biobanks in Europe to provide human DNA, cell and tissue samples as a service to the scientific community conducting research on rare diseases (RDs). The EBB was established in 2001 to facilitate access to RD biospecimens and associated data; it obtained funding from the European Commission in 2002 (5th framework programme) and started operation in 2003. The set-up phase, during the EC funding period 2003-2006, established the basis for running the network; the following consolidation phase has seen the growth of the network through the joining of new partners, better network cohesion, improved coordination of activities, and the development of a quality-control system. During this phase the network participated in the EC-funded TREAT-NMD programme and was involved in planning of the European Biobanking and Biomolecular Resources Research Infrastructure. Recently, EBB became a partner of RD-Connect, an FP7 EU programme aimed at linking RD biobanks, registries, and bioinformatics data. Within RD-Connect, EBB contributes expertise, promotes high professional standards, and best practices in RD biobanking, is implementing integration with RD patient registries and 'omics' data, thus challenging the fragmentation of international cooperation on the field.
Repisalud
Publicación Artículo de revisión (ReviewArticle)

Current trends in biobanking for rare diseases: a review

  • Graham, Caroline E
  • Molster, Caron
  • Baynam, Gareth
  • Bushby, Kate
  • Hansson, Mats
  • Kole, Anna
  • Mora, Marina
  • Monaco, Lucia
  • Bellgard, Matthew I
  • Carpentieri, David
  • Posada De la Paz, Manuel
  • Riess, Olaf
  • Rubinstein, Yaffa R
  • Schaefer, Franz
  • Taruscio, Domenica
  • Terry, Sharon F
  • Zatloukal, Kurt
  • Knoppers, Bartha
  • Lochmüller, Hanns
  • Dawkins, Hugh
Rare diseases (RD) refer to a collection of approximately 5,000–8,000 individual diseases that have a low prevalence and are often genetic in origin. While RD can manifest throughout life, they frequently affect children and newborns. Common characteristics include being severe, disabling, life-threatening, degenerative and affecting different organ systems. The burden of RD is often exacerbated by a lack of specific treatments. Whilst there is etiological heterogeneity, there is overlap in cellular and molecular pathways. Amongst specialists, there is legitimate hope that based on genetic knowledge and pathway definition, a new medical classification system, currently called “precision medicine”, will be developed, which may change our view on how to apply shared therapeutic targets. Thus, collection of clinical and genetic data and biospecimens (in biobanks) will play an increasing role in diagnoses and development of therapies for RD. Biobanks are maintained collaboratively by researchers or their institutions, and involve a delicate balance between health policy objectives, academic research, public good outcomes, and community trust. Due to the nature of RD, international cooperation is critical for sharing limited numbers of RD samples and achieving a critical mass. Here we review the current and future direction of RD biobanks and discuss research and development stemming from the use of biospecimens to improve management of RD.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

The RD-connect genome-phenome analysis platform: accelerating diagnosis, research, and gene discovery for rare diseases

  • Laurie, Steven
  • Piscia, Davide
  • Matalonga, Leslie
  • Corvó, Alberto
  • Fernández-Callejo, Marcos
  • Garcia-Linares, Carles
  • Hernandez-Ferrer, Carles
  • Luengo, Cristina
  • Martínez, Inés
  • Papakonstantinou, Anastasios
  • Picó-Amador, Daniel
  • Protasio, Joan
  • Thompson, Rachel
  • Tonda, Raúl
  • Bayés, Mónica
  • Bullich, Gemma
  • Camps-Puchadas, Jordi
  • Paramonov, Ida
  • Trotta, Jean Remí
  • Alonso Sánchez, Ángel Miguel
  • Attimonelli, Marcella
  • Béroud, Christophe
  • Bros-Facer, Virginie
  • Buske, Orion J.
  • Cañada-Pallarés, Andrés
  • Fernández, José M.
  • Hansson, Mats G.
  • Horvath, Rita
  • Jacobsen, Julius O. B.
  • Kaliyaperumal, Rajaram
  • Lair-Préterre, Séverine
  • Licata, Luana
  • Lopes, Pedro
  • López-Martín, Estrella
  • Mascalzoni, Deborah
  • Monaco, Lucia
  • Pérez-Jurado, Luis A.
  • Posada-de-la-Paz, Manuel
  • Rambla, Jordi
  • Rath, Ana
  • Riess, Olaf
  • Robinson, Peter N.
  • Salgado, David
  • Smedley, Damian
  • Spalding, Dylan
  • &apos;t Hoen, Peter A. C.
  • Töpf, Ana
  • Zaharieva, Irina
  • Graessner, Holm
  • Gut, Ivo Glynne
  • Lochmüller, Hanns
  • Beltrán, Sergi
Rare disease patients are more likely to receive a rapid molecular diagnosis nowadays thanks to the wide adoption of next-generation sequencing. However, many cases remain undiagnosed even after exome or genome analysis, because the methods used missed the molecular cause in a known gene, or a novel causative gene could not be identified and/or confirmed. To address these challenges, the RD-Connect Genome-Phenome Analysis Platform (GPAP) facilitates the collation, discovery, sharing, and analysis of standardized genome-phenome data within a collaborative environment. Authorized clinicians and researchers submit pseudonymised phenotypic profiles encoded using the Human Phenotype Ontology, and raw genomic data which is processed through a standardized pipeline. After an optional embargo period, the data are shared with other platform users, with the objective that similar cases in the system and queries from peers may help diagnose the case. Additionally, the platform enables bidirectional discovery of similar cases in other databases from the Matchmaker Exchange network. To facilitate genome-phenome analysis and interpretation by clinical researchers, the RD-Connect GPAP provides a powerful user-friendly interface and leverages tens of information sources. As a result, the resource has already helped diagnose hundreds of rare disease patients and discover new disease causing genes., RD-Connect (RD-Connect, an integrated platform connecting registries, biobanks, and clinical bioinformatics) received funding from the Seventh Framework (FP7) Programme of the European Union under grant agreement No 305444. Data were analyzed using the RD-Connect GPAP, which received funding from EU projects Solve-RD, EJP-RD (grant numbers H2020 779257, H2020 825575), Instituto de Salud Carlos III (Grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB), ELIXIR-EXCELERATE (Grant number EU H2020 #676559) and ELIXIR Implementation Studies (Remote real-time visualization of human rare disease genomics data (RD-Connect) stored at the EGA ELIXIR. 2017-2018; ELIXIR IT-2017-INTEGRATION, Rare Disease Infrastructure ELIXIR, 2019-2020 and the Beacon ELIXIR, 2019-2021). The RD-Connect GPAP has leveraged developments funded through project VEIS (001-P-001647 co-financed by the European Regional Development Fund of the European Union in the framework of the Operational Program FEDER of Catalonia 2014-2020 with the support of the Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement de la Generalitat de Catalunya) and URD-Cat (PERIS SLT002/16/00174, Departament de Salut, Generalitat de Catalunya). The research leading to these results has received funding from Consequitur (Newton Fund UK/Turkey, MR/N027302/1), BBMRI-LPC (EU FP7 #313010), NeurOmics (EU FP7 #305121), the Economic Development Department of the Navarra Government (Grant number 001114112017), the European Reference Network for Rare Neurological Diseases (Project ID number 739510) and NIH, National Institute of Child Health and Human Development (1R01HD103805-01). We acknowledge the support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program/Generalitat de Catalunya. We also acknowledge the support of the Generalitat de Catalunya through Departament de Salut and Departament d'Empresa i Coneixement and Co-financing by the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) with funds from the European Regional Development Fund (ERDF) corresponding to the 2014-2020 Smart Growth Operating Program. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279).
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Improved diagnosis of rare disease patients through systematic detection of runs of homozygosity

  • Matalonga Borrel, Lesley
  • Laurie, Steven
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Mereu, Elisabetta
  • Bullich, Gemma
  • Thompson, Rachel
  • Horvath, Rita
  • Pérez Jurado, Luis A.
  • Riess, Olaf
  • Gut, Ivo
  • van Ommen, Gert Jan
  • Lochmüller, Hanns
  • Beltrán, Sergi
  • Rare Disease-Connect Genome-Phenome Analysis Platform data contributors
  • Undiagnosed Rare Disease Programme of Catalonia data contibutors
  • Cormand Rifà, Bru
  • Balcells Comas, Susana
  • Grinberg Vaisman, Daniel Raúl
  • Urreizti, Roser
  • Garrabou Tornos, Glòria
Autozygosity is associated with an increased risk of genetic rare disease, thus being a relevant factor for clinical genetic studies. More than 2400 exome sequencing data sets were analyzed and screened for autozygosity on the basis of detection of >1 Mbp runs of homozygosity (ROHs). A model was built to predict if an individual is likely to be a consanguineous offspring (accuracy, 98%), and probability of consanguinity ranges were established according to the total ROH size. Application of the model resulted in the reclassification of the consanguinity status of 12% of the patients. The analysis of a subset of 79 consanguineous cases with the Rare Disease (RD)-Connect Genome-Phenome Analysis Platform, combining variant filtering and homozygosity mapping, enabled a 50% reduction in the number of candidate variants and the identification of homozygous pathogenic variants in 41 patients, with an overall diagnostic yield of 52%. The newly defined consanguinity ranges provide, for the first time, specific ROH thresholds to estimate inbreeding within a pedigree on disparate exome sequencing data, enabling confirmation or (re)classification of consanguineous status, hence increasing the efficiency of molecular diagnosis and reporting on secondary consanguinity findings, as recommended by American College of Medical Genetics and Genomics guidelines
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The European Genome-phenome Archive of human data consented for biomedical research

  • Lappalainen, Ilkka
  • Navarro, Arcadi
  • Flicek, Paul
Lappalainen, Ilkka et al., The European Genome-phenome Archive (EGA) is a permanent archive that promotes the distribution and sharing of genetic and phenotypic data consented for specific approved uses but not fully open, public distribution. The EGA follows strict protocols for information management, data storage, security and dissemination. Authorized access to the data is managed in partnership with the data-providing organizations. The EGA includes major reference data collections for human genetics research., The EGA has received support from the European Molecular Biology Laboratory, the European Union ELIXIR Technical Feasibility Study, the Wellcome Trust (grant WT 085475/C/08/Z), the UK Medical Research Council (grant G0800681), the Spanish Instituto de Salud Carlos III Instituto Nacional de Bioinformática (grant PT13/0001/0026), the Spanish Ministerio de Economía y Competitividad (MINECO) and Centro de Excelencia Severo Ochoa (grant SEV-2012-0208), the Fundació La Caixa and the Barcelona Supercomputing Centre. The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013 under grant agreements 211601–ELIXIR, 200754–GEN2PHEN, 262055–ESGI, 242006–BASIS, 261376–IHMS and 305444–RD-CONNECT)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Identification of symbol digit modality test score extremes in Huntington's disease

  • Braisch, Ulrike
  • Muche, Rainer
  • Rothenbacher, Dietrich
  • Landwehrmeyer, Georg Bernhard
  • Long, Jeffrey D.
  • Orth, Michael
  • Carrillo, Fátima
  • Cáceres-Redondo, María T.
  • Mir, Pablo
  • Vargas-González, Laura
  • García-Moreno, José Manuel
REGISTRY Investigators of the European Huntington's Disease Network and COHORT Investigators of the Huntington Study Group., Studying individuals with extreme phenotypes could facilitate the understanding of disease modification by genetic or environmental factors. Our aim was to identify Huntington's disease (HD) patients with extreme symbol digit modality test (SDMT) scores. We first examined in HD the contribution of cognitive measures of the Unified Huntington's Disease Rating Scale (UHDRS) in predicting clinical endpoints. The language-independent SDMT was used to identify patients performing very well or very poorly relative to their CAG and age cohort. We used data from REGISTRY and COHORT observational study participants (5,603 HD participants with CAG repeats above 39 with 13,868 visits) and of 1,006 healthy volunteers (with 2,241 visits), included to identify natural aging and education effects on cognitive measures. Separate Cox proportional hazards models with CAG, age at study entry, education, sex, UHDRS total motor score and cognitive (SDMT, verbal fluency, Stroop tests) scores as covariates were used to predict clinical endpoints. Quantile regression for longitudinal language-independent SDMT data was used for boundary (2.5% and 97.5% quantiles) estimation and extreme score analyses stratified by age, education, and CAG repeat length. Ten percent of HD participants had an extreme SDMT phenotype for at least one visit. In contrast, only about 3% of participants were consistent SDMT extremes at two or more visits. The thresholds for the one-visit and two-visit extremes can be used to classify existing and new individuals. The identification of these phenotype extremes can be useful in the search for disease modifiers., This work was in part funded by a grant from the EuropeanCommission under the 7th framework programme (RD-Connect, grantagreement number 305444).
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

Comparison of algorithms for the detection of cancer drivers at subgene resolution

  • Porta-Pardo, Eduard
  • Kamburov, Atanas
  • Tamborero, David
  • Pons, Tirso
  • Grases, Daniela
  • Valencia, Alfonso|||0000-0002-8937-6789
  • Lopez-Bigas, Nuria
  • Getz, Gad
  • Godzik, Adam
Understanding genetic events that lead to cancer initiation and progression remains one of the biggest challenges in cancer biology. Traditionally, most algorithms for cancer-driver identification look for genes that have more mutations than expected from the average background mutation rate. However, there is now a wide variety of methods that look for nonrandom distribution of mutations within proteins as a signal for the driving role of mutations in cancer. Here we classify and review such subgene-resolution algorithms, compare their findings on four distinct cancer data sets from The Cancer Genome Atlas and discuss how predictions from these algorithms can be interpreted in the emerging paradigms that challenge the simple dichotomy between driver and passenger genes., We would like to thank the people working at The Cancer Genome Atlas for their efforts and for making all the data publicly available. E.P.-P. and A.G. acknowledge the support from the Cancer Center grants P30 CA030199 (to our institute) and R35 GM118187 (A.G.). A.K. was supported by startup funds of G.G. and by a collaboration with Bayer AG. D.T. is supported by project SAF2015- 74072-JIN, which is funded by the Agencia Estatal de Investigacion (AEI) and Fondo Europeo de Desarrollo Regional (FEDER). N.L.-B. acknowledges funding from the European Research Council (consolidator grant 682398). A.V. and T.P. acknowledge funding by the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 305444 (RD-Connect)., Peer Reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Solving the genetic aetiology of hereditary gastrointestinal tumour syndromes- a collaborative multicentre endeavour within the project Solve-RD

  • Sommer, Anna K.
  • Te Paske, Iris B.A.W.
  • Garcia-Pelaez, José
  • Laner, Andreas
  • Holinski-Feder, Elke
  • Steinke-Lange, Verena
  • Peters, Sophia
  • Valle, Laura
  • Spier, Isabel
  • Huntsman, David
  • Solve-RD-GENTURIS group
  • Oliveira, Carla
  • de Voer, Richarda M.
  • Hoogerbrugge, Nicoline
  • Aretz, Stefan
Background: Patients and families with suspected, but genetically unexplained (unsolved) genetic tumour risk syndromes lack appropriate treatment and prevention, leading to preventable morbidity and mortality. To tackle this problem, patients from the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS) are analysed in the European Commission's research project "Solving the unsolved rare diseases" (Solve-RD). The aim is to uncover known and novel cancer predisposing genes by reanalysing available whole-exome sequencing (WES) data of large cohorts in a combined manner, and applying a multidimensional omics approach. Approach: Around 500 genetically unsolved cases with suspected hereditary gastrointestinal tumour syndromes (polyposis, early-onset/familial colorectal cancer and gastric cancer) from multiple European centres are aimed to be included. Currently, clinical and germline WES data from 294 cases have been analysed. In addition, an extensive molecular profiling of gastrointestinal tumours from these patients is planned and deep learning techniques will be applied. The ambitious, multidisciplinary project is accompanied by a number of methodical, technical, and logistic challenges, which require the development and implementation of new analysis tools, the standardisation of bioinformatics pipelines, and strategies to exchange data and knowledge. Results: and Outlook. The first re-analysis of 229 known and proposed cancer predisposition genes allowed solving 2-3% of previously unsolved GENTURIS cases. The integration of expert knowledge and new technologies will help to identify the genetic basis of additional unsolved cases within the ongoing project. The ERN GENTURIS approach might serve as a model for other genomic initiatives., This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 779257 (Solve-RD). This study makes use of data shared/provided through RD-Connect, which received funding from the European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement No. 305444.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease

  • Wood, Libby
  • Lochmüller, Hanns
Background: Myotonic Dystrophy is the most common form of muscular dystrophy in adults, affecting an estimated 10 per 100,000 people. It is a multisystemic disorder affecting multiple generations with increasing severity. There are currently no licenced therapies to reverse, slow down or cure its symptoms. In 2009 TREAT-NMD (a global alliance with the mission of improving trial readiness for neuromuscular diseases) and the Marigold Foundation held a workshop of key opinion leaders to agree a minimal dataset for patient registries in myotonic dystrophy. Eight years after this workshop, we surveyed 22 registries collecting information on myotonic dystrophy patients to assess the proliferation and utility the dataset agreed in 2009. These registries represent over 10,000 myotonic dystrophy patients worldwide (Europe, North America, Asia and Oceania). Results: The registries use a variety of data collection methods (e.g. online patient surveys or clinician led) and have a variety of budgets (from being run by volunteers to annual budgets over €200,000). All registries collect at least some of the originally agreed data items, and a number of additional items have been suggested in particular items on cognitive impact. Conclusions: The community should consider how to maximise this collective resource in future therapeutic programmes., This work has received funding from the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 305444 “RD-CONNECT: An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research”, Hanns Lochmüller has received funding from the Medical Research Council UK (grant reference G1002274, grant ID 98482).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A novel, pathogenic dinucleotide deletion in the mitochondrial MT-TY gene causing myasthenia-like features

  • Lim, Albert Z.
  • McMacken, Grace M.
  • Rastelli, Francesca
  • Oláhová, Monika
  • Baty, Karen
  • Hopton, Sila
  • Falkous, Gavin
  • Töpf, Ana
  • Lochmüller, Hanns
  • Marini-Bettolo, Chiara
  • McFarland, Robert
  • Taylor, Robert W.
Mitochondrial DNA (mtDNA)-related diseases often pose a diagnostic challenge and require rigorous clinical and laboratory investigation. Pathogenic variants in the mitochondrial tRNA gene MT-TY, which encodes the tRNATyr, are a rare cause of mitochondrial disease. Here we describe a novel m.5860delTA anticodon variant in the MT-TY gene in a patient who initially presented with features akin to a childhood onset myasthenic syndrome. Using histochemical, immunohistochemical and protein studies we demonstrate that this mutation leads to severe biochemical defects of mitochondrial translation, which is reflected in the early onset and progressive phenotype. This case highlights the clinical overlap between mtDNA-related diseases and other neuromuscular disorders, and demonstrates the potential pitfalls in analysis of next generation sequencing results, given whole exome sequencing of a blood DNA sample failed to make a genetics diagnosis. Muscle biopsy remains an important requirement in the diagnosis of mitochondrial disease and in establishing the pathogenicity of novel mtDNA variants., AL, RM and RWT are supported by the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z); RM and RWT also receive support from the Medical Research Council (MRC) International Centre for Genomic Medicine in Neuromuscular Disease, the Mitochondrial Disease Patient Cohort (UK) (G0800674), Newcastle University Centre for Ageing and Vitality (supported by the Biotechnology and Biological Sciences Research Council and Medical Research Council L016354), UK NIHR Biomedical Research Centre for Ageing and Age-related disease award to the Newcastle upon Tyne Hospitals NHS Foundation Trust, the Lily Foundation and the UK NHS Specialist Commissioners which funds the “Rare Mitochondrial Disorders of Adults and Children” Diagnostic Service in Newcastle upon Tyne (http://www.newcastle-mitochondria.com/). GM is supported by the Association of British Neurologists Clinical Research Training Fellowship. Biobanking and Biomedical Resources Research Infrastructure ‐ large prospective cohorts (BBMRI‐LPC) 2016 access call for Whole Exome Sequencing (FP7/2007‐2013), Grant Number: 313010. Data were analyzed using the RD‐Connect Genome‐Phenome Analysis platform developed under FP7/2007‐2013 funded project, Grant Number: 305444.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Clinical manifestations in a girl with NAA10-related syndrome and genotype-phenotype correlation in females

  • Maini, Ilenia
  • Caraffi, Stefano G.
  • Peluso, Francesca
  • Valeri, Lara
  • Nicoli, Davide
  • Laurie, Steven, 1973-
  • Baldo, Chiara
  • Zuffardi, Orsetta
  • Garavelli, Livia
Since 2011, eight males with an X-linked recessive disorder (Ogden syndrome, MIM #300855) associated with the same missense variant p.(Ser37Pro) in the NAA10 gene have been described. After the advent of whole exome sequencing, many NAA10 variants have been reported as causative of syndromic or non-syndromic intellectual disability in both males and females. The NAA10 gene lies in the Xq28 region and encodes the catalytic subunit of the major N-terminal acetyltransferase complex NatA, which acetylates almost half the human proteome. Here, we present a young female carrying a de novo NAA10 [NM_003491:c.247C > T, p.(Arg83Cys)] variant. The 18-year-old girl has severely delayed motor and language development, autistic traits, postnatal growth failure, facial dysmorphisms, interventricular septal defect, neuroimaging anomalies and epilepsy. Our attempt is to expand and compare genotype-phenotype correlation in females with NAA10-related syndrome. A detailed clinical description could have relevant consequences for the clinical management of known and newly identified individuals., This work has received funding from the European Community’s Seventh Framework Program (FP7/2007–2013) under grant agreement n 305444 “RD-CONNECT: An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research”.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Solving patients with rare diseases through programmatic reanalysis of genome-phenome data

  • Matalonga, Leslie
  • Hernández Ferrer, Carles
  • Piscia, Davide
  • Tonda, Raúl
  • Laurie, Steven, 1973-
  • Fernández Callejo, Marcos
  • Picó, Daniel
  • Garcia-Linares, Carles
  • Papakonstantinou, Anastasios
  • Corvò, Alberto
  • Joshi, Ricky S.
  • Diez, Hector
  • Gut, Ivo Glynne
  • Beltran, Sergi
  • Solve-RD Consortium
Reanalysis of inconclusive exome/genome sequencing data increases the diagnosis yield of patients with rare diseases. However, the cost and efforts required for reanalysis prevent its routine implementation in research and clinical environments. The Solve-RD project aims to reveal the molecular causes underlying undiagnosed rare diseases. One of the goals is to implement innovative approaches to reanalyse the exomes and genomes from thousands of well-studied undiagnosed cases. The raw genomic data is submitted to Solve-RD through the RD-Connect Genome-Phenome Analysis Platform (GPAP) together with standardised phenotypic and pedigree data. We have developed a programmatic workflow to reanalyse genome-phenome data. It uses the RD-Connect GPAP's Application Programming Interface (API) and relies on the big-data technologies upon which the system is built. We have applied the workflow to prioritise rare known pathogenic variants from 4411 undiagnosed cases. The queries returned an average of 1.45 variants per case, which first were evaluated in bulk by a panel of disease experts and afterwards specifically by the submitter of each case. A total of 120 index cases (21.2% of prioritised cases, 2.7% of all exome/genome-negative samples) have already been solved, with others being under investigation. The implementation of solutions as the one described here provide the technical framework to enable periodic case-level data re-evaluation in clinical settings, as recommended by the American College of Medical Genetics., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257. Data were analysed using the RD‐Connect Genome‐Phenome Analysis Platform, which received funding from EU projects RD‐Connect, Solve-RD and EJP-RD (grant numbers FP7 305444, H2020 779257, H2020 825575), Instituto de Salud Carlos III (grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB) and ELIXIR Implementation Studies.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

RD-Connect, NeurOmics and EURenOmics: collaborative European initiative for rare diseases

  • Lochmüller, Hanns
  • Badowska, Dorota M.
  • Thompson, Rachel
  • Knoers, Nine V.
  • Aartsma-Rus, Annemieke
  • Gut, Ivo Glynne
  • Wood, Libby
  • Harmuth, Tina
  • Durudas, Andre
  • Graessner, Holm
  • Schaefer, Franz
  • Riess, Olaf
  • RD-Connect consortium
  • NeurOmics consortium
  • EURenOmics consortium
Although individually uncommon, rare diseases (RDs) collectively affect 6-8% of the population. The unmet need of the rare disease community was recognized by the European Commission which in 2012 funded three flagship projects, RD-Connect, NeurOmics, and EURenOmics, to help move the field forward with the ambition of advancing -omics research and data sharing at their core in line with the goals of IRDiRC (International Rare Disease Research Consortium). NeurOmics and EURenOmics generate -omics data and improve diagnosis and therapy in rare renal and neurological diseases, with RD-Connect developing an infrastructure to facilitate the sharing, systematic integration and analysis of these data. Here, we summarize the achievements of these three projects, their impact on the RD community and their vision for the future. We also report from the Joint Outreach Day organized by the three projects on the 3rd of May 2017 in Berlin. The workshop stimulated an open, multi-stakeholder discussion on the challenges of the rare diseases, and highlighted the cross-project cooperation and the common goal: the use of innovative genomic technologies in rare disease research., This work has received funding from the European Community’s Seventh Framework Program (FP7/2007–2013) under grant agreement n° 305444 “RD-CONNECT: An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research”, grant agreement n° 2012-305121 “Integrated European –omics research project for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases (NEUROMICS)” and n° 305608 “EURenOmics”. Hanns Lochmüller has received funding from the Medical Research Council UK (grant reference G1002274, grant ID 98482). We would like to thank Victoria Hedley for her support in dissemination of the RD-Connect project and Ana Töpf for her feedback, which helped to develop the Genome-Phenome Analysis Platform.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

GFPT1 deficiency in muscle leads to myasthenia and myopathy in mice

  • Issop, Yasmin
  • Hathazi, Denisa
  • Khan, Muzamil Majid
  • Rudolf, Rüdiger
  • Weis, Joachim
  • Spendiff, Sally
  • Slater, Clarke R.
  • Roos, Andreas
  • Lochmüller, Hanns
Glutamine-fructose-6-phosphate transaminase 1 (GFPT1) is the rate-limiting enzyme in the hexosamine biosynthetic pathway which yields precursors required for protein and lipid glycosylation. Mutations in GFPT1 and other genes downstream of this pathway cause congenital myasthenic syndrome (CMS) characterized by fatigable muscle weakness owing to impaired neurotransmission. The precise pathomechanisms at the neuromuscular junction (NMJ) owing to a deficiency in GFPT1 is yet to be discovered. One of the challenges we face is the viability of Gfpt1-/- knockout mice. In this study, we use Cre/LoxP technology to generate a muscle-specific GFPT1 knockout mouse model, Gfpt1tm1d/tm1d, characteristic of the human CMS phenotype. Our data suggest a critical role for muscle derived GFPT1 in the development of the NMJ, neurotransmission, skeletal muscle integrity and highlight that a deficiency in skeletal muscle alone is sufficient to cause morphological postsynaptic NMJ changes that are accompanied by presynaptic alterations despite the conservation of neuronal GFPT1 expression. In addition to the conventional morphological NMJ changes and fatigable muscle weakness, Gfpt1tm1d/tm1d mice display a progressive myopathic phenotype with the presence of tubular aggregates in muscle, characteristic of the GFPT1-CMS phenotype. We further identify an upregulation of skeletal muscle proteins glypican-1, farnesyltransferase/geranylgeranyltransferase type-1 subunit α and muscle-specific kinase, which are known to be involved in the differentiation and maintenance of the NMJ. The Gfpt1tm1d/tm1d model allows for further investigation of pathophysiological consequences on genes and pathways downstream of GFPT1 likely to involve misglycosylation or hypoglycosylation of NMJs and muscle targets., This work was supported by a studentship of The Barbour Foundation and the Medical Research Council (UK) to Y.I.; the Medical Research Council as part of the MRC Centre for Neuromuscular Diseases (reference G1002274, grant ID 98482), a Wellcome Trust Pathfinder Award (201064/Z/16/Z) to H.L.; the European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement No. 305444 (RD-Connect) and 305121 (NeurOmics) to H.L.; an award from the French Muscular Dystrophy Association (AFM-Téléthon) No. 20870 to H.L.; the German Research Fund (RU923/8-2) to R.R., and by the Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen, the Senatsverwaltung für Wirtschaft, Technologie und Forschung des Landes Berlin, and the Bundesministerium für Bildung und Forschung. Funding to pay the Open Access publication charges for this article was provided by The Medical Research Council (MRC).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Improved diagnosis of rare disease patients through systematic detection of runs of homozygosity

  • Matalonga, Leslie
  • Laurie, Steven, 1973-
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Mereu, Elisabetta
  • Bullich, Gemma
  • Thompson, Rachel
  • Horvath, Rita
  • Pérez Jurado, Luis Alberto
  • Riess, Olaf
  • Gut, Ivo Glynne
  • van Ommen, Gert-Jan
  • Lochmüller, Hanns
  • Beltran, Sergi
  • RD–Connect Genome-Phenome Analysis Platform and URD-Cat Data Contributors
Autozygosity is associated with an increased risk of genetic rare disease, thus being a relevant factor for clinical genetic studies. More than 2400 exome sequencing data sets were analyzed and screened for autozygosity on the basis of detection of >1 Mbp runs of homozygosity (ROHs). A model was built to predict if an individual is likely to be a consanguineous offspring (accuracy, 98%), and probability of consanguinity ranges were established according to the total ROH size. Application of the model resulted in the reclassification of the consanguinity status of 12% of the patients. The analysis of a subset of 79 consanguineous cases with the Rare Disease (RD)-Connect Genome-Phenome Analysis Platform, combining variant filtering and homozygosity mapping, enabled a 50% reduction in the number of candidate variants and the identification of homozygous pathogenic variants in 41 patients, with an overall diagnostic yield of 52%. The newly defined consanguinity ranges provide, for the first time, specific ROH thresholds to estimate inbreeding within a pedigree on disparate exome sequencing data, enabling confirmation or (re)classification of consanguineous status, hence increasing the efficiency of molecular diagnosis and reporting on secondary consanguinity findings, as recommended by American College of Medical Genetics and Genomics guidelines., Supported by European Union projects RD-Connect, Solve-RD, and European Joint Programme of Rare Diseases (EJP-RD) grants FP7 305444, H2020 779257, and H2020 825575; Instituto de Salud Carlos III grants PT13/0001/0044 and PT17/0009/0019; Instituto Nacional de Bioinformática; ELIXIR Implementation Studies; European Union projects BBMRI-LPC EU FP7 313010, NeurOmics EU FP7 305121, and Undiagnosed Rare Disease Program of Catalonia (Departament de Salut, Generalitat de CatalunyaSLT002/16/00174); Canadian Institutes of Health Research Foundation grant FDN-167281 (H.L.); the European Research Council309548 (R.H.); the Wellcome Investigator Award 109915/Z/15/Z (R.H.); the Medical Research Council (United Kingdom) MR/N025431/1 (R.H.); the Wellcome Trust Pathfinder Scheme 201064/Z/16/Z (R.H. and H.L.); the Newton Fund (United Kingdom/Turkey) MR/N027302/1 (R.H. and H.L.); the Spanish Ministry of Economy, Industry and Competitiveness to the European Molecular Biology Laboratory (EMBL) partnership; the Centro de Excelencia Severo Ochoa; the Centres de Recerca de Catalunya (CERCA) Program/Generalitat de Catalunya; the Generalitat de Catalunya through the Department of Health and Department of Business and Knowledge; the Spanish Ministry of Economy, Industry and Competitiveness with funds from the European Regional Development Fund corresponding to the 2014 to 2020 Smart Growth Operating Program.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion

  • McMacken, Grace M.
  • Lochmüller, Hanns
  • Bansagi, Boglarka
  • Pyle, Angela
  • Lochmüller, Angela
  • Chinnery, Patrick F.
  • Laurie, Steven, 1973-
  • Beltran, Sergi
  • Matalonga, Leslie
  • Horvath, Rita
Background: Behr syndrome is a clinically distinct, but genetically heterogeneous disorder characterized by optic atrophy, progressive spastic paraparesis, and motor neuropathy often associated with ataxia. The molecular diagnosis is based on gene panel testing or whole-exome/genome sequencing. Methods: Here, we report the clinical presentation of two siblings with a novel genetic form of Behr syndrome. We performed whole-exome sequencing in the two patients and their mother. Results: Both patients had a childhood-onset, slowly progressive disease resembling Behr syndrome, starting with visual impairment, followed by progressive spasticity, weakness, and atrophy of the lower legs and ataxia. They also developed scoliosis, leading to respiratory problems. In their late 30's, both siblings developed a hypertrophic cardiomyopathy and died of sudden cardiac death at age 43 and 40, respectively. Whole-exome sequencing identified the novel homozygous c.627_629del; p.(Gly210del) deletion in UCHL1. Conclusions: The presentation of our patients raises the possibility that hypertrophic cardiomyopathy may be an additional feature of the clinical syndrome associated with UCHL1 mutations, and highlights the importance of cardiac follow-up and treatment in neurodegenerative disease associated with UCHL1 mutations., The study was supported by the Newton Fund UK/Turkey (MR/N027302/1 to HL and RH), the Medical Research Council (UK) (MR/N025431/1 to RH), the Wellcome Investigator fund (109915/Z/15/Z to RH), the Lily Foundation UK (to RH), the European Research Council (309548 to RH), and the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z to HL and RH). HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). The study was further supported by the Horizon 2020 research and innovation program via grant 779257 “Solve-RD”. Data were analyzed using the RD-Connect Genome-Phenome Analysis platform developed under FP7/2007-2013 funded project (grant agreement no. 305444).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Phenotypic similarity-based approach for variant prioritization for unsolved rare disease: a preliminary methodological report

  • Lagorce, David
  • Lebreton, Emeline
  • Matalonga, Leslie
  • Hongnat, Oscar
  • Chahdil, Maroua
  • Piscia, Davide
  • Paramonov, Ida
  • Ellwanger, Kornelia
  • Köhler, Sebastian
  • Robinson, Peter N.
  • Graessner, Holm
  • Beltran, Sergi
  • Lucano, Caterina
  • Hanauer, Marc
  • Rath, Ana
Data de publicació electrònica: 06-11-2023, Rare diseases (RD) have a prevalence of not more than 1/2000 persons in the European population, and are characterised by the difficulty experienced in obtaining a correct and timely diagnosis. According to Orphanet, 72.5% of RD have a genetic origin although 35% of them do not yet have an identified causative gene. A significant proportion of patients suspected to have a genetic RD receive an inconclusive exome/genome sequencing. Working towards the International Rare Diseases Research Consortium (IRDiRC)'s goal for 2027 to ensure that all people living with a RD receive a diagnosis within one year of coming to medical attention, the Solve-RD project aims to identify the molecular causes underlying undiagnosed RD. As part of this strategy, we developed a phenotypic similarity-based variant prioritization methodology comparing submitted cases with other submitted cases and with known RD in Orphanet. Three complementary approaches based on phenotypic similarity calculations using the Human Phenotype Ontology (HPO), the Orphanet Rare Diseases Ontology (ORDO) and the HPO-ORDO Ontological Module (HOOM) were developed; genomic data reanalysis was performed by the RD-Connect Genome-Phenome Analysis Platform (GPAP). The methodology was tested in 4 exemplary cases discussed with experts from European Reference Networks. Variants of interest (pathogenic or likely pathogenic) were detected in 8.8% of the 725 cases clustered by similarity calculations. Diagnostic hypotheses were validated in 42.1% of them and needed further exploration in another 10.9%. Based on the promising results, we are devising an automated standardized phenotypic-based re-analysis pipeline to be applied to the entire unsolved cases cohort., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257. This study makes use of data shared/provided through RD-Connect, which received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement No. 305444.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Linked Registries: Connecting Rare Diseases Patient Registries through a Semantic Web Layer

  • Sernadela, Pedro
  • Queralt Rosinach, Núria
  • Oliveira, José Luis
Patient registries are an essential tool to increase current knowledge regarding rare diseases. Understanding these data is a vital step to improve patient treatments and to create the most adequate tools for personalized medicine. However, the growing number of disease-specific patient registries brings also new technical challenges. Usually, these systems are developed as closed data silos, with independent formats and models, lacking comprehensive mechanisms to enable data sharing. To tackle these challenges, we developed a Semantic Web based solution that allows connecting distributed and heterogeneous registries, enabling the federation of knowledge between multiple independent environments. This semantic layer creates a holistic view over a set of anonymised registries, supporting semantic data representation, integrated access, and querying. The implemented system gave us the opportunity to answer challenging questions across disperse rare disease patient registries. The interconnection between those registries using Semantic Web technologies benefits our final solution in a way that we can query single or multiple instances according to our needs. The outcome is a unique semantic layer, connecting miscellaneous registries and delivering a lightweight holistic perspective over the wealth of knowledge stemming from linked rare disease patient registries., The research leading to these results has received funding from the European Community’s Seventh Framework Programme (FP7/2007–2013) under Grant Agreement no.305444—the RD-Connect project. Pedro Sernadela is funded by Fundac¸ao para a Ci ˜ encia e Tecnologia (FCT) under the ˆGrant Agreement SFRH/BD/52484/2014. Lorena Gonzalez- ´Castro is funded by the Xunta de Galicia, including funding from the operative program FSE Galicia 2007–2013, under the Grant Agreement IN809A 19/2015.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

From Wet-Lab to Variations: Concordance and Speed of Bioinformatics Pipelines for Whole Genome and Whole Exome Sequencing

  • Laurie, Steven, 1973-
  • Fernández Callejo, Marcos
  • Marco Sola, Santiago
  • Trotta, Jean-Remi
  • Camps-Puchadas, Jordi
  • Chacón, Alejandro
  • Espinosa, Antonio
  • Gut, Marta
  • Gut, Ivo Glynne
  • Heath, Simon
  • Beltran, Sergi
As whole genome sequencing becomes cheaper and faster, it will progressively substitute targeted next-generation sequencing as standard practice in research and diagnostics. However, computing cost–performance ratio is not advancing at an equivalent rate. Therefore, it is essential to evaluate the robustness of the variant detection process taking into account the computing resources required. We have benchmarked six combinations of state-of-the-art read aligners (BWA-MEM and GEM3) and variant callers (FreeBayes, GATK HaplotypeCaller, SAMtools) on whole genome and whole exome sequencing data from the NA12878 human sample. Results have been compared between them and against the NIST Genome in a Bottle (GIAB) variants reference dataset. We report differences in speed of up to 20 times in some steps of the process and have observed that SNV, and to a lesser extent InDel, detection is highly consistent in 70% of the genome. SNV, and especially InDel, detection is less reliable in 20% of the genome, and almost unfeasible in the remaining 10%. These findings will aid in choosing the appropriate tools bearing in mind objectives, workload, and computing infrastructure available., Contract Grant Sponsors: Spanish Ministry of Economy and Competitiveness; Generalitat de Catalunya; European Regional Development Fund (ERDF); RD-Connect Project (EC FP7/2007-2013 #305444); ELIXIR-EXCELERATE (EC H2020 #676559); MICINN (TIN2014-53234- C2-1-R).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Novel insights into PORCN mutations, associated phenotypes and pathophysiological aspects

  • Arlt, Annabelle
  • Kohlschmidt, Nicolai
  • Hentschel, Andreas
  • Bartels, Enrika
  • Groß, Claudia
  • Töpf, Ana
  • Edem, Pinar
  • Szabo, Nora
  • Sickmann, Albert
  • Meyer, Nancy
  • Schara-Schmidt, Ulrike
  • Lau, Jarred
  • Lochmüller, Hanns
  • Horvath, Rita
  • Oktay, Yavuz
  • Roos, Andreas
  • Hiz, Semra
Background: Goltz syndrome (GS) is a X-linked disorder defined by defects of mesodermal- and ectodermal-derived structures and caused by PORCN mutations. Features include striated skin-pigmentation, ocular and skeletal malformations and supernumerary or hypoplastic nipples. Generally, GS is associated with in utero lethality in males and most of the reported male patients show mosaicism (only three non-mosaic surviving males have been described so far). Also, precise descriptions of neurological deficits in GS are rare and less severe phenotypes might not only be caused by mosaicism but also by less pathogenic mutations suggesting the need of a molecular genetics and functional work-up of these rare variants. Results: We report two cases: one girl suffering from typical skin and skeletal abnormalities, developmental delay, microcephaly, thin corpus callosum, periventricular gliosis and drug-resistant epilepsy caused by a PORCN nonsense-mutation (c.283C > T, p.Arg95Ter). Presence of these combined neurological features indicates that CNS-vulnerability might be a guiding symptom in the diagnosis of GS patients. The other patient is a boy with a supernumerary nipple and skeletal anomalies but also, developmental delay, microcephaly, cerebral atrophy with delayed myelination and drug-resistant epilepsy as predominant features. Skin abnormalities were not observed. Genotyping revealed a novel PORCN missense-mutation (c.847G > C, p.Asp283His) absent in the Genome Aggregation Database (gnomAD) but also identified in his asymptomatic mother. Given that non-random X-chromosome inactivation was excluded in the mother, fibroblasts of the index had been analyzed for PORCN protein-abundance and -distribution, vulnerability against additional ER-stress burden as well as for protein secretion revealing changes. Conclusions: Our combined findings may suggest incomplete penetrance for the p.Asp283His variant and provide novel insights into the molecular etiology of GS by adding impaired ER-function and altered protein secretion to the list of pathophysiological processes resulting in the clinical manifestation of GS., Open Access funding enabled and organized by Projekt DEAL. We gratefully acknowledge the financial support by the Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen and the Bundesministerium für Bildung und Forschung. This work was also supported by a Grant of the French Muscular Dystrophy Association (AFM-Téléthon) (#21466) to AR. Parts of this study were financed in the framework of the NME-GPS project by the European Regional Development Fund (ERDF). The project is supported by TUBITAK (The Scientific and Technological Research Council of Turkey) Project No. 216S771. RH was supported by the European Research Council [309548], the Wellcome Investigator Award [109915/Z/15/Z]. The Medical Research Council (UK) [MR/N025431/1]; the Wellcome Trust Pathfinder Scheme [201064/Z/16/Z], the Newton Fund [UK/Turkey, MR/N027302/1], the Lily Foundation and the Evelyn Trust. Sequencing and analysis of patient 2 were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute Grant UM1 HG008900 and in part by National Human Genome Research Institute Grant R01 HG009141. Sequencing of patient 1 was carried out through the Biobanking and Biomedical Resources Research Infrastructure ‐ large prospective cohorts (BBMRI‐LPC) 2016 access call for Whole Exome Sequencing (FP7/2007‐2013), Grant Number: 313010. Data was analyzed using the RD‐Connect Genome‐Phenome Analysis platform developed under FP7/2007‐2013 funded project, Grant Number: 305444. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). The study was further supported by the Horizon 2020 research and innovation program via Grant 779257 “Solve-RD” (RH and HL). USS, RH and HL are members of the European Reference Network for Rare Neuromuscular Diseases (EURO-NMD). YO is supported by the Turkish Academy of Sciences’ Young Investigator Award (TÜBA-GEBIP).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Remote visualization of large-scale genomic alignments for collaborative clinical research and diagnosis of rare diseases

  • Corvò, Alberto
  • Matalonga, Leslie
  • Laurie, Steven, 1973-
  • Picó-Amador, Daniel
  • Fernández Callejo, Marcos
  • Paramonov, Ida
  • Gut, Ivo Glynne
  • Piscia, Davide
  • Beltran, Sergi
The Solve-RD project objectives include solving undiagnosed rare diseases (RD) through collaborative research on shared genome-phenome datasets. The RD-Connect Genome-Phenome Analysis Platform (GPAP), for data collation and analysis, and the European Genome-Phenome Archive (EGA), for file storage, are two key components of the Solve-RD infrastructure. Clinical researchers can identify candidate genetic variants within the RD-Connect GPAP and, thanks to the developments presented here as part of joint ELIXIR activities, are able to remotely visualize the corresponding alignments stored at the EGA. The Global Alliance for Genomics and Health (GA4GH) htsget streaming application programming interface (API) is used to retrieve alignment slices, which are rendered by an integrated genome viewer (IGV) instance embedded in the GPAP. As a result, it is no longer necessary for over 11,000 datasets to download large alignment files to visualize them locally. This work highlights the advantages, from both the user and infrastructure perspectives, of implementing interoperability standards for establishing federated genomics data networks., This study was partially funded by ELIXIR Implementation Studies “Remote real-time visualization of human RDs genomics data (RD-Connect) stored at the EGA ELIXIR” (2017–2018), “Integration of ELIXIR-IIB in ELIXIR Rare Disease activities (2017–2018),” and “Rare Disease Infrastructure ELIXIR (2019–2020)” and the Solve-RD project, which received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 779257. Data were analyzed using the RD-Connect Genome-Phenome Analysis Platform, which has received funding from EU projects RD-Connect, Solve-RD, and EJP-RD (grant nos. FP7 305444, H2020 779257, and H2020 825575), Instituto de Salud Carlos III (grant nos. PT13/0001/0044 and PT17/0009/0019; Instituto Nacional de Bioinformática, INB), and ELIXIR Implementation Studies. We acknowledge the support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

CARGO: effective format-free compressed storage of genomic information

  • Roguski, Łukasz
  • Ribeca, Paolo
Includes supplementary materials for the online appendix., The recent super-exponential growth in the amount of sequencing data generated worldwide has put techniques for compressed storage into the focus. Most available solutions, however, are strictly tied to specific bioinformatics formats, sometimes inheriting from them suboptimal design choices; this hinders flexible and effective data sharing. Here, we present CARGO (Compressed ARchiving for GenOmics), a high-level framework to automatically generate software systems optimized for the compressed storage of arbitrary types of large genomic data collections. Straightforward applications of our approach to FASTQ and SAM archives require a few lines of code, produce solutions that match and sometimes outperform specialized format-tailored compressors and scale well to multi-TB datasets. All CARGO software components can be freely downloaded for academic and non-commercial use from http://bio-cargo.sourceforge.net., Biotechnology and Biological Sciences Research Council (BBSRC) [grant BBS/E/I/00001942 to P.R.]; European Union's Seventh Framework Programme (FP7/2007-2013) [grant agreement No. 305444 (RD-Connect) to Ł.R.]; European Union's European Social Fund [INTERKADRA project UDAPOKL-04.01.01-00-014/10-00 to Ł.R.]. Funding for open access charge: CNAG (own funds) and BBSRC (grant for article processing charges to The Pirbright Institute).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Improved diagnosis of rare disease patients through systematic detection of runs of homozygosity

  • Matalonga Borrel, Lesley
  • Laurie, Steven
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Mereu, Elisabetta
  • Bullich, Gemma
  • Thompson, Rachel
  • Horvath, Rita
  • Pérez Jurado, Luis A.
  • Riess, Olaf
  • Gut, Ivo
  • van Ommen, Gert Jan
  • Lochmüller, Hanns
  • Beltrán, Sergi
  • Rare Disease-Connect Genome-Phenome Analysis Platform data contributors
  • Undiagnosed Rare Disease Programme of Catalonia data contibutors
  • Cormand Rifà, Bru
  • Balcells Comas, Susana
  • Grinberg Vaisman, Daniel Raúl
  • Urreizti, Roser
  • Garrabou Tornos, Glòria
Autozygosity is associated with an increased risk of genetic rare disease, thus being a relevant factor for clinical genetic studies. More than 2400 exome sequencing data sets were analyzed and screened for autozygosity on the basis of detection of >1 Mbp runs of homozygosity (ROHs). A model was built to predict if an individual is likely to be a consanguineous offspring (accuracy, 98%), and probability of consanguinity ranges were established according to the total ROH size. Application of the model resulted in the reclassification of the consanguinity status of 12% of the patients. The analysis of a subset of 79 consanguineous cases with the Rare Disease (RD)-Connect Genome-Phenome Analysis Platform, combining variant filtering and homozygosity mapping, enabled a 50% reduction in the number of candidate variants and the identification of homozygous pathogenic variants in 41 patients, with an overall diagnostic yield of 52%. The newly defined consanguinity ranges provide, for the first time, specific ROH thresholds to estimate inbreeding within a pedigree on disparate exome sequencing data, enabling confirmation or (re)classification of consanguineous status, hence increasing the efficiency of molecular diagnosis and reporting on secondary consanguinity findings, as recommended by American College of Medical Genetics and Genomics guidelines
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Targeted therapies for congenital myasthenic syndromes: systematic review and steps towards a treatabolome

  • Thompson, Rachel
  • Bonne, Gisèle
  • Missier, Paolo
  • Lochmüller, Hanns
Despite recent scientific advances, most rare genetic diseases - including most neuro-muscular diseases - do not currently have curative gene-based therapies available. However, in some cases, such as vitamin, cofactor or enzyme deficiencies, channelopathies and disorders of the neuromuscular junction, a confirmed genetic diagnosis provides guidance on treatment, with drugs available that may significantly alter the disease course, improve functional ability and extend life expectancy. Nevertheless, many treatable patients remain undiagnosed or do not receive treatment even after genetic diagnosis. The growth of computer-aided genetic analysis systems that enable clinicians to diagnose their undiagnosed patients has not yet been matched by genetics-based decision-support systems for treatment guidance. Generating a 'treatabolome' of treatable variants and the evidence for the treatment has the potential to increase treatment rates for treatable conditions. Here, we use the congenital myasthenic syndromes (CMS), a group of clinically and genetically heterogeneous but frequently treatable neuromuscular conditions, to illustrate the steps in the creation of a treatabolome for rare inherited diseases. We perform a systematic review of the evidence for pharmacological treatment of each CMS type, gathering evidence from 207 studies of over 1000 patients and stratifying by genetic defect, as treatment varies depending on the underlying cause. We assess the strength and quality of the evidence and create a dataset that provides the foundation for a computer-aided system to enable clinicians to gain easier access to information about treatable variants and the evidence they need to consider., H.L. and R.T. received support from the EU under RD-Connect [FP7 Grant Agreement No. 305444] and the U.K. Medical Research Council [G1002274/98482]. G.B. receives support under the Solve-RD project, which has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 779257 [H2020 Grant Agreement No. 779257].
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Solving unsolved rare neurological diseases-a Solve-RD viewpoint

  • Matalonga, Leslie
  • Timmann, Dagmar
  • Erasmus, Corrie E.
  • Reichbauer, Jennifer
  • Wayand, Melanie
  • Solve-RD-DITF-RND
  • van de Warrenburg, Bart
  • Schöls, Ludger
  • Wilke, Carlo
  • Bevot, Andrea
  • Zuchner, Stephan
  • Beltran, Sergi
  • Laurie, Steven, 1973-
  • Matalonga, Leslie
  • Graessner, Holm
  • Synofzik, Matthis
  • Solve-RD Consortium
Rare genetic neurological disorders (RND; ORPHA:71859) are a heterogeneous group of disorders comprising >1700 distinct genetic disease entities. However, genetic discoveries have not yet translated into dramatic increases of diagnostic yield and indeed rates of molecular genetic diagnoses have been stuck at about 30–50% across NGS modalities and RND phenotypes [1, 2]. Existence of yet unknown disease genes as well as shortcomings of commonly employed NGS technologies and analysis pipelines in detecting certain variant types are typically cited to explain the low diagnosis rates. To increase the diagnostic yield in RNDs - one of the four focus disease groups in Solve-RD - we follow two major approaches, that we will here present and exemplify: (i) systematic state-of the art re-analysis of large cohorts of unsolved whole-exome/genome sequencing (WES/WGS) RND datasets; and (ii) novel-omics approaches. Based on the way Solve-RD systematically organizes researchers’ expertise to channel this approach [3], the European Reference Network for Rare Neurological Diseases (ERN-RND) has established its own Data Interpretation Task Force (DITF) within SOLVE-RD, which is currently composed of clinical and genetic experts from 29 sites in 15 European countries., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No. 779257. Data were analysed using the RD‐Connect Genome‐Phenome Analysis Platform, which received funding from EU projects RD‐Connect, Solve-RD and EJP-RD (Grant Numbers FP7 305444, H2020 779257, H2020 825575), Instituto de Salud Carlos III (Grant Numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB) and ELIXIR Implementation Studies. The study was further funded by the Federal Ministry of Education and Research, Germany, through the TreatHSP network (01GM1905 to RS and LS), the National Institute of Neurological Diseases and Stroke (R01NS072248 to SZ and RS), the European Joint Program on Rare Diseases-EJP-RD COFUND-EJP N° 825575 through funding for the PROSPAX consortium (441409627 to MS, RS and BvW). CW was supported by the PATE program of the Medical Faculty, University of Tübingen. CEE received support from the Dutch Princess Beatrix Muscle Fund and the Dutch Spieren voor Spieren Muscle fund. Authors on this paper are members of the European Reference Network for Rare Neurological Diseases (ERN-RND, Project ID 739510)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The European Genome-phenome Archive of human data consented for biomedical research

  • Lappalainen, Ilkka
  • Carreño Torres, Angel
  • Rambla de Argila, Jordi
  • Martinez Llobet, Oscar
  • Sitges Puy, Marc
  • Alberich, Mario
  • Torre, Sabela de la
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Flicek, Paul
The European Genome-phenome Archive (EGA) is a permanent archive that promotes the distribution and sharing of genetic and phenotypic data consented for specific approved uses but not fully open, public distribution. The EGA follows strict protocols for information management, data storage, security and dissemination. Authorized access to the data is managed in partnership with the data-providing organizations. The EGA includes major reference data collections for human genetics research., The EGA has received support from the European Molecular Biology Laboratory, the European Union ELIXIR Technical Feasibility Study, the Wellcome Trust (grant WT 085475/C/08/Z), the UK Medical Research Council (grant G0800681), the Spanish Instituto de Salud Carlos III Instituto Nacional de Bioinformática (grant PT13/0001/0026), the Spanish Ministerio de Economía y Competitividad (MINECO) and Centro de Excelencia Severo Ochoa (grant SEV-2012-0208), the Fundació La Caixa and the Barcelona Supercomputing Centre. The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013 under grant agreements 211601–ELIXIR, 200754–GEN2PHEN, 262055–ESGI, 242006–BASIS, 261376–IHMS and 305444–RD-CONNECT).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Comparison of algorithms for the detection of cancer drivers at subgene resolution

  • Porta-Pardo, Eduard
  • Kamburov, Atanas
  • Tamborero, David
  • Pons, Tirso
  • Grases, Daniela
  • Valencia, Alfonso
  • Lopez-Bigas, Nuria
  • Getz, Gad
  • Godzik, Adam
Understanding genetic events that lead to cancer initiation and progression remains one of the biggest challenges in cancer biology. Traditionally, most algorithms for cancer-driver identification look for genes that have more mutations than expected from the average background mutation rate. However, there is now a wide variety of methods that look for nonrandom distribution of mutations within proteins as a signal for the driving role of mutations in cancer. Here we classify and review such subgene-resolution algorithms, compare their findings on four distinct cancer data sets from The Cancer Genome Atlas and discuss how predictions from these algorithms can be interpreted in the emerging paradigms that challenge the simple dichotomy between driver and passenger genes., We would like to thank the people working at The Cancer Genome Atlas for their efforts and for making all the data publicly available. E.P.-P. and A.G. acknowledge the support from the Cancer Center grants P30 CA030199 (to our institute) and R35 GM118187 (A.G.). A.K. was supported by startup funds of G.G. and by a collaboration with Bayer AG. D.T. is supported by project SAF2015- 74072-JIN, which is funded by the Agencia Estatal de Investigacion (AEI) and Fondo Europeo de Desarrollo Regional (FEDER). N.L.-B. acknowledges funding from the European Research Council (consolidator grant 682398). A.V. and T.P. acknowledge funding by the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 305444 (RD-Connect)., Peer Reviewed, Postprint (author's final draft)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

High diagnostic rate of trio exome sequencing in consanguineous families with neurogenetic diseases

  • Kurul, Semra Hiz
  • Matalonga, Leslie
  • Paramonov, Ida
  • Laurie, Steven, 1973-
  • Beltran, Sergi
  • Lochmüller, Hanns
  • Horvath, Rita
Consanguineous marriages have a prevalence rate of 24% in Turkey. These carry an increased risk of autosomal recessive genetic conditions, leading to severe disability or premature death, with a significant health and economic burden. A definitive molecular diagnosis could not be achieved in these children previously, as infrastructures and access to sophisticated diagnostic options were limited. We studied the cause of neurogenetic disease in 246 children from 190 consanguineous families, recruited in three Turkish hospitals between 2016 and 2020. All patients underwent deep phenotyping and trio whole exome sequencing, and data were integrated in advanced international bioinformatics platforms. We detected causative variants in 119 known disease genes in 72% of families. Due to overlapping phenotypes 52% of the confirmed genetic diagnoses would have been missed on targeted diagnostic gene panels. Likely pathogenic variants in 27 novel genes in 14% of the families increased the diagnostic yield to 86%. Eighty-two% of causative variants (141/172) were homozygous, 11 of which were detected in genes previously only associated with autosomal dominant inheritance. Eight families carried two pathogenic variants in different disease genes. De novo (9.3%), X-linked recessive (5.2%) and compound heterozygous (3.5%) variants were less frequent compared to non-consanguineous populations. This cohort provided a unique opportunity to better understand the genetic characteristics of neurogenetic diseases in a consanguineous population. Contrary to what may be expected, causative variants were often not on the longest run of homozygosity and the diagnostic yield was lower in families with the highest degree of consanguinity, due to the high number of homozygous variants in these patients. Pathway analysis highlighted that protein synthesis/degradation defects and metabolic diseases are the most common pathways underlying paediatric neurogenetic disease. In our cohort 164 families (86%) received a diagnosis, enabling prevention of transmission and targeted treatments in 24 patients (10%). We generated an important body of genomic data with lasting impacts on the health and wellbeing of consanguineous families, and economic benefit for the healthcare system in Turkey and elsewhere. We demonstrate that an untargeted next generation sequencing approach is far superior to a more targeted gene panel approach, and can be performed without specialised bioinformatics knowledge by clinicians using established pipelines in populations with high rates of consanguinity., The project is supported by TUBITAK (The Scientific and Technological Research Council of Turkey) Project No. 216S771. YO is supported by the Turkish Academy of Sciences’ Young Investigator award, TÜBA-GEBİP (2017). PFC is a Wellcome Trust Principal Research Fellow (212219/Z/18/Z), and a UK NIHR Senior Investigator, who receives support from the Medical Research Council Mitochondrial Biology Unit (MC_UU_00015/9), the Leverhulme Trust (RPG-2018-408), an MRC research grant (MR/S035699/1), an Alzheimer's Society Project Grant (AS-PG-18b-022). This research was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). RH was supported by the European Research Council [309548], the Wellcome Investigator Award [109915/Z/15/Z]. the Medical Research Council (UK) [MR/N025431/1]; the Wellcome Trust Pathfinder Scheme [201064/Z/16/Z], the Newton Fund [UK/Turkey, MR/N027302/1], the Lily Foundation and the Evelyn Trust. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). Sequencing and analysis were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant UM1 HG008900 and in part by National Human Genome Research Institute grant R01 HG009141. Data was analysed using the RD-Connect Genome-Phenome Analysis platform developed under FP7/2007-2013 funded project (grant agreement nº 305444) and funding from EJP-RD and INB/ELIXIR-ES. The study was further supported by the Horizon 2020 research and innovation program via grant 779257 “Solve-RD” (RH, SB, AT and HL). RH, PFC and YO were supported by an MRC strategic award to establish an International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD) MR/S005021/1
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Autosomal recessive variants in TUBGCP2 alter the γ-tubulin ring complex leading to neurodevelopmental disease

  • Gungor, Serdal
  • Aranguren-Ibáñez, Álvaro
  • Laurie, Steven, 1973-
  • Beltran, Sergi
  • Vernos, Isabelle, 1959-
  • Horvath, Rita
Microtubules help building the cytoskeleton of neurons and other cells. Several components of the gamma-tubulin (γ-tubulin) complex have been previously reported in human neurodevelopmental diseases. We describe two siblings from a consanguineous Turkish family with dysmorphic features, developmental delay, brain malformation, and epilepsy carrying a homozygous mutation (p.Glu311Lys) in TUBGCP2 encoding the γ-tubulin complex 2 (GCP2) protein. This variant is predicted to disrupt the electrostatic interaction of GCP2 with GCP3. In primary fibroblasts carrying the variant, we observed a faint delocalization of γ-tubulin during the cell cycle but normal GCP2 protein levels. Through mass spectrometry, we observed dysregulation of multiple proteins involved in the assembly and organization of the cytoskeleton and the extracellular matrix, controlling cellular adhesion and of proteins crucial for neuronal homeostasis including axon guidance. In summary, our functional and proteomic studies link TUBGCP2 and the γ-tubulin complex to the development of the central nervous system in humans., This study was supported by the Turkish Scientific and Research Council (TÜBITAK) research grant 216S771. Y.O. is supported by Turkish Academy of Sciences Young Investigator Programme (TUBA-GEBIP). R.H. is a Wellcome Trust Investigator (109915/Z/15/Z), who receives support from the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), Medical Research Council (UK) (MR/N025431/1), the European Research Council (309548), the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z), the Newton Fund (UK/Turkey, MR/N027302/1), Evelyn Trust, Lily Foundation, and MRC strategic award to establish an International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD, MR/S005021/1). A.R. received financial support by the French Muscular Dystrophy Association (AFM-Téléthon; grant 21466). Sequence analysis was provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics and was funded by the National Human Genome Research Institute (UM1 HG008900 and R01 HG009141) with supplemental funding provided by the National Heart, Lung, and Blood Institute under the Trans-Omics for Precision Medicine (TOPMed) program and the National Eye Institute. I.V. and Á.A.I. were supported by the CRG internal funds, grant 2017 SGR 478 from AGAUR and grant PGC2018-096976-B-I00 from the Spanish ministry of science, innovation and universities. H.L. receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). Data were analyzed using the RD-Connect Genome-Phenome Analysis Platform developed under FP7/2007-2013 funded project (grant agreement nº 305444) and funding from European Joint Programme in Rare Disease (EJP-RD) and INB/ELIXIR-ES
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

GNE genotype explains 20% of phenotypic variability in GNE myopathy

  • Pogoryelova, Oksana
  • Wilson, Ian J.
  • Mansbach, Hank
  • Argov, Zohar
  • Nishino, Ichizo
  • Lochmüller, Hanns
Objective: To test the hypothesis that common GNE mutations influence disease severity; using statistical analysis of patient cohorts from different countries. Methods: Systematic literature review identified 11 articles reporting 759 patients. GNE registry data were used as a second data set. The relative contributions of the GNE mutations, homozygosity, and country to the age at onset were explored using linear modeling, and relative importance measures were calculated. The rate of ambulation loss for GNE mutations, homozygosity, country, and age at onset was analyzed using Cox proportional hazards models. Results: A spectrum of symptoms and large variability of age at onset and nonambulatory status was observed within families and cohorts. We estimated that 20% of variability is explained by GNE mutations. Individuals harboring p.Asp207Val have an expected age at onset 8.0 (s.e1.0) years later than those without and probability of continued ambulation at age 40 of 0.98 (95% confidence interval [CI] 0.96–1). In contrast, p.Leu539Ser results in onset on average 7.2 (s.e.2.7) years earlier than those without this mutation, and p.Val603Leu has a probability of continued ambulance of 0.61 (95% CI 0.50–0.74) at age 40, but has a nonsignificant effect on age at onset. Conclusions: GNE myopathy severity significantly varies in all cohorts, with 20% of variability explained by the GNE mutation. Atypical symptoms and clinical presentation suggest that physical and instrumental examination should include additional clinical tests. Proven and measurable effect of GNE mutations on the disease severity should be factored in patient management and clinical research study for a better data interpretation., This work was supported by European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement No. 305444 (RD-Connect) and Medical Research Council UK (reference G1002274, grant ID 98482).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A Solve-RD ClinVar-based reanalysis of 1522 index cases from ERN-ITHACA reveals common pitfalls and misinterpretations in exome sequencing

  • Denommé-Pichon, Anne-Sophie
  • Matalonga, Leslie
  • Faivre, Laurence
Purpose: Within the Solve-RD project (https://solve-rd.eu/), the European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies aimed to investigate whether a reanalysis of exomes from unsolved cases based on ClinVar annotations could establish additional diagnoses. We present the results of the "ClinVar low-hanging fruit" reanalysis, reasons for the failure of previous analyses, and lessons learned. Methods: Data from the first 3576 exomes (1522 probands and 2054 relatives) collected from European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies was reanalyzed by the Solve-RD consortium by evaluating for the presence of single-nucleotide variant, and small insertions and deletions already reported as (likely) pathogenic in ClinVar. Variants were filtered according to frequency, genotype, and mode of inheritance and reinterpreted. Results: We identified causal variants in 59 cases (3.9%), 50 of them also raised by other approaches and 9 leading to new diagnoses, highlighting interpretation challenges: variants in genes not known to be involved in human disease at the time of the first analysis, misleading genotypes, or variants undetected by local pipelines (variants in off-target regions, low quality filters, low allelic balance, or high frequency). Conclusion: The "ClinVar low-hanging fruit" analysis represents an effective, fast, and easy approach to recover causal variants from exome sequencing data, herewith contributing to the reduction of the diagnostic deadlock., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement number 779257. Data were analyzed using the RD-Connect Genome-Phenome Analysis Platform, which received funding from the EU projects RD-Connect, Solve-RD, and European Joint Programme on Rare Diseases (grant numbers FP7 305444, H2020 779257, H2020 825575), Instituto de Salud Carlos III (grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática), and ELIXIR Implementation Studies. The collaborations in this study were facilitated by the European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies, one of the 24 European Reference Networks approved by the European Reference Network Board of Member States, cofunded by the European Commission. This project was supported by the Czech Ministry of Health (number 00064203) and by the Czech Ministry of Education, Youth and Sports (number - LM2018132) to M.M.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The RD-Connect Genome-Phenome Analysis Platform: Accelerating diagnosis, research, and gene discovery for rare diseases

  • Laurie, Steven, 1973-
  • Piscia, Davide
  • Matalonga, Leslie
  • Corvò, Alberto
  • Fernández Callejo, Marcos
  • Garcia-Linares, Carles
  • Hernandez-Ferrer, Carles, 1987-
  • Luengo, Cristina
  • Martínez, Inés
  • Papakonstantinou, Anastasios
  • Picó-Amador, Daniel
  • Protasio, Joan
  • Tonda, Raúl
  • Bayés, Mònica
  • Bullich, Gemma
  • Camps-Puchadas, Jordi
  • Paramonov, Ida
  • Trotta, Jean-Remi
  • Pérez Jurado, Luis Alberto
  • Rambla de Argila, Jordi
  • Gut, Ivo Glynne
  • Lochmüller, Hanns
  • Beltran, Sergi
Rare disease patients are more likely to receive a rapid molecular diagnosis nowadays thanks to the wide adoption of next-generation sequencing. However, many cases remain undiagnosed even after exome or genome analysis, because the methods used missed the molecular cause in a known gene, or a novel causative gene could not be identified and/or confirmed. To address these challenges, the RD-Connect Genome-Phenome Analysis Platform (GPAP) facilitates the collation, discovery, sharing, and analysis of standardized genome-phenome data within a collaborative environment. Authorized clinicians and researchers submit pseudonymised phenotypic profiles encoded using the Human Phenotype Ontology, and raw genomic data which is processed through a standardized pipeline. After an optional embargo period, the data are shared with other platform users, with the objective that similar cases in the system and queries from peers may help diagnose the case. Additionally, the platform enables bidirectional discovery of similar cases in other databases from the Matchmaker Exchange network. To facilitate genome-phenome analysis and interpretation by clinical researchers, the RD-Connect GPAP provides a powerful user-friendly interface and leverages tens of information sources. As a result, the resource has already helped diagnose hundreds of rare disease patients and discover new disease causing genes., We acknowledge the support of the developers of PhenoTips, which was used in the past by RD-Connect and NeurOmics as the primary tool to collate phenotypic data. We would also like to thank the leaders and members of the Instituto Nacional de Bioinformática (INB) and ELIXIR for their support and collaboration throughout the years. RD-Connect (RD-Connect, an integrated platform connecting registries, biobanks, and clinical bioinformatics) received funding from the Seventh Framework (FP7) Programme of the European Union under grant agreement No 305444. Data were analyzed using the RD-Connect GPAP, which received funding from EU projects Solve-RD, EJP-RD (grant numbers H2020 779257, H2020 825575), Instituto de Salud Carlos III (Grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB), ELIXIR-EXCELERATE (Grant number EU H2020 #676559) and ELIXIR Implementation Studies (Remote real-time visualization of human rare disease genomics data (RD-Connect) stored at the EGA ELIXIR. 2017-2018; ELIXIR IT-2017-INTEGRATION, Rare Disease Infrastructure ELIXIR, 2019-2020 and the Beacon ELIXIR, 2019-2021). The RD-Connect GPAP has leveraged developments funded through project VEIS (001-P-001647 co-financed by the European Regional Development Fund of the European Union in the framework of the Operational Program FEDER of Catalonia 2014-2020 with the support of the Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement de la Generalitat de Catalunya) and URD-Cat (PERIS SLT002/16/00174, Departament de Salut, Generalitat de Catalunya). The research leading to these results has received funding from Consequitur (Newton Fund UK/Turkey, MR/N027302/1), BBMRI-LPC (EU FP7 #313010), NeurOmics (EU FP7 #305121), the Economic Development Department of the Navarra Government (Grant number 001114112017), the European Reference Network for Rare Neurological Diseases (Project ID number 739510) and NIH, National Institute of Child Health and Human Development (1R01HD103805-01). We acknowledge the support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program/Generalitat de Catalunya. We also acknowledge the support of the Generalitat de Catalunya through Departament de Salut and Departament d'Empresa i Coneixement and Co-financing by the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) with funds from the European Regional Development Fund (ERDF) corresponding to the 2014-2020 Smart Growth Operating Program. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Severe neurodevelopmental disease caused by a homozygous TLK2 variant

  • Topf, Ana
  • Oktay, Yavuz
  • Balaraju, Sunitha
  • Yilmaz, Elmasnur
  • Sonmezler, Ece
  • Yis, Uluc
  • Laurie, Steven, 1973-
  • Thompson, Rachel
  • Roos, Andreas
  • MacArthur, Daniel G.
  • Yaramis, Ahmet
  • Güngör, Serdal
  • Lochmüller, Hanns
  • Hiz, Semra
  • Horvath, Rita
A distinct neurodevelopmental phenotype characterised mainly by mild motor and language delay and facial dysmorphism, caused by heterozygous de novo or dominant variants in the TLK2 gene has recently been described. All cases reported carried either truncating variants located throughout the gene, or missense changes principally located at the C-terminal end of the protein mostly resulting in haploinsufficiency of TLK2. Through whole exome sequencing, we identified a homozygous missense variant in TLK2 in a patient showing more severe symptoms than those previously described, including cerebellar vermis hypoplasia and West syndrome. Both parents are heterozygous for the variant and clinically unaffected highlighting that recessive variants in TLK2 can also be disease causing and may act through a different pathomechanism., The project is supported by TUBITAK (The Scientific and Technological Research Council of Turkey) Project No. 216S771. RH is a Wellcome Trust Investigator (109915/Z/15/Z), who receives support from the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), Medical Research Council (UK) (MR/N025431/1), the European Research Council (309548), the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z) and the Newton Fund (UK/Turkey, MR/N027302/1). The Broad Centre for Mendelian Genomics (UM1 HG008900) is funded by the National Human Genome Research Institute with supplemental funding provided by the National Heart, Lung, and Blood Institute under the Trans-Omics for Precision Medicine (TOPMed) programme and the National Eye Institute. Data were analysed using the RD-Connect Genome-Phenome Analysis platform developed under FP7/2007-2013 funded project (grant agreement no. 305444)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

GA4GH: International policies and standards for data sharing across genomic research and healthcare

  • Rehm, Heidi L.
  • Beltran, Sergi
  • Guigó Serra, Roderic
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Palumbo, Emilio
  • Rambla de Argila, Jordi
  • Birney, Ewan
The Global Alliance for Genomics and Health (GA4GH) aims to accelerate biomedical advances by enabling the responsible sharing of clinical and genomic data through both harmonized data aggregation and federated approaches. The decreasing cost of genomic sequencing (along with other genome-wide molecular assays) and increasing evidence of its clinical utility will soon drive the generation of sequence data from tens of millions of humans, with increasing levels of diversity. In this perspective, we present the GA4GH strategies for addressing the major challenges of this data revolution. We describe the GA4GH organization, which is fueled by the development efforts of eight Work Streams and informed by the needs of 24 Driver Projects and other key stakeholders. We present the GA4GH suite of secure, interoperable technical standards and policy frameworks and review the current status of standards, their relevance to key domains of research and clinical care, and future plans of GA4GH. Broad international participation in building, adopting, and deploying GA4GH standards and frameworks will catalyze an unprecedented effort in data sharing that will be critical to advancing genomic medicine and ensuring that all populations can access its benefits., B.P.C. acknowledges funding from Abigail Wexner Research Institute at Nationwide Children’s Hospital; T.H. Nyrönen acknowledges funding from Academy of Finland grant #31996; A.M.-J., K.N., T.F.B., O.M.H., and Z.S. acknowledge funding from Australian Medical Research Future Fund; M.S. acknowledges funding from Biobank Japan; D. Bujold and S.J.M.J. acknowledge funding from Canada Foundation for Innovation; L.J.D. acknowledges funding from Canada Foundation for Innovation Cyber Infrastructure grant #34860; D. Bujold and G.B. acknowledge funding from CANARIE; L.J.D. acknowledges funding from CANARIE Research Data Management contract #RDM-090 (CHORD) and #RDM2-053 (ClinDIG); K.K.-L. acknowledges funding from CanSHARE; T.L.T. acknowledges funding from Chan Zuckerberg Initiative; T. Burdett acknowledges funding from Chan Zuckerberg Initiative grant #2017-171671; D. Bujold, G.B., and L.D.S. acknowledge funding from CIHR; L.J.D. acknowledges funding from CIHR grant #404896; M.J.S.B. acknowledges funding from CIHR grant #SBD-163124; M. Courtot and M. Linden acknowledge funding from CINECA project EU Horizon 2020 grant #825775; D. Bujold and G.B. acknowledge funding from Compute Canada; F.M.-G. acknowledges funding from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – NFDI 1/1 “GHGA – German Human Genome-Phenome Archive; R.M.H.-S. acknowledges funding from Duke-Margolis Center for Health Policy; S.B. and A.J.B. acknowledge funding from EJP-RD EU Horizon 2020 grant #825575; A. Niewielska, A.K., D.S., G.I.S., J.A.T., J.R., M.A.K., M. Baudis, M. Linden, S.B., S.S., T.H. Nyrönen, and T.M.K. acknowledge funding from ELIXIR; A. Niewielska acknowledges funding from EOSC-Life EU Horizon 2020 grant #824087; J.-P.H. acknowledges funding from ETH Domain Strategic Focal Area “Personalized Health and Related Technologies (PHRT)” grant #2017-201; F.M.-G. acknowledges funding from EUCANCan EU Horizon 2020 grant #825835; B.M.K., D. Bujold, G.B., L.D.S., M.J.S.B., N.S., S.E.W., and Y.J. acknowledge funding from Genome Canada; B.M.K., M.J.S.B., S.E.W., and Y.J. acknowledge funding from Genome Quebec; F.M.-G. acknowledges funding from German Human Genome-Phenome Archive; C. Voisin acknowledges funding from Google; A.J.B. acknowledges funding from Health Data Research UK Substantive Site Award; D.H. acknowledges funding from Howard Hughes Medical Institute; S.B. acknowledges funding from Instituto de Salud Carlos III; S.-S.K. and K.T. acknowledge funding from Japan Agency for Medical Research and Development (AMED); S. Ogishima acknowledges funding from Japan Agency for Medical Research and Development (AMED) grant #20kk0205014h0005; C.Y. and K. Kosaki acknowledge funding from Japan Agency for Medical Research and Development (AMED) grant #JP18kk0205012; GEM Japan acknowledges funding from Japan Agency for Medical Research and Development (AMED) grants #19kk0205014h0004, #20kk0205014h0005, #20kk0205013h0005, #20kk0205012h0005, #20km0405401h0003, and #19km0405001h0104; J.R. acknowledges funding from La Caixa Foundation under project #LCF/PR/GN13/50260009; R.R.F. acknowledges funding from Mayo Clinic Center for Individualized Medicine; Y.J. and S.E.W. acknowledge funding from Ministère de l’Économie et de l’Innovation du Québec for the Can-SHARE Connect Project; S.E.W. and S.O.M.D. acknowledge funding from Ministère de l’Économie et de l’Innovation du Québec for the Can-SHARE grant #141210; M.A.H., M.C.M.-T., J.O.J., H.E.P., and P.N.R. acknowledge funding from Monarch Initiative grant #R24OD011883 and Phenomics First NHGRI grant #1RM1HG010860; A.L.M. and E.B. acknowledge funding from MRC grant #MC_PC_19024; P.T. acknowledges funding from National University of Singapore and Agency for Science, Technology and Research; J.M.C. acknowledges funding from NHGRI; A.H.W. acknowledges funding from NHGRI awards K99HG010157, R00HG010157, and R35HG011949; A.M.-J., K.N., D.P.H., O.M.H., T.F.B., and Z.S. acknowledge funding from NHMRC grants #GNT1113531 and #GNT2000001; D.L.C. acknowledges funding from NHMRC Ideas grant #1188098; A.B.S. acknowledges funding from NHMRC Investigator Fellowship grant #APP177524; J.M.C. and L.D.S. acknowledge funding from NIH; A.A.P. acknowledges funding from NIH Anvil; A.V.S. acknowledges funding from NIH contract #HHSN268201800002I (TOPMed Informatics Research Center); S.U. acknowledges funding from NIH ENCODE grant #UM1HG009443; M.C.M.-T. and M.A.H. acknowledge funding from NIH grant #1U13CA221044; R.J.C. acknowledges funding from NIH grants #1U24HG010262 and #1U2COD023196; M.G. acknowledges funding from NIH grant #R00HG007940; J.B.A., S.L., P.G., E.B., H.L.R., and L.S. acknowledge funding from NIH grant #U24HG011025; K.P.E. acknowledges funding from NIH grant #U2C-RM-160010; J.A.E. acknowledges funding from NIH NCATS grant #U24TR002306; M.M. acknowledges funding from NIH NCI contract #HHSN261201400008c and ID/IQ Agreement #17X146 under contract #HHSN2612015000031 and #75N91019D00024; R.M.C.-D. acknowledges funding from NIH NCI grant #R01CA237118; M. Cline acknowledges funding from NIH NCI grant #U01CA242954; K.P.E. acknowledges funding from NIH NCI ITCR grant #1U24CA231877-01; O.L.G. acknowledges funding from NIH NCI ITCR grant #U24CA237719; R.L.G. acknowledges funding from NIH NCI task order #17X147F10 under contract #HHSN261200800001E; A.F.R. acknowledges funding from NIH NHGRI grant #RM1HG010461; N.M. and L.J.Z. acknowledge funding from NIH NHGRI grant #U24HG006941; R.R.F., T.H. Nelson, L.J.B., and H.L.R. acknowledge funding from NIH NHGRI grant #U41HG006834; B.J.W. acknowledges funding from NIH NHGRI grant #UM1HG009443A; M. Cline acknowledges funding from NIH NHLBI BioData Catalyst Fellowship grant #5118777; M.M. acknowledges funding from NIH NHLBI BioData Catalyst Program grant #1OT3HL142478-01; N.C.S. acknowledges funding from NIH NIGMS grant #R35-GM128636; M.C.M.-T., M.A.H., P.N.R., and R.R.F. acknowledge funding from NIH NLM contract #75N97019P00280; E.B. and A.L.M. acknowledge funding from NIHR; R.G. acknowledges funding from Project Ris3CAT VEIS; S.B. acknowledges funding from RD-Connect, Seventh Framework Program grant #305444; J.K. acknowledges funding from Robertson Foundation; S.B. and A.J.B. acknowledge funding from Solve-RD, EU Horizon 2020 grant #779257; T.S. and S. Oesterle acknowledge funding from Swiss Institute of Bioinformatics (SIB) and Swiss Personalized Health Network (SPHN), supported by the Swiss State Secretariat for Education, Research and Innovation SERI; S.J.M.J. acknowledges funding from Terry Fox Research Institute; A.E.H., M.P.B., M. Cupak, M.F., and J.F. acknowledge funding from the Digital Technology Supercluster; D.F.V. acknowledges funding from the Australian Medical Research Future Fund, as part of the Genomics Health Futures Mission grant #76749; M. Baudis acknowledges funding from the BioMedIT Network project of Swiss Institute of Bioinformatics (SIB) and Swiss Personalized Health Network (SPHN); B.M.K. acknowledges funding from the Canada Research Chair in Law and Medicine and CIHR grant #SBD-163124; D.S., G.I.S., M.A.K., S.B., S.S., and T.H. Nyrönen acknowledge funding from the EU Horizon 2020 Beyond 1 Million Genomes (B1MG) Project grant #951724; P.F., A.D.Y., F.C., H.S., I.U.L., D. Gupta, M. Courtot, S.E.H., T. Burdett, T.M.K., and S.F. acknowledge funding from the European Molecular Biology Laboratory; Y.J. and S.E.W. acknowledge funding from the Government of Canada; P.G. acknowledges funding from the Government of Canada through Genome Canada and the Ontario Genomics Institute (OGI-206); J.Z. acknowledges funding from the Government of Ontario; C.K.Y. acknowledges funding from the Government of Ontario, Canada Foundation for Innovation; C. Viner and M.M.H. acknowledge funding from the Natural Sciences and Engineering Research Council of Canada (grant #RGPIN-2015-03948 to M.M.H. and Alexander Graham Bell Canada Graduate Scholarship to C.V.); K.K.-L. acknowledges funding from the Program for Integrated Database of Clinical and Genomic Information; J.K. acknowledges funding from the Robertson Foundation; D.F.V. acknowledges funding from the Victorian State Government through the Operational Infrastructure Support (OIS) Program; A.M.L., R.N., and H.V.F. acknowledge funding from Wellcome (collaborative award); F.C., H.S., P.F., and S.E.H. acknowledge funding from Wellcome Trust grant #108749/Z/15/Z; A.D.Y., H.S., I.U.L., M. Courtot, H.E.P., P.F., and T.M.K. acknowledge funding from Wellcome Trust grant #201535/Z/16/Z; A.M., J.K.B., R.J.M., R.M.D., and T.M.K. acknowledge funding from Wellcome Trust grant #206194; E.B., P.F., P.G., and S.F. acknowledge funding from Wellcome Trust grant #220544/Z/20/Z; A. Hamosh acknowledges funding from NIH NHGRI grant U41HG006627 and U54HG006542; J.S.H. acknowledges funding from National Taiwan University #91F701-45C and #109T098-02; the work of K.W.R. was supported by the Intramural Research Program of the National Library of Medicine, NIH. For the purpose of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. H.V.F. acknowledges funding from Wellcome Grant 200990/A/16/Z ‘Designing, developing and delivering integrated foundations for genomic medicine'.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Recommendations for improving the quality of rare disease registries

  • Kodra, Yllka
  • Lochmüller, Hanns
  • Taruscio, Domenica
Rare diseases (RD) patient registries are powerful instruments that help develop clinical research, facilitate the planning of appropriate clinical trials, improve patient care, and support healthcare management. They constitute a key information system that supports the activities of European Reference Networks (ERNs) on rare diseases. A rapid proliferation of RD registries has occurred during the last years and there is a need to develop guidance for the minimum requirements, recommendations and standards necessary to maintain a high-quality registry. In response to these heterogeneities, in the framework of RD-Connect, a European platform connecting databases, registries, biobanks and clinical bioinformatics for rare disease research, we report on a list of recommendations, developed by a group of experts, including members of patient organizations, to be used as a framework for improving the quality of RD registries. This list includes aspects of governance, Findable, Accessible, Interoperable and Reusable (FAIR) data and information, infrastructure, documentation, training, and quality audit. The list is intended to be used by established as well as new RD registries. Further work includes the development of a toolkit to enable continuous assessment and improvement of their organizational and data quality., Supported by the RD-CONNECT: an integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research, which received funding from the European Union within the framework of FP7 Collaborative projectHEALTH.2012.2.1.1-1-C [Grant agreement number: 305444]. Supported partly also by EuRRECa: European Registries for Rare Endocrine Conditions, which received funding from the European Union within the framework of CHAFEA Health Programme (2014–2020) [Grant agreement number: 777215] and the COST Action CA16210 “Maximising Impact of research in NeuroDevelopmental Disorders”.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A mosaic PIK3CA variant in a young adult with diffuse gastric cancer: case report

  • Te Paske, Iris B.A.W.
  • Garcia-Pelaez, José
  • Sommer, Anna K.
  • Matalonga, Leslie
  • Starzynska, Teresa
  • Jakubowska, Anna
  • Solve-RD-GENTURIS group
  • van der Post, Rachel S.
  • Lubinski, Jan
  • Oliveira, Carla
  • Hoogerbrugge, Nicoline
  • de Voer, Richarda M.
Hereditary diffuse gastric cancer (HDGC) is associated with germline deleterious variants in CDH1 and CTNNA1. The majority of HDGC-suspected patients are still genetically unresolved, raising the need for identification of novel HDGC predisposing genes. Under the collaborative environment of the SOLVE-RD consortium, re-analysis of whole-exome sequencing data from unresolved gastric cancer cases (n = 83) identified a mosaic missense variant in PIK3CA in a 25-year-old female with diffuse gastric cancer (DGC) without familial history for cancer. The variant, c.3140A>G p.(His1047Arg), a known cancer-related somatic hotspot, was present at a low variant allele frequency (18%) in leukocyte-derived DNA. Somatic variants in PIK3CA are usually associated with overgrowth, a phenotype that was not observed in this patient. This report highlights mosaicism as a potential, and understudied, mechanism in the etiology of DGC., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257. The research work at i3S/Ipatimup is supported by the European Regional Development Fund (ERDF) through COMPETE 2020 - Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020, and by Portuguese funds through FCT/ Ministério da Ciência, Tecnologia e Inovação in the framework of the project “Institute for Research and Innovation in Health Sciences” (POCI-01-0145-FEDER-007274) and Project Ref. POCI-01-0145-FEDER-030164. Data was reanalysed using the RD‐Connect Genome‐Phenome Analysis Platform, which received funding from EU projects RD‐Connect, Solve-RD and EJP-RD (grant numbers FP7 305444, H2020 779257, H2020 825575), Instituto de Salud Carlos III (grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB) and ELIXIR Implementation Studies.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Increasing phenotypic annotation improves the diagnostic rate of exome sequencing in a rare neuromuscular disorder

  • Thompson, Rachel
  • Papakonstantinou, Anastasios
  • Beltran, Sergi
  • Topf, Ana
  • de Paula Estephan, Eduardo
  • Poloavarapu, Kiran
  • Hoen, Peter A. C.
  • Missier, Paolo
  • Lochmüller, Hanns
Phenotype-based filtering and prioritization contribute to the interpretation of genetic variants detected in exome sequencing. However, it is currently unclear how extensive this phenotypic annotation should be. In this study, we compare methods for incorporating phenotype into the interpretation process and assess the extent to which phenotypic annotation aids prioritization of the correct variant. Using a cohort of 29 patients with congenital myasthenic syndromes with causative variants in known or newly discovered disease genes, exome data and the Human Phenotype Ontology (HPO)-coded phenotypic profiles, we show that gene-list filters created from phenotypic annotations perform similarly to curated disease-gene virtual panels. We use Exomiser, a prioritization tool incorporating phenotypic comparisons, to rank candidate variants while varying phenotypic annotation. Analyzing 3,712 combinations, we show that increasing phenotypic annotation improved prioritization of the causative variant, from 62% ranked first on variant alone to 90% with seven HPO annotations. We conclude that any HPO-based phenotypic annotation aids variant discovery and that annotation with over five terms is recommended in our context. Although focused on a constrained cohort, this provides real-world validation of the utility of phenotypic annotation for variant prioritization. Further research is needed to extend this concept to other diseases and more diverse cohorts., Data was analyzed using the RD‐Connect Genome‐Phenome Analysis Platform developed under the 2012‐2018 FP7‐funded project RD‐ Connect (Grant Agreement No.: 305444). R. T., S. B., A. P. N., P. tH., and H. L. received support from the EU FP7 projects 305444 (RD‐ Connect) and 305121 (NeurOmics). S. B. received support from the EU FP7 project 313010 (BBMRI‐LPC). S. B. and P. tH. received support from the EU Horizon 2020 project 779257 (Solve‐RD). S. B., P. tH., and H. L. received support from the EU Horizon 2020 project 825575 (EJP‐RD). H. L. is supported by a project grant of the Canadian Institutes of Health Research (CIHR PJT 162265)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Comparison of algorithms for the detection of cancer drivers at subgene resolution

  • Porta-Pardo, Eduard
  • Kamburov, Atanas
  • Tamborero Noguera, David
  • Pons, Tirso
  • Grases, Daniela
  • Valencia, Alfonso
  • López Bigas, Núria
  • Getz, Gad
  • Godzik, Adam
Understanding genetic events that lead to cancer initiation and progression remains one of the biggest challenges in cancer biology. Traditionally, most algorithms for cancer-driver identification look for genes that have more mutations than expected from the average background mutation rate. However, there is now a wide variety of methods that look for nonrandom distribution of mutations within proteins as a signal for the driving role of mutations in cancer. Here we classify and review such subgene-resolution algorithms, compare their findings on four distinct cancer data sets from The Cancer Genome Atlas and discuss how predictions from these algorithms can be interpreted in the emerging paradigms that challenge the simple dichotomy between driver and passenger genes., E.P.-P. and A.G. acknowledge the support from the Cancer Center grants P30 CA030199 (to our institute) and R35 GM118187 (A.G.). A.K. was supported by startup funds of G.G. and by a collaboration with Bayer AG. D.T. is supported by project SAF2015-74072-JIN, which is funded by the Agencia Estatal de Investigacion (AEI) and Fondo Europeo de Desarrollo Regional (FEDER). N.L.-B. acknowledges funding from the European Research Council (consolidator grant 682398). A.V. and T.P. acknowledge funding by the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 305444 (RD-Connect)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy

  • Signorelli, Mirko
  • Ayoglu, Burcu
  • Johansson, Camilla
  • Lochmüller, Hanns
  • Straub, Volker
  • Muntoni, Francesco
  • Niks, Erik
  • Tsonaka, Roula
  • Persson, Anja
  • Aartsma-Rus, Annemieke
  • Nilsson, Peter
  • Al-Khalili Szigyarto, Cristina
  • Spitali, Pietro
BACKGROUND: Duchenne muscular dystrophy (DMD) is a fatal disease for which no cure is available. Clinical trials have shown to be largely underpowered due to inter-individual variability and noisy outcome measures. The availability of biomarkers able to anticipate clinical benefit is highly needed to improve clinical trial design and facilitate drug development. METHODS: In this study, we aimed to appraise the value of protein biomarkers to predict prognosis and monitor disease progression or treatment outcome in patients affected by DMD. We collected clinical data and 303 blood samples from 157 DMD patients in three clinical centres; 78 patients contributed multiple blood samples over time, with a median follow-up time of 2 years. We employed linear mixed models to identify biomarkers that are associated with disease progression, wheelchair dependency, and treatment with corticosteroids and performed survival analysis to find biomarkers whose levels are associated with time to loss of ambulation. RESULTS: Our analysis led to the identification of 21 proteins whose levels significantly decrease with age and nine proteins whose levels significantly increase. Seven of these proteins are also differentially expressed in non-ambulant patients, and three proteins are differentially expressed in patients treated with glucocorticosteroids. Treatment with corticosteroids was found to partly counteract the effect of disease progression on two biomarkers, namely, malate dehydrogenase 2 (MDH2, P = 0.0003) and ankyrin repeat domain 2 (P = 0.0005); however, patients treated with corticosteroids experienced a further reduction on collagen 1 serum levels (P = 0.0003), especially following administration of deflazacort. A time to event analysis allowed to further support the use of MDH2 as a prognostic biomarker as it was associated with an increased risk of wheelchair dependence (P = 0.0003). The obtained data support the prospective evaluation of the identified biomarkers in natural history and clinical trials as exploratory biomarkers. CONCLUSIONS: We identified a number of serum biomarkers associated with disease progression, loss of ambulation, and treatment with corticosteroids. The identified biomarkers are promising candidate prognostic and surrogate biomarkers, which may support drug developers if confirmed in prospective studies. The serum levels of MDH2 are of particular interest, as they correlate with disease stage and response to treatment with corticosteroids, and are also associated with the risk of wheelchair dependency and pulmonary function., We acknowledge the Association Française Contre les Myopathies (grant no. 17724) and the Stichting Duchenne Parent Project for funding this work. We thank all members of the Affinity Proteomics group at SciLifeLab for technical assistance, as well as Prof. Mathias Uhlén and the entire staff of the Human Protein Atlas for their efforts. H.L. received funding by the Medical Research Council (MRC) Centre for Neuromuscular Diseases UK (reference G1002274 and grant ID 98482) and by the European Commission through the projects Neuromics (no. 305121) and RD‐Connect (no. 305444). The authors thank the MRC Centre for Neuromuscular Diseases for its support through the Neuromuscular Disease BioBank and the Muscular Dystrophy UK for its support to the Neuromuscular Centre at UCL. F.M. is supported by the NIHR Great Ormond Street Hospital Biomedical Research Centre; the views expressed in this paper are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. The authors of this manuscript certify that they comply with the ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Systematic collaborative reanalysis of genomic data improves diagnostic yield in neurologic rare diseases

  • Bullich, Gemma
  • Matalonga, Leslie
  • Pujadas, Montserrat
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Tonda, Raúl
  • González, Juan Ramón
  • Laurie, Steven, 1973-
  • Luengo, Cristina
  • Ovelleiro, David
  • Parra Farré, Genís
  • Pérez Jurado, Luis Alberto
  • Beltran, Sergi
  • Undiagnosed Rare Disease Program of Catalonia (URD-Cat) Consortium
Many patients experiencing a rare disease remain undiagnosed even after genomic testing. Reanalysis of existing genomic data has shown to increase diagnostic yield, although there are few systematic and comprehensive reanalysis efforts that enable collaborative interpretation and future reinterpretation. The Undiagnosed Rare Disease Program of Catalonia project collated previously inconclusive good quality genomic data (panels, exomes, and genomes) and standardized phenotypic profiles from 323 families (543 individuals) with a neurologic rare disease. The data were reanalyzed systematically to identify relatedness, runs of homozygosity, consanguinity, single-nucleotide variants, insertions and deletions, and copy number variants. Data were shared and collaboratively interpreted within the consortium through a customized Genome-Phenome Analysis Platform, which also enables future data reinterpretation. Reanalysis of existing genomic data provided a diagnosis for 20.7% of the patients, including 1.8% diagnosed after the generation of additional genomic data to identify a second pathogenic heterozygous variant. Diagnostic rate was significantly higher for family-based exome/genome reanalysis compared with singleton panels. Most new diagnoses were attributable to recent gene-disease associations (50.8%), additional or improved bioinformatic analysis (19.7%), and standardized phenotyping data integrated within the Undiagnosed Rare Disease Program of Catalonia Genome-Phenome Analysis Platform functionalities (18%)., Supported by Generalitat de Catalunya through Departament de Salut (SLT002/16/00174 to URD-Cat consortium) and Departament d’Empresa i Coneixement and the CERCA Program; FP7 and H2020 EU projects RD-Connect, Solve-RD, and EJP-RD grants FP7 305444, H2020 779257, and H2020 825575 for CNAG-CRG; Spanish Ministry of Science and Innovation to the EMBL partnership and through the Instituto de Salud Carlos III grants PT13/0001/0044 and PT17/0009/0019 for CNAG-CRG and grants PI16/01048, PI19/01310, PI18/00451, PI18/00498, and PI21/00935 for IDIBAPS (Instituto Nacional de Bioinformática); ELIXIR Implementation Studies (CNAG-CRG); Centro de Investigaciones Biomédicas en Red de Enfermedades Raras; Centro de Excelencia Severo Ochoa grant SEV-2016-0571 (CNAG-CRG) and grant CEX 2018-000806-S (ISGLOBAL); and cofinancing with funds from the European Regional Development Fund by the Spanish Ministry of Science and Innovation corresponding to the Programa Operativo FEDER Plurirregional de España (POPE) 2014 to 2020 and by the Secretaria d’Universitats i Recerca, Departament d’Empresa i Coneixement of the Generalitat de Catalunya corresponding to the Programa Operatiu FEDER de Catalunya 2014 to 2020.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Mutations in glycyl-tRNA synthetase impair mitochondrial metabolism in neurons

  • Boczonadi, Veronika
  • Meyer, Kathrin
  • Gonczarowska-Jorge, Humberto
  • Griffin, Helen
  • Roos, Andreas
  • Bartsakoulia, Marina
  • Bansagi, Boglarka
  • Ricci, Giulia
  • Palinkas, Fanni
  • Zahedi, René P.
  • Bruni, Francesco
  • Kaspar, Brian
  • Lochmüller, Hanns
  • Boycott, Kym M.
  • Müller, Juliane
  • Horvath, Rita
The nuclear-encoded glycyl-tRNA synthetase gene (GARS) is essential for protein translation in both cytoplasm and mitochondria. In contrast, different genes encode the mitochondrial and cytosolic forms of most other tRNA synthetases. Dominant GARS mutations were described in inherited neuropathies, while recessive mutations cause severe childhood-onset disorders affecting skeletal muscle and heart. The downstream events explaining tissue-specific phenotype-genotype relations remained unclear. We investigated the mitochondrial function of GARS in human cell lines and in the GarsC210R mouse model. Human-induced neuronal progenitor cells (iNPCs) carrying dominant and recessive GARS mutations showed alterations of mitochondrial proteins, which were more prominent in iNPCs with dominant, neuropathy-causing mutations. Although comparative proteomic analysis of iNPCs showed significant changes in mitochondrial respiratory chain complex subunits, assembly genes, Krebs cycle enzymes and transport proteins in both recessive and dominant mutations, proteins involved in fatty acid oxidation were only altered by recessive mutations causing mitochondrial cardiomyopathy. In contrast, significant alterations of the vesicle-associated membrane protein-associated protein B (VAPB) and its downstream pathways such as mitochondrial calcium uptake and autophagy were detected in dominant GARS mutations. The role of VAPB has been supported by similar results in the GarsC210R mice. Our data suggest that altered mitochondria-associated endoplasmic reticulum (ER) membranes (MAM) may be important disease mechanisms leading to neuropathy in this condition., R.H. is a Wellcome Investigator (109915/Z/15/Z) supported by the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), who receives support from the Medical Research Council (UK) (MR/N025431/1), the European Research Council (309548) and the Mitochondrial European Educational Training (MEET), ITN MARIE CURIE PEOPLE, (317433). H.L. receives funding from the European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement No. 305444 (RD-Connect), 305121 (Neuromics), the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z) and the Newton Fund (UK/Turkey, MR/N027302/1). H.J.G., A.R. and R.P.Z. acknowledge the financial support by the Ministeriumfür Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen, the SenatsverwaltungfürWirtschaft, Technologie und Forschung des Landes Berlin, and the BundesministeriumfürBildung und Forschung. H.G.J. further thanks the CAPES Foundation for financial support.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

GNE myopathy: from clinics and genetics to pathology and research strategies

  • Pogoryelova, Oksana
  • González Coraspe, José Andrés
  • Nikolenko, Nikoletta
  • Lochmüller, Hanns
  • Roos, Andreas
GNE myopathy is an ultra-rare autosomal recessive disease, which starts as a distal muscle weakness and ultimately leads to a wheelchair bound state. Molecular research and animal modelling significantly moved forward understanding of GNE myopathy mechanisms and suggested therapeutic interventions to alleviate the symptoms. Multiple therapeutic attempts are being made to supplement sialic acid depleted in GNE myopathy muscle cells. Translational research field provided valuable knowledge through natural history studies, patient registries and clinical trial, which significantly contributed to bringing forward an era of GNE myopathy treatment. In this review, we are summarising current GNE myopathy, scientific trends and open questions, which would be of significant interest for a wide neuromuscular diseases community., We gratefully acknowledge the financial support from the Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen. Work by the authors has been supported by the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement No. 305444 (RD-Connect) and 305121 (NeurOmics). This work was further supported by a grant from the DGM (Deutsche Gesellschaft für Muskelkranke).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Multifocal demyelinating motor neuropathy and hamartoma syndrome associated with a de novo PTEN mutation

  • Bansagi, Boglarka
  • Phan, Vietxuan
  • Baker, Mark R.
  • O&apos;Sullivan, Julia
  • Jennings, Matthew J.
  • Whittaker, Roger G.
  • Müller, Juliane
  • Duff, Jennifer
  • Griffin, Helen
  • Miller, James A.L.
  • Gorman, Grainne S.
  • Lochmüller, Hanns
  • Chinnery, Patrick F.
  • Roos, Andreas
  • Swan, Laura E.
  • Horvath, Rita
Objective: To describe a patient with a multifocal demyelinating motor neuropathy with onset in childhood and a mutation in phosphatase and tensin homolog (PTEN), a tumor suppressor gene associated with inherited tumor susceptibility conditions, macrocephaly, autism, ataxia, tremor, and epilepsy. Functional implications of this protein have been investigated in Parkinson and Alzheimer diseases. Methods: We performed whole-exome sequencing in the patient's genomic DNA validated by Sanger sequencing. Immunoblotting, in vitro enzymatic assay, and label-free shotgun proteomic profiling were performed in the patient's fibroblasts. Results: The predominant clinical presentation of the patient was a childhood onset, asymmetric progressive multifocal motor neuropathy. In addition, he presented with macrocephaly, autism spectrum disorder, and skin hamartomas, considered as clinical criteria for PTEN-related hamartoma tumor syndrome. Extensive tumor screening did not detect any malignancies. We detected a novel de novo heterozygous c.269T>C, p.(Phe90Ser) PTEN variant, which was absent in both parents. The pathogenicity of the variant is supported by altered expression of several PTEN-associated proteins involved in tumorigenesis. Moreover, fibroblasts showed a defect in catalytic activity of PTEN against the secondary substrate, phosphatidylinositol 3,4-trisphosphate. In support of our findings, focal hypermyelination leading to peripheral neuropathy has been reported in PTEN-deficient mice. Conclusion: We describe a novel phenotype, PTEN-associated multifocal demyelinating motor neuropathy with a skin hamartoma syndrome. A similar mechanism may potentially underlie other forms of Charcot-Marie-Tooth disease with involvement of the phosphatidylinositol pathway., R.H. is a Wellcome Trust Investigator (109915/Z/15/Z) who receives support from the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), Medical Research Council (UK) (MR/N025431/1), and the European Research Council (309548). H.L. receives funding from the European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement no. 305444 (RD-Connect) and 305121 (Neuromics), from the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z), and from the Newton Fund (UK/Turkey, MR/N027302/1). P.F.C. is a Wellcome Trust Senior Fellow in Clinical Science (101876/Z/13/Z) and a UK NIHR Senior Investigator, who receives support from the Medical Research Council Mitochondrial Biology Unit (MC_UP_1501/2), the Medical Research Council (UK) Centre for Translational Muscle Disease (G0601943), EU FP7 TIRCON, and the National Institute for Health Research (NIHR) Biomedical Research Centre based at Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. A.R. received financial support from the Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen, the Senatsverwaltung für Wirtschaft, Technologie und Forschung des Landes Berlin and the Bundesministerium für Bildung und Forschung. L.E.S. was supported by Wellcome Trust (105616/Z/14/Z) and the Medical Research Council (MRC/N010035/1).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Consent codes: upholding standard data use conditions

  • Dyke, Stephanie O. M.
  • Philippakis, Anthony A.
  • Rambla de Argila, Jordi
  • Paltoo, Dina N.
  • Luetkemeier, Erin S.
  • Knoppers, Bartha M.
  • Brookes, Anthony J.
  • Spalding, J. Dylan
  • Thompson, Mark
  • Roos, Marco
  • Boycott, Kym M.
  • Brudno, Michael
  • Hurles, Matthew
  • Rehm, Heidi L.
  • Matern, Andreas
  • Fiume, Marc
  • Sherry, Stephen T.
A systematic way of recording data use conditions that are based on consent permissions as found in the datasets of the main public genome archives (NCBI dbGaP and EMBL-EBI/CRG EGA)., SOMD is supported by the Canadian Institutes of Health Research (grants EP1-120608; EP2-120609), the Canada Research Chair in Law and Medicine, and the Public Population Project in Genomics and Society (P3G). DNP and ESL are supported, in part, by the Intramural Research Program of the NIH, Office of the Director, Office of Science Policy. BMK is supported by the Canada Research Chairs Program. MT and MR are sponsored by ODEX4all (NWO 650.002.002) and funding from the European Commission (FP-7 project RD-Connect, grant agreement No. 305444)
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Systematic Collaborative Reanalysis of Genomic Data Improves Diagnostic Yield in Neurologic Rare Diseases

  • Bullich Vilanova, Gemma|||0000-0002-0737-4422
  • Matalonga, Leslie
  • Pujadas, Montserrat
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Tonda, Raúl
  • Artuch, R.|||0000-0002-3422-9685
  • Gallano, Pia|||0000-0001-8104-2197
  • Garrabou, Glòria|||0000-0001-8973-9933
  • González, Juan R.|||0000-0003-3267-2146
  • Grinberg, Daniel|||0000-0001-9859-2590
  • Guitart, Maria|||0000-0003-2957-7404
  • Laurie, Steven|||0000-0003-3913-5829
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Luengo, Cristina
  • Martí, Ramon A.|||0000-0002-8273-9540
  • Milà, Montserrat
  • Ovelleiro, David|||0000-0002-9415-2229
  • Parra, Genís
  • Pujol, Aurora|||0000-0002-9606-0600
  • Tizzano, Eduardo F.|||0000-0002-7116-6310
  • Macaya Ruiz, Alfons|||0000-0001-7998-4185
  • Palau, Francesc|||0000-0002-8635-5421
  • Ribes, Antònia
  • Pérez-Jurado, Luis Alberto|||0000-0002-1988-3005
  • Beltran i Agulló, Sergi|||0000-0002-2810-3445
  • Schlüter, Agatha|||0000-0001-6732-1528
  • Rodríguez-Palmero, Agustí|||0000-0002-4141-5515
  • Cáceres, Alejandro|||0000-0001-8551-6695
  • Nascimento, Andrés
  • García-Cazorla, Àngels
  • Cueto-González, Anna Mª|||0000-0001-7694-6124
  • Marcé-Grau, Anna|||0000-0001-5762-4023
  • Ruiz Nel Lo, Anna
  • Martínez-Monseny, Antonio
  • Sánchez, Aurora|||0000-0003-1167-1451
  • García, Belén
  • Pérez-Dueñas, Belén|||0000-0002-4979-2788
  • Gel, Bernat|||0000-0001-8878-349X
  • Fusté, Berta
  • Hernández Ferrer, Carles
  • Casasnovas, Carlos|||0000-0002-7933-4681
  • Ortez González, Carlos Ignacio|||0000-0001-8187-8103
  • Arjona, César
  • Hernando Davalillo, Cristina
  • Natera de Benito, Daniel
  • Picó Amador, Daniel
  • Gómez-Andrés, David|||0000-0001-5654-7791
  • Yubero, Délia
  • Pelegrí-Sisó, Dolors|||0000-0002-5993-3003
  • Verdura, Edgard|||0000-0003-3856-2060
  • García Arumí, Elena|||0000-0003-1848-005X
  • Castellanos, Elisabeth|||0000-0002-8133-5325
  • Gabau, Elisabeth|||0000-0001-8120-7393
  • Tobías, Ester|||0000-0002-9968-3651
  • López-Grondona, Fermina
  • Cardellach, Francesc|||0000-0003-3286-3436
  • García García, Francesc Josep|||0000-0001-9021-0324
  • Munell Casadesus, Francina|||0000-0001-8580-2819
  • Tort, Frederic|||0000-0003-2733-1603
  • Aznar, Gemma
  • Olive Cirera, Gemma
  • Tell-Martí, Gemma|||0000-0003-2728-6961
  • Muñoz-Pujol, Gerard|||0000-0002-6863-3993
  • Paramonov, Ida
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Madrigal, Irene|||0000-0002-7229-1199
  • Valenzuela, Irene|||0000-0003-2350-6058
  • Gut, Ivo|||0000-0001-7219-632X
  • Cusco, Ivon|||0000-0003-2104-9332
  • Trotta, Jean-Rémi
  • Cruz, Jordi
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Milisenda, José César|||0000-0003-0151-7872
  • Ma Grau, Josep
  • Garcia-Villoria, Judit
  • Armstrong, Judith|||0000-0003-0588-9307
  • Cantó, Judith
  • Sala-Coromina, Júlia|||0000-0001-5116-6316
  • Rodríguez-Revenga, Laia
  • Alías, Laura|||0000-0003-2193-6185
  • Gort, Laura|||0000-0003-4746-1034
  • González Quereda, Lidia|||0000-0003-0715-6414
  • Costa, Mar
  • Fernández-Callejo, Marcos
  • López Sánchez, Marcos|||0000-0002-1517-5968
  • Álvarez Mora, María Isabel|||0000-0003-3788-8915
  • Gut, Marta|||0000-0002-4063-7159
  • Serrano, Mercedes|||0000-0002-2056-2428
  • Raspall-Chaure, Miquel|||0000-0002-3132-3342
  • Del Toro, Mireia|||0000-0002-8163-1853
  • Bayés, Mònica
  • Baena Díez, Neus|||0000-0003-0677-240X
  • Spataro, Nino|||0000-0002-2127-2238
  • Capdevila, Núria|||0000-0003-2080-7381
  • Ugarteburu, Olatz|||0000-0003-4214-3301
  • Muñoz-Cabello, Patricia|||0000-0002-5242-9605
  • Romero Duque, Penélope|||0000-0003-3509-1320
  • Rabionet, Raquel|||0000-0001-5006-8140
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Calvo-Escalona, Rosa|||0000-0001-9572-4228
  • Urreizti, Roser|||0000-0003-3617-7134
  • Bernal, Sara|||0000-0003-4427-0574
  • Boronat Guerrero, Susana|||0000-0001-7096-5578
  • Balcells, Susana|||0000-0003-1211-1907
  • Vendrell, Teresa
Many patients experiencing a rare disease remain undiagnosed even after genomic testing. Reanalysis of existing genomic data has shown to increase diagnostic yield, although there are few systematic and comprehensive reanalysis efforts that enable collaborative interpretation and future reinterpretation. The Undiagnosed Rare Disease Program of Catalonia project collated previously inconclusive good quality genomic data (panels, exomes, and genomes) and standardized phenotypic profiles from 323 families (543 individuals) with a neurologic rare disease. The data were reanalyzed systematically to identify relatedness, runs of homozygosity, consanguinity, single-nucleotide variants, insertions and deletions, and copy number variants. Data were shared and collaboratively interpreted within the consortium through a customized Genome-Phenome Analysis Platform, which also enables future data reinterpretation. Reanalysis of existing genomic data provided a diagnosis for 20.7% of the patients, including 1.8% diagnosed after the generation of additional genomic data to identify a second pathogenic heterozygous variant. Diagnostic rate was significantly higher for family-based exome/genome reanalysis compared with singleton panels. Most new diagnoses were attributable to recent gene-disease associations (50.8%), additional or improved bioinformatic analysis (19.7%), and standardized phenotyping data integrated within the Undiagnosed Rare Disease Program of Catalonia Genome-Phenome Analysis Platform functionalities (18%).